|
US5456663A
(en)
*
|
1984-05-25 |
1995-10-10 |
Lemelson; Jerome H. |
Drugs and methods for treating diseases
|
|
US5882330A
(en)
*
|
1984-05-25 |
1999-03-16 |
Lemelson; Jerome H. |
Drugs and methods for treating diseases
|
|
US5925375A
(en)
*
|
1987-05-22 |
1999-07-20 |
The Liposome Company, Inc. |
Therapeutic use of multilamellar liposomal prostaglandin formulations
|
|
JPH0720857B2
(ja)
*
|
1988-08-11 |
1995-03-08 |
テルモ株式会社 |
リポソームおよびその製法
|
|
GB8824593D0
(en)
*
|
1988-10-20 |
1988-11-23 |
Royal Free Hosp School Med |
Liposomes
|
|
US6132763A
(en)
*
|
1988-10-20 |
2000-10-17 |
Polymasc Pharmaceuticals Plc |
Liposomes
|
|
US5153000A
(en)
*
|
1988-11-22 |
1992-10-06 |
Kao Corporation |
Phosphate, liposome comprising the phosphate as membrane constituent, and cosmetic and liposome preparation comprising the liposome
|
|
US5620689A
(en)
*
|
1989-10-20 |
1997-04-15 |
Sequus Pharmaceuuticals, Inc. |
Liposomes for treatment of B-cell and T-cell disorders
|
|
US5843473A
(en)
*
|
1989-10-20 |
1998-12-01 |
Sequus Pharmaceuticals, Inc. |
Method of treatment of infected tissues
|
|
US5013556A
(en)
*
|
1989-10-20 |
1991-05-07 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
US5356633A
(en)
*
|
1989-10-20 |
1994-10-18 |
Liposome Technology, Inc. |
Method of treatment of inflamed tissues
|
|
US5527528A
(en)
*
|
1989-10-20 |
1996-06-18 |
Sequus Pharmaceuticals, Inc. |
Solid-tumor treatment method
|
|
US20010051183A1
(en)
*
|
1989-10-20 |
2001-12-13 |
Alza Corporation |
Liposomes with enhanced circulation time and method of treatment
|
|
US5542935A
(en)
*
|
1989-12-22 |
1996-08-06 |
Imarx Pharmaceutical Corp. |
Therapeutic delivery systems related applications
|
|
US5922304A
(en)
|
1989-12-22 |
1999-07-13 |
Imarx Pharmaceutical Corp. |
Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents
|
|
US6146657A
(en)
|
1989-12-22 |
2000-11-14 |
Imarx Pharmaceutical Corp. |
Gas-filled lipid spheres for use in diagnostic and therapeutic applications
|
|
US5305757A
(en)
*
|
1989-12-22 |
1994-04-26 |
Unger Evan C |
Gas filled liposomes and their use as ultrasonic contrast agents
|
|
US5469854A
(en)
*
|
1989-12-22 |
1995-11-28 |
Imarx Pharmaceutical Corp. |
Methods of preparing gas-filled liposomes
|
|
US5585112A
(en)
*
|
1989-12-22 |
1996-12-17 |
Imarx Pharmaceutical Corp. |
Method of preparing gas and gaseous precursor-filled microspheres
|
|
US6551576B1
(en)
|
1989-12-22 |
2003-04-22 |
Bristol-Myers Squibb Medical Imaging, Inc. |
Container with multi-phase composition for use in diagnostic and therapeutic applications
|
|
US6001335A
(en)
*
|
1989-12-22 |
1999-12-14 |
Imarx Pharmaceutical Corp. |
Contrasting agents for ultrasonic imaging and methods for preparing the same
|
|
US20020150539A1
(en)
|
1989-12-22 |
2002-10-17 |
Unger Evan C. |
Ultrasound imaging and treatment
|
|
US5580575A
(en)
*
|
1989-12-22 |
1996-12-03 |
Imarx Pharmaceutical Corp. |
Therapeutic drug delivery systems
|
|
US5441746A
(en)
*
|
1989-12-22 |
1995-08-15 |
Molecular Bioquest, Inc. |
Electromagnetic wave absorbing, surface modified magnetic particles for use in medical applications, and their method of production
|
|
US5776429A
(en)
*
|
1989-12-22 |
1998-07-07 |
Imarx Pharmaceutical Corp. |
Method of preparing gas-filled microspheres using a lyophilized lipids
|
|
US5733572A
(en)
*
|
1989-12-22 |
1998-03-31 |
Imarx Pharmaceutical Corp. |
Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
|
|
US5352435A
(en)
*
|
1989-12-22 |
1994-10-04 |
Unger Evan C |
Ionophore containing liposomes for ultrasound imaging
|
|
US5773024A
(en)
*
|
1989-12-22 |
1998-06-30 |
Imarx Pharmaceutical Corp. |
Container with multi-phase composition for use in diagnostic and therapeutic applications
|
|
US5705187A
(en)
*
|
1989-12-22 |
1998-01-06 |
Imarx Pharmaceutical Corp. |
Compositions of lipids and stabilizing materials
|
|
US6088613A
(en)
|
1989-12-22 |
2000-07-11 |
Imarx Pharmaceutical Corp. |
Method of magnetic resonance focused surgical and therapeutic ultrasound
|
|
US5656211A
(en)
*
|
1989-12-22 |
1997-08-12 |
Imarx Pharmaceutical Corp. |
Apparatus and method for making gas-filled vesicles of optimal size
|
|
US5882678A
(en)
*
|
1990-01-12 |
1999-03-16 |
The Liposome Co, Inc. |
Interdigitation-fusion liposomes containing arachidonic acid metabolites
|
|
US5162361A
(en)
*
|
1990-04-10 |
1992-11-10 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Method of treating diseases associated with elevated levels of interleukin 1
|
|
US6465188B1
(en)
*
|
1990-06-11 |
2002-10-15 |
Gilead Sciences, Inc. |
Nucleic acid ligand complexes
|
|
US20060084797A1
(en)
*
|
1990-06-11 |
2006-04-20 |
Gilead Sciences, Inc. |
High affinity TGFbeta nucleic acid ligands and inhibitors
|
|
US20030113369A1
(en)
*
|
1991-01-16 |
2003-06-19 |
Martin Francis J. |
Liposomes with enhanced circulation time and method of treatment
|
|
US5205290A
(en)
|
1991-04-05 |
1993-04-27 |
Unger Evan C |
Low density microspheres and their use as contrast agents for computed tomography
|
|
US5874062A
(en)
*
|
1991-04-05 |
1999-02-23 |
Imarx Pharmaceutical Corp. |
Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents
|
|
JP3220180B2
(ja)
*
|
1991-05-23 |
2001-10-22 |
三菱化学株式会社 |
薬剤含有タンパク質結合リポソーム
|
|
GB9111611D0
(en)
*
|
1991-05-30 |
1991-07-24 |
Sandoz Ltd |
Liposomes
|
|
WO1993019768A1
(fr)
|
1992-04-03 |
1993-10-14 |
The Regents Of The University Of California |
Systeme de livraison d'un polynucleotide a assemblage autonome
|
|
ZA933926B
(en)
*
|
1992-06-17 |
1994-01-03 |
Amgen Inc |
Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
|
|
DE69324591T3
(de)
*
|
1992-08-05 |
2004-02-12 |
Meito Sangyo K.K., Nagoya |
Verbundmaterial mit kleinem durchmesser, welches ein wasserlösliches carboxylpolysaccharid und magnetisches eisenoxid enthaltet
|
|
NL9201722A
(nl)
*
|
1992-10-05 |
1994-05-02 |
Stichting Tech Wetenschapp |
Farmaceutische samenstelling voor de plaatsgebonden afgifte van een stolsel oplossend eiwit en werkwijze voor de bereiding daarvan.
|
|
DE4236237A1
(de)
*
|
1992-10-27 |
1994-04-28 |
Behringwerke Ag |
Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
|
|
US6764693B1
(en)
*
|
1992-12-11 |
2004-07-20 |
Amaox, Ltd. |
Free radical quenching composition and a method to increase intracellular and/or extracellular antioxidants
|
|
JP3351476B2
(ja)
*
|
1993-01-22 |
2002-11-25 |
三菱化学株式会社 |
リン脂質誘導体及びそれを含有するリポソーム
|
|
US5395619A
(en)
*
|
1993-03-03 |
1995-03-07 |
Liposome Technology, Inc. |
Lipid-polymer conjugates and liposomes
|
|
AU6368394A
(en)
*
|
1993-03-23 |
1994-10-11 |
Liposome Technology, Inc. |
Polymer-polypeptide composition and method
|
|
US6326353B1
(en)
*
|
1993-03-23 |
2001-12-04 |
Sequus Pharmaceuticals, Inc. |
Enhanced circulation effector composition and method
|
|
US6180134B1
(en)
*
|
1993-03-23 |
2001-01-30 |
Sequus Pharmaceuticals, Inc. |
Enhanced ciruclation effector composition and method
|
|
AU6785094A
(en)
*
|
1993-05-07 |
1994-12-12 |
Sequus Pharmaceuticals, Inc. |
Subcutaneous liposome delivery method
|
|
US5681811A
(en)
*
|
1993-05-10 |
1997-10-28 |
Protein Delivery, Inc. |
Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
|
|
US20050181976A1
(en)
*
|
1993-05-10 |
2005-08-18 |
Ekwuribe Nnochiri N. |
Amphiphilic oligomers
|
|
US6191105B1
(en)
|
1993-05-10 |
2001-02-20 |
Protein Delivery, Inc. |
Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
|
|
US5359030A
(en)
*
|
1993-05-10 |
1994-10-25 |
Protein Delivery, Inc. |
Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
|
|
NZ267310A
(en)
*
|
1993-05-21 |
1996-09-25 |
Liposome Co Inc |
Liposome compositions with reduced adverse physiological reactions
|
|
US5744155A
(en)
*
|
1993-08-13 |
1998-04-28 |
Friedman; Doron |
Bioadhesive emulsion preparations for enhanced drug delivery
|
|
US5514670A
(en)
*
|
1993-08-13 |
1996-05-07 |
Pharmos Corporation |
Submicron emulsions for delivery of peptides
|
|
KR960704524A
(ko)
*
|
1993-10-25 |
1996-10-09 |
카롤 질레스피 |
디피신을 함유한 리포좀(liposomal defensins)
|
|
US5415869A
(en)
*
|
1993-11-12 |
1995-05-16 |
The Research Foundation Of State University Of New York |
Taxol formulation
|
|
US5468499A
(en)
*
|
1993-11-15 |
1995-11-21 |
Ohio State University |
Liposomes containing the salt of phosphoramide mustard and related compounds
|
|
US7083572B2
(en)
|
1993-11-30 |
2006-08-01 |
Bristol-Myers Squibb Medical Imaging, Inc. |
Therapeutic delivery systems
|
|
CA2178902A1
(fr)
*
|
1993-12-14 |
1995-06-22 |
Drew Pardoll |
Liberation controlee de substances pharmaceutiquement actives pour l'immunotherapie
|
|
US6312719B1
(en)
*
|
1994-03-04 |
2001-11-06 |
The University Of British Columbia |
Liposome compositions and methods for the treatment of atherosclerosis
|
|
US6773719B2
(en)
*
|
1994-03-04 |
2004-08-10 |
Esperion Luv Development, Inc. |
Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias
|
|
US20010055581A1
(en)
*
|
1994-03-18 |
2001-12-27 |
Lawrence Tamarkin |
Composition and method for delivery of biologically-active factors
|
|
US5736121A
(en)
*
|
1994-05-23 |
1998-04-07 |
Imarx Pharmaceutical Corp. |
Stabilized homogenous suspensions as computed tomography contrast agents
|
|
DE4423131A1
(de)
*
|
1994-07-01 |
1996-01-04 |
Bayer Ag |
Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
|
|
US5626862A
(en)
|
1994-08-02 |
1997-05-06 |
Massachusetts Institute Of Technology |
Controlled local delivery of chemotherapeutic agents for treating solid tumors
|
|
US6132764A
(en)
*
|
1994-08-05 |
2000-10-17 |
Targesome, Inc. |
Targeted polymerized liposome diagnostic and treatment agents
|
|
US5512294A
(en)
*
|
1994-08-05 |
1996-04-30 |
Li; King C. |
Targeted polymerized liposome contrast agents
|
|
US6471956B1
(en)
|
1994-08-17 |
2002-10-29 |
The Rockefeller University |
Ob polypeptides, modified forms and compositions thereto
|
|
US6048837A
(en)
*
|
1994-08-17 |
2000-04-11 |
The Rockefeller University |
OB polypeptides as modulators of body weight
|
|
US6001968A
(en)
|
1994-08-17 |
1999-12-14 |
The Rockefeller University |
OB polypeptides, modified forms and compositions
|
|
US6124439A
(en)
*
|
1994-08-17 |
2000-09-26 |
The Rockefeller University |
OB polypeptide antibodies and method of making
|
|
US6309853B1
(en)
|
1994-08-17 |
2001-10-30 |
The Rockfeller University |
Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
|
|
US6124448A
(en)
*
|
1994-08-17 |
2000-09-26 |
The Rockfeller University |
Nucleic acid primers and probes for the mammalian OB gene
|
|
US6350730B1
(en)
|
1994-08-17 |
2002-02-26 |
The Rockefeller University |
OB polypeptides and modified forms as modulators of body weight
|
|
ATE219660T1
(de)
*
|
1994-09-30 |
2002-07-15 |
Inex Pharmaceuticals Corp |
Mittel zum einbringen polyanionischer materialien in zellen
|
|
US5820873A
(en)
*
|
1994-09-30 |
1998-10-13 |
The University Of British Columbia |
Polyethylene glycol modified ceramide lipids and liposome uses thereof
|
|
US5885613A
(en)
*
|
1994-09-30 |
1999-03-23 |
The University Of British Columbia |
Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
|
|
CN1080575C
(zh)
*
|
1994-10-14 |
2002-03-13 |
蛋白质传送股份有限公司 |
结合稳定的多肽组合物、其治疗、诊断制剂及其制备和使用方法
|
|
DK0785773T3
(da)
*
|
1994-10-14 |
2001-01-29 |
Liposome Co Inc |
Etherlipidliposomer og deres terapeutiske anvendelse
|
|
US6214388B1
(en)
*
|
1994-11-09 |
2001-04-10 |
The Regents Of The University Of California |
Immunoliposomes that optimize internalization into target cells
|
|
US6743779B1
(en)
|
1994-11-29 |
2004-06-01 |
Imarx Pharmaceutical Corp. |
Methods for delivering compounds into a cell
|
|
US5827531A
(en)
*
|
1994-12-02 |
1998-10-27 |
The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration |
Microcapsules and methods for making
|
|
US5795587A
(en)
*
|
1995-01-23 |
1998-08-18 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
|
US6008202A
(en)
*
|
1995-01-23 |
1999-12-28 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
|
US5830430A
(en)
*
|
1995-02-21 |
1998-11-03 |
Imarx Pharmaceutical Corp. |
Cationic lipids and the use thereof
|
|
IL112834A
(en)
*
|
1995-03-01 |
2000-12-06 |
Yeda Res & Dev |
Pharmaceutical compositions for controlled release of soluble receptors
|
|
US5658588A
(en)
*
|
1995-03-31 |
1997-08-19 |
University Of Cincinnati |
Fibrinogen-coated liposomes
|
|
GB9509016D0
(en)
*
|
1995-05-03 |
1995-06-21 |
Royal Free Hosp School Med |
Tissue entrapment
|
|
US8071737B2
(en)
*
|
1995-05-04 |
2011-12-06 |
Glead Sciences, Inc. |
Nucleic acid ligand complexes
|
|
US6420549B1
(en)
|
1995-06-06 |
2002-07-16 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide analogs having modified dimers
|
|
US5997898A
(en)
*
|
1995-06-06 |
1999-12-07 |
Imarx Pharmaceutical Corp. |
Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery
|
|
US5981501A
(en)
*
|
1995-06-07 |
1999-11-09 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating plasmids in lipid bilayers
|
|
US5976567A
(en)
*
|
1995-06-07 |
1999-11-02 |
Inex Pharmaceuticals Corp. |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
|
US6139819A
(en)
|
1995-06-07 |
2000-10-31 |
Imarx Pharmaceutical Corp. |
Targeted contrast agents for diagnostic and therapeutic use
|
|
US6231834B1
(en)
|
1995-06-07 |
2001-05-15 |
Imarx Pharmaceutical Corp. |
Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same
|
|
US6673364B1
(en)
|
1995-06-07 |
2004-01-06 |
The University Of British Columbia |
Liposome having an exchangeable component
|
|
US6521211B1
(en)
|
1995-06-07 |
2003-02-18 |
Bristol-Myers Squibb Medical Imaging, Inc. |
Methods of imaging and treatment with targeted compositions
|
|
US6033645A
(en)
*
|
1996-06-19 |
2000-03-07 |
Unger; Evan C. |
Methods for diagnostic imaging by regulating the administration rate of a contrast agent
|
|
US7422902B1
(en)
|
1995-06-07 |
2008-09-09 |
The University Of British Columbia |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
|
CA2227989A1
(fr)
*
|
1995-08-01 |
1997-02-13 |
Karen Ophelia Hamilton |
Compositions d'oligonucleotides et de liposomes
|
|
US6051600A
(en)
*
|
1995-09-12 |
2000-04-18 |
Mayhew; Eric |
Liposomal hydrolysis-promoting hydrophobic taxane derivatives
|
|
US6107332A
(en)
|
1995-09-12 |
2000-08-22 |
The Liposome Company, Inc. |
Hydrolysis-promoting hydrophobic taxane derivatives
|
|
US5834025A
(en)
|
1995-09-29 |
1998-11-10 |
Nanosystems L.L.C. |
Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
|
|
US5858397A
(en)
*
|
1995-10-11 |
1999-01-12 |
University Of British Columbia |
Liposomal formulations of mitoxantrone
|
|
CN1119145C
(zh)
*
|
1995-10-11 |
2003-08-27 |
埃斯佩里安Luv发展公司 |
脂质体组合物及其使用方法
|
|
US6936439B2
(en)
*
|
1995-11-22 |
2005-08-30 |
Amgen Inc. |
OB fusion protein compositions and methods
|
|
US20030040467A1
(en)
*
|
1998-06-15 |
2003-02-27 |
Mary Ann Pelleymounter |
Ig/ob fusions and uses thereof.
|
|
US5626654A
(en)
|
1995-12-05 |
1997-05-06 |
Xerox Corporation |
Ink compositions containing liposomes
|
|
US5817856A
(en)
*
|
1995-12-11 |
1998-10-06 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Radiation-protective phospholipid and method
|
|
US20050025742A1
(en)
*
|
1996-01-08 |
2005-02-03 |
Canji, Inc. |
Methods and compositions for interferon therapy
|
|
US5789244A
(en)
*
|
1996-01-08 |
1998-08-04 |
Canji, Inc. |
Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
|
|
US20040014709A1
(en)
*
|
1996-01-08 |
2004-01-22 |
Canji, Inc. |
Methods and compositions for interferon therapy
|
|
US7002027B1
(en)
|
1996-01-08 |
2006-02-21 |
Canji, Inc. |
Compositions and methods for therapeutic use
|
|
CA2241564C
(fr)
|
1996-01-08 |
2013-09-03 |
Genentech, Inc. |
Recepteur et ligands wsx
|
|
US6392069B2
(en)
|
1996-01-08 |
2002-05-21 |
Canji, Inc. |
Compositions for enhancing delivery of nucleic acids to cells
|
|
US6096336A
(en)
*
|
1996-01-30 |
2000-08-01 |
The Stehlin Foundation For Cancer Research |
Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
|
|
US5908624A
(en)
*
|
1996-06-27 |
1999-06-01 |
Albany Medical College |
Antigenic modulation of cells
|
|
US5942246A
(en)
*
|
1996-02-16 |
1999-08-24 |
The Liposome Company, Inc. |
Etherlipid containing multiple lipid liposomes
|
|
US5965159A
(en)
|
1996-02-16 |
1999-10-12 |
The Liposome Company, Inc. |
Etherlipid-containing multiple lipid liposomes
|
|
US6667053B1
(en)
|
1996-02-16 |
2003-12-23 |
Elan Pharmaceuticals, Inc. |
D and L etherlipid stereoisomers and liposomes
|
|
USRE39042E1
(en)
*
|
1996-02-16 |
2006-03-28 |
The Liposome Company, Inc. |
Etherlipid-containing multiple lipid liposomes
|
|
US6007839A
(en)
*
|
1996-02-16 |
1999-12-28 |
The Liposome Company, Inc. |
Preparation of pharmaceutical compositions containing etherlipid-containing multiple lipid liposomes
|
|
WO1997035560A1
(fr)
|
1996-03-28 |
1997-10-02 |
The Board Of Trustees Of The University Of Illinois |
Materiels et procedes de fabrication de compositions liposomales echogenes ameliorees
|
|
DE69736981D1
(de)
|
1996-05-01 |
2007-01-04 |
Imarx Pharmaceutical Corp |
In vitro verfahren zum einbringen von nukleinsäuren in eine zelle
|
|
US20050042647A1
(en)
*
|
1996-06-06 |
2005-02-24 |
Baker Brenda F. |
Phosphorous-linked oligomeric compounds and their use in gene modulation
|
|
US20070275921A1
(en)
*
|
1996-06-06 |
2007-11-29 |
Isis Pharmaceuticals, Inc. |
Oligomeric Compounds That Facilitate Risc Loading
|
|
US9096636B2
(en)
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
|
US7812149B2
(en)
|
1996-06-06 |
2010-10-12 |
Isis Pharmaceuticals, Inc. |
2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
|
US5919480A
(en)
|
1996-06-24 |
1999-07-06 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Liposomal influenza vaccine composition and method
|
|
US8007784B1
(en)
|
1996-06-27 |
2011-08-30 |
Albany Medical College |
Antigenic modulation of cells
|
|
US6284267B1
(en)
|
1996-08-14 |
2001-09-04 |
Nutrimed Biotech |
Amphiphilic materials and liposome formulations thereof
|
|
US7368129B1
(en)
|
1996-08-14 |
2008-05-06 |
Nutrimed Biotech |
Amphiphilic materials and liposome formulations thereof
|
|
US6159462A
(en)
*
|
1996-08-16 |
2000-12-12 |
Genentech, Inc. |
Uses of Wnt polypeptides
|
|
US5851984A
(en)
*
|
1996-08-16 |
1998-12-22 |
Genentech, Inc. |
Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
|
|
ES2208946T3
(es)
*
|
1996-08-23 |
2004-06-16 |
Sequus Pharmaceuticals, Inc. |
Liposomas que contienen un compuesto de cisplatino.
|
|
US6271208B1
(en)
|
1996-08-26 |
2001-08-07 |
Transgene S.A. |
Process of making cationic lipid-nucleic acid complexes
|
|
US6414139B1
(en)
|
1996-09-03 |
2002-07-02 |
Imarx Therapeutics, Inc. |
Silicon amphiphilic compounds and the use thereof
|
|
US5846517A
(en)
*
|
1996-09-11 |
1998-12-08 |
Imarx Pharmaceutical Corp. |
Methods for diagnostic imaging using a renal contrast agent and a vasodilator
|
|
DK1323434T3
(da)
*
|
1996-09-11 |
2007-11-12 |
Bristol Myers Squibb Medical I |
Fremgangsmåde til diagnostisk billeddannelse af nyreregioner under anvendelse af et kontrastmiddel og en vasodilator
|
|
TW520297B
(en)
*
|
1996-10-11 |
2003-02-11 |
Sequus Pharm Inc |
Fusogenic liposome composition and method
|
|
US6224903B1
(en)
|
1996-10-11 |
2001-05-01 |
Sequus Pharmaceuticals, Inc. |
Polymer-lipid conjugate for fusion of target membranes
|
|
US6056973A
(en)
*
|
1996-10-11 |
2000-05-02 |
Sequus Pharmaceuticals, Inc. |
Therapeutic liposome composition and method of preparation
|
|
JP2001503396A
(ja)
*
|
1996-10-11 |
2001-03-13 |
アルザ コーポレイション |
治療用リポソーム組成物および方法
|
|
AU725376B2
(en)
*
|
1996-10-15 |
2000-10-12 |
Transave, Inc. |
Peptide-lipid conjugates, liposomes and liposomal drug delivery
|
|
US6339069B1
(en)
*
|
1996-10-15 |
2002-01-15 |
Elan Pharmaceuticalstechnologies, Inc. |
Peptide-lipid conjugates, liposomes and lipsomal drug delivery
|
|
US6264917B1
(en)
*
|
1996-10-28 |
2001-07-24 |
Nycomed Imaging As |
Targeted ultrasound contrast agents
|
|
US6331289B1
(en)
|
1996-10-28 |
2001-12-18 |
Nycomed Imaging As |
Targeted diagnostic/therapeutic agents having more than one different vectors
|
|
US20070036722A1
(en)
*
|
1996-10-28 |
2007-02-15 |
Pal Rongved |
Separation processes
|
|
US6261537B1
(en)
*
|
1996-10-28 |
2001-07-17 |
Nycomed Imaging As |
Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
|
|
US5827533A
(en)
*
|
1997-02-06 |
1998-10-27 |
Duke University |
Liposomes containing active agents aggregated with lipid surfactants
|
|
US6207186B1
(en)
*
|
1997-02-14 |
2001-03-27 |
The Regents Of The University Of California |
Lamellar gels and methods for making and using
|
|
US6537246B1
(en)
|
1997-06-18 |
2003-03-25 |
Imarx Therapeutics, Inc. |
Oxygen delivery agents and uses for the same
|
|
US6143276A
(en)
*
|
1997-03-21 |
2000-11-07 |
Imarx Pharmaceutical Corp. |
Methods for delivering bioactive agents to regions of elevated temperatures
|
|
US6120751A
(en)
|
1997-03-21 |
2000-09-19 |
Imarx Pharmaceutical Corp. |
Charged lipids and uses for the same
|
|
US6090800A
(en)
|
1997-05-06 |
2000-07-18 |
Imarx Pharmaceutical Corp. |
Lipid soluble steroid prodrugs
|
|
IL132120A0
(en)
|
1997-04-03 |
2001-03-19 |
Guilford Pharm Inc |
Biodegradable terephthalate polyester-poly (phosphate) polymers compositions articles and methods for making and using the same
|
|
ES2273415T3
(es)
|
1997-04-07 |
2007-05-01 |
Genentech, Inc. |
Anticuerpos anti-vegf.
|
|
ES2361267T3
(es)
|
1997-04-07 |
2011-06-15 |
Genentech Inc. |
Procedimiento para la produccion de anticuerpos humanizados mediante mutagénesis aleatoria.
|
|
WO1998044910A1
(fr)
|
1997-04-09 |
1998-10-15 |
Philipp Lang |
NOUVELLE TECHNIQUE DE CONTROLE DE L'ADMINISTRATION DE MEDICAMENTS NON VULNERANTE $i(IN VIVO)
|
|
US7452551B1
(en)
|
2000-10-30 |
2008-11-18 |
Imarx Therapeutics, Inc. |
Targeted compositions for diagnostic and therapeutic use
|
|
US20020039594A1
(en)
*
|
1997-05-13 |
2002-04-04 |
Evan C. Unger |
Solid porous matrices and methods of making and using the same
|
|
US6416740B1
(en)
|
1997-05-13 |
2002-07-09 |
Bristol-Myers Squibb Medical Imaging, Inc. |
Acoustically active drug delivery systems
|
|
EP1027033B1
(fr)
*
|
1997-05-14 |
2009-07-22 |
The University Of British Columbia |
Encapsulation hautement éfficace d'acides nucléiques dans des vésicules lipidiques
|
|
DE19724796A1
(de)
*
|
1997-06-06 |
1998-12-10 |
Max Delbrueck Centrum |
Mittel zur Antitumortherapie
|
|
US6663899B2
(en)
*
|
1997-06-13 |
2003-12-16 |
Genentech, Inc. |
Controlled release microencapsulated NGF formulation
|
|
US6113947A
(en)
*
|
1997-06-13 |
2000-09-05 |
Genentech, Inc. |
Controlled release microencapsulated NGF formulation
|
|
US6217886B1
(en)
|
1997-07-14 |
2001-04-17 |
The Board Of Trustees Of The University Of Illinois |
Materials and methods for making improved micelle compositions
|
|
US6548047B1
(en)
|
1997-09-15 |
2003-04-15 |
Bristol-Myers Squibb Medical Imaging, Inc. |
Thermal preactivation of gaseous precursor filled compositions
|
|
ES2343767T3
(es)
*
|
1997-09-18 |
2010-08-09 |
Pacira Pharmaceuticals, Inc. |
Composiciones anestesicas liposomicas de liberacion sostenida.
|
|
US6734171B1
(en)
|
1997-10-10 |
2004-05-11 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating nucleic acids in lipid bilayers
|
|
US6083923A
(en)
*
|
1997-10-31 |
2000-07-04 |
Isis Pharmaceuticals Inc. |
Liposomal oligonucleotide compositions for modulating RAS gene expression
|
|
US7229841B2
(en)
*
|
2001-04-30 |
2007-06-12 |
Cytimmune Sciences, Inc. |
Colloidal metal compositions and methods
|
|
EP1030652B1
(fr)
|
1997-11-14 |
2012-04-25 |
Pacira Pharmaceuticals, Inc. |
Production de liposomes multivesiculaires
|
|
US7192589B2
(en)
|
1998-09-16 |
2007-03-20 |
Genentech, Inc. |
Treatment of inflammatory disorders with STIgMA immunoadhesins
|
|
ES2316175T3
(es)
|
1997-11-21 |
2009-04-01 |
Genentech, Inc. |
Antigenos especificos de plaquetas y sus usos farmacologicos.
|
|
US6787132B1
(en)
*
|
1997-12-04 |
2004-09-07 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Combined chemo-immunotherapy with liposomal drugs and cytokines
|
|
AU756109B2
(en)
*
|
1997-12-04 |
2003-01-02 |
Hadasit Medical Research Services & Development Company Ltd |
Methods for antitumor therapy
|
|
EP1947119A3
(fr)
|
1997-12-12 |
2012-12-19 |
Genentech, Inc. |
Traitement du cancer avec un anticorps Anti-ERBB2 combiné à une chimiothérapie
|
|
US6123923A
(en)
|
1997-12-18 |
2000-09-26 |
Imarx Pharmaceutical Corp. |
Optoacoustic contrast agents and methods for their use
|
|
US20010003580A1
(en)
|
1998-01-14 |
2001-06-14 |
Poh K. Hui |
Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
|
|
DE69920405T2
(de)
|
1998-02-04 |
2006-01-05 |
Genentech, Inc., South San Francisco |
Verwendung des heregulins als epithelzellenwachstumsfaktor
|
|
ES2244169T3
(es)
*
|
1998-02-09 |
2005-12-01 |
Bracco International B.V. |
Suministro direccionado de medios biologicamente activos.
|
|
US6942859B2
(en)
|
1998-03-13 |
2005-09-13 |
University Of Southern California |
Red blood cells covalently bound with polymers
|
|
US6312685B1
(en)
|
1998-03-13 |
2001-11-06 |
Timothy C. Fisher |
Red blood cells covalently bound with two different polyethylene glycol derivatives
|
|
EP1064382B1
(fr)
|
1998-03-17 |
2008-08-20 |
Genentech, Inc. |
Polypeptides homologues aux vegf et bmp1
|
|
IL138572A0
(en)
*
|
1998-03-25 |
2001-10-31 |
Biosource Genetics Corp |
Benzoate derivatives and pharmaceutical compositions containing the same
|
|
US6433012B1
(en)
*
|
1998-03-25 |
2002-08-13 |
Large Scale Biology Corp. |
Method for inhibiting inflammatory disease
|
|
US6858706B2
(en)
|
1998-04-07 |
2005-02-22 |
St. Jude Children's Research Hospital |
Polypeptide comprising the amino acid of an N-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof
|
|
ATE283034T1
(de)
*
|
1998-04-27 |
2004-12-15 |
Opperbas Holding Bv |
Pharmazeutische zusammensetzungen enthaltend faktor viii und neutrale liposomen
|
|
US6986902B1
(en)
*
|
1998-04-28 |
2006-01-17 |
Inex Pharmaceuticals Corporation |
Polyanionic polymers which enhance fusogenicity
|
|
US6331407B1
(en)
|
1998-05-06 |
2001-12-18 |
St. Jude Children's Research Hospital |
Antibiotics and methods of using the same
|
|
US6448224B1
(en)
|
1998-05-06 |
2002-09-10 |
St. Jude Children's Research Hospital |
Antibiotics and methods of using the same
|
|
US6169078B1
(en)
*
|
1998-05-12 |
2001-01-02 |
University Of Florida |
Materials and methods for the intracellular delivery of substances
|
|
EP3112468A1
(fr)
|
1998-05-15 |
2017-01-04 |
Genentech, Inc. |
Polypeptides allogéniques il-17 et utilisations thérapeutiques
|
|
PT1076703E
(pt)
|
1998-05-15 |
2007-10-10 |
Genentech Inc |
''utilizações terapêuticas de polipéptido homólogos de il-17''
|
|
EP1865061A3
(fr)
|
1998-05-15 |
2007-12-19 |
Genentech, Inc. |
Polypeptides allogéniques IL-17 et utilisations thérapeutiques
|
|
ES2395693T3
(es)
|
1998-06-12 |
2013-02-14 |
Genentech, Inc. |
Anticuerpos monoclonales, anticuerpos que reaccionan de forma cruzada y procedimiento para la fabricación de los mismos
|
|
US6726925B1
(en)
*
|
1998-06-18 |
2004-04-27 |
Duke University |
Temperature-sensitive liposomal formulation
|
|
US6200598B1
(en)
*
|
1998-06-18 |
2001-03-13 |
Duke University |
Temperature-sensitive liposomal formulation
|
|
US20040229363A1
(en)
*
|
1998-06-24 |
2004-11-18 |
Ed Nolan |
High efficiency transfection based on low electric field strength, long pulse length
|
|
US6693086B1
(en)
*
|
1998-06-25 |
2004-02-17 |
National Jewish Medical And Research Center |
Systemic immune activation method using nucleic acid-lipid complexes
|
|
US20030022854A1
(en)
*
|
1998-06-25 |
2003-01-30 |
Dow Steven W. |
Vaccines using nucleic acid-lipid complexes
|
|
US20040247662A1
(en)
*
|
1998-06-25 |
2004-12-09 |
Dow Steven W. |
Systemic immune activation method using nucleic acid-lipid complexes
|
|
IL140899A0
(en)
|
1998-07-17 |
2002-02-10 |
Skyepharma Inc |
Lipid/polymer containing pharmaceutical compositions and processes for the preparation thereof
|
|
US20020172678A1
(en)
|
2000-06-23 |
2002-11-21 |
Napoleone Ferrara |
EG-VEGF nucleic acids and polypeptides and methods of use
|
|
US6703381B1
(en)
*
|
1998-08-14 |
2004-03-09 |
Nobex Corporation |
Methods for delivery therapeutic compounds across the blood-brain barrier
|
|
BR9914601A
(pt)
*
|
1998-09-16 |
2001-10-23 |
Alza Corp |
Inibidor de topoisomerase capturado por lipossoma
|
|
US6077709A
(en)
|
1998-09-29 |
2000-06-20 |
Isis Pharmaceuticals Inc. |
Antisense modulation of Survivin expression
|
|
US6419709B1
(en)
|
1998-10-02 |
2002-07-16 |
Guilford Pharmaceuticals, Inc. |
Biodegradable terephthalate polyester-poly(Phosphite) compositions, articles, and methods of using the same
|
|
US6153212A
(en)
*
|
1998-10-02 |
2000-11-28 |
Guilford Pharmaceuticals Inc. |
Biodegradable terephthalate polyester-poly (phosphonate) compositions, articles, and methods of using the same
|
|
ATE348163T1
(de)
*
|
1998-10-23 |
2007-01-15 |
Amgen Inc |
Thrombopoietin substitute
|
|
US6660843B1
(en)
*
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
|
SI1135498T1
(sl)
|
1998-11-18 |
2008-06-30 |
Genentech Inc |
Variante protitelesa z višjo vezavno afiniteto vprimerjavi z izvirnimi protitelesi
|
|
AU1740900A
(en)
*
|
1998-11-20 |
2000-06-13 |
Genentech Inc. |
Method of inhibiting angiogenesis
|
|
US6773911B1
(en)
|
1998-11-23 |
2004-08-10 |
Amgen Canada Inc. |
Apoptosis-inducing factor
|
|
EP1484338B1
(fr)
|
1998-12-22 |
2007-02-07 |
Genentech, Inc. |
Méthode et composition pour l'inhibition de la croissance des cellules néoplastiques
|
|
ATE300957T1
(de)
|
1998-12-22 |
2005-08-15 |
Genentech Inc |
Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung
|
|
US6350464B1
(en)
|
1999-01-11 |
2002-02-26 |
Guilford Pharmaceuticals, Inc. |
Methods for treating ovarian cancer, poly (phosphoester) compositions, and biodegradable articles for same
|
|
US6818227B1
(en)
*
|
1999-02-08 |
2004-11-16 |
Alza Corporation |
Liposome composition and method for administration of a radiosensitizer
|
|
US6537585B1
(en)
|
1999-03-26 |
2003-03-25 |
Guilford Pharmaceuticals, Inc. |
Methods and compositions for treating solid tumors
|
|
US6379698B1
(en)
|
1999-04-06 |
2002-04-30 |
Isis Pharmaceuticals, Inc. |
Fusogenic lipids and vesicles
|
|
US7098192B2
(en)
|
1999-04-08 |
2006-08-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of STAT3 expression
|
|
US7112337B2
(en)
|
1999-04-23 |
2006-09-26 |
Alza Corporation |
Liposome composition for delivery of nucleic acid
|
|
WO2000066126A2
(fr)
*
|
1999-04-29 |
2000-11-09 |
Alza Corporation |
Composition liposomique pour une retention medicamenteuse amelioree
|
|
CA2270600A1
(fr)
*
|
1999-05-03 |
2000-11-03 |
Infectio Recherche Inc. |
Methode et preparations pour le traitement de maladies, en particulier de celles causees par le virus de l'immunodeficience humaine et leishmania
|
|
EP1649870A3
(fr)
|
1999-05-07 |
2006-05-03 |
Genentech, Inc. |
Traitement de maladies auto-immunes au moyen d'antagnosites se liant aux marqueurs de surface de lymphocytes B
|
|
WO2000067760A1
(fr)
*
|
1999-05-11 |
2000-11-16 |
Sankyo Company, Limited |
Preparation de liposomes a base de medicaments antitumoraux liposolubles
|
|
US20040023874A1
(en)
*
|
2002-03-15 |
2004-02-05 |
Burgess Catherine E. |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
|
US20040229779A1
(en)
*
|
1999-05-14 |
2004-11-18 |
Ramesh Kekuda |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
|
US6974684B2
(en)
*
|
2001-08-08 |
2005-12-13 |
Curagen Corporation |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
|
US20040067490A1
(en)
*
|
2001-09-07 |
2004-04-08 |
Mei Zhong |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
|
DE60043367D1
(de)
|
1999-06-15 |
2009-12-31 |
Genentech Inc |
Sekretierte und Transmembran-Polypeptide sowie Nukleinsäuren zu deren Kodierung
|
|
US20030021792A1
(en)
*
|
2001-06-08 |
2003-01-30 |
Roben Paul W. |
Tissue-specific endothelial membrane proteins
|
|
US7169889B1
(en)
|
1999-06-19 |
2007-01-30 |
Biocon Limited |
Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
|
|
US6309633B1
(en)
|
1999-06-19 |
2001-10-30 |
Nobex Corporation |
Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
|
|
AU780194B2
(en)
*
|
1999-06-24 |
2005-03-10 |
Kyowa Hakko Kirin Co., Ltd. |
Method of regulating leakage of drug encapsulated in liposomes
|
|
PL203326B1
(pl)
|
1999-06-25 |
2009-09-30 |
Genentech Inc |
Przeciwciało, kompozycja farmaceutyczna, koniugat, izolowany kwas nukleinowy, wektor, komórka gospodarza i sposób wytwarzania przeciwciała
|
|
US6352996B1
(en)
|
1999-08-03 |
2002-03-05 |
The Stehlin Foundation For Cancer Research |
Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
|
|
GB9918670D0
(en)
|
1999-08-06 |
1999-10-13 |
Celltech Therapeutics Ltd |
Biological product
|
|
DE60042693D1
(de)
|
1999-08-27 |
2009-09-17 |
Genentech Inc |
Dosierung für die behandlung mit anti erbb2-antikörpern
|
|
KR100510795B1
(en)
*
|
1999-08-31 |
2005-08-30 |
|
Compositions and Methods for the Treatment of Tumor
|
|
ES2287028T3
(es)
*
|
1999-09-03 |
2007-12-16 |
Amgen Inc. |
Composiciones y metodos para la prevencion o el tratamiento de cancer y de la perdida osea asociada con el cancer.
|
|
AU7868400A
(en)
|
1999-10-08 |
2001-04-23 |
Alza Corporation |
Neutral-cationic lipid for nucleic acid and drug delivery
|
|
IT1315253B1
(it)
*
|
1999-10-22 |
2003-02-03 |
Novuspharma Spa |
Preparazione liposomiale di 6,9-bis-(2-amminoetil)ammino|benzog|isochinolin-5,10-dione dimaleato
|
|
US7067111B1
(en)
*
|
1999-10-25 |
2006-06-27 |
Board Of Regents, University Of Texas System |
Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
|
|
US6511676B1
(en)
*
|
1999-11-05 |
2003-01-28 |
Teni Boulikas |
Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
|
|
PT1234031T
(pt)
|
1999-11-30 |
2017-06-26 |
Mayo Foundation |
B7-h1, uma nova molécula imunoregulatória
|
|
EP1672070A3
(fr)
|
1999-12-01 |
2006-10-04 |
Genentech, Inc. |
Polypeptides secrétés et transmembranaires et acides nucléiques codant pour ceux-ci
|
|
US6593308B2
(en)
*
|
1999-12-03 |
2003-07-15 |
The Regents Of The University Of California |
Targeted drug delivery with a hyaluronan ligand
|
|
AU2136501A
(en)
*
|
1999-12-10 |
2001-06-18 |
Celator Technologies Inc. |
Lipid carrier compositions with protected surface reactive functions
|
|
DK1897944T3
(da)
|
1999-12-23 |
2011-10-24 |
Genentech Inc |
IL-17 homologe polypeptider og terapeutisk anvendelse deraf
|
|
EP1246608A4
(fr)
*
|
2000-01-05 |
2005-05-18 |
Imarx Therapeutics Inc |
Formulations pharmaceutiques pour l'administration de medicaments ayant une faible solubilite aqueuse
|
|
US20040009229A1
(en)
*
|
2000-01-05 |
2004-01-15 |
Unger Evan Charles |
Stabilized nanoparticle formulations of camptotheca derivatives
|
|
AU785055B2
(en)
*
|
2000-01-13 |
2006-09-07 |
Genentech Inc. |
Novel stra6 polypeptides
|
|
US20020055479A1
(en)
|
2000-01-18 |
2002-05-09 |
Cowsert Lex M. |
Antisense modulation of PTP1B expression
|
|
US6261840B1
(en)
|
2000-01-18 |
2001-07-17 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
|
ES2236181T3
(es)
*
|
2000-01-28 |
2005-07-16 |
Alza Corporation |
Liposomas que contienen un compuesto atrapado en una solucion supersaturada.
|
|
US20030176385A1
(en)
*
|
2000-02-15 |
2003-09-18 |
Jingfang Ju |
Antisense modulation of protein expression
|
|
JP4922824B2
(ja)
*
|
2000-04-03 |
2012-04-25 |
参天製薬株式会社 |
送達性物質およびそれを利用した薬物デリバリーシステム
|
|
PT2857516T
(pt)
|
2000-04-11 |
2017-08-28 |
Genentech Inc |
Anticorpos multivalentes e utilizações dos mesmos
|
|
DE60132184T2
(de)
*
|
2000-04-12 |
2009-01-15 |
Liplasome Pharma A/S |
Auf lipiden basierende arzneistoffabgabesysteme gegen parasitäre infektionen
|
|
ES2260219T3
(es)
|
2000-04-21 |
2006-11-01 |
Amgen Inc. |
Derivados de peptidos apo-ai/aii.
|
|
US6667300B2
(en)
*
|
2000-04-25 |
2003-12-23 |
Icos Corporation |
Inhibitors of human phosphatidylinositol 3-kinase delta
|
|
US7030219B2
(en)
*
|
2000-04-28 |
2006-04-18 |
Johns Hopkins University |
B7-DC, Dendritic cell co-stimulatory molecules
|
|
US6677136B2
(en)
|
2000-05-03 |
2004-01-13 |
Amgen Inc. |
Glucagon antagonists
|
|
WO2001085131A2
(fr)
*
|
2000-05-11 |
2001-11-15 |
Celator Technologies Inc. |
Compositions d'excipient a base de lipides pour retention medicamenteuse amelioree
|
|
US6680172B1
(en)
|
2000-05-16 |
2004-01-20 |
Regents Of The University Of Michigan |
Treatments and markers for cancers of the central nervous system
|
|
IL153218A0
(en)
|
2000-06-02 |
2003-07-06 |
Univ Texas |
Ethylenedicysteine (ec) -drug conjugates
|
|
AU6531101A
(en)
|
2000-06-02 |
2001-12-17 |
Genentech Inc |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
|
US20030072794A1
(en)
*
|
2000-06-09 |
2003-04-17 |
Teni Boulikas |
Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
|
|
JP2004512262A
(ja)
|
2000-06-20 |
2004-04-22 |
アイデック ファーマスーティカルズ コーポレイション |
非放射性抗cd20抗体/放射標識抗cd22抗体の組合せ
|
|
EP2275549A1
(fr)
|
2000-06-23 |
2011-01-19 |
Genentech, Inc. |
Compositions et procédés pour le traitement et le diagnostic des troubles impliquant une angiogénèse
|
|
CA2648051A1
(fr)
|
2000-06-23 |
2002-01-03 |
Genentech, Inc. |
Compositions et procedes de diagnostic et de traitement de troubles dont l'angiogenese
|
|
US20040023259A1
(en)
*
|
2000-07-26 |
2004-02-05 |
Luca Rastelli |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
|
ATE412009T1
(de)
|
2000-08-24 |
2008-11-15 |
Genentech Inc |
Methode zur inhibierung von il-22 induziertem pap1
|
|
EP1944317A3
(fr)
|
2000-09-01 |
2008-09-17 |
Genentech, Inc. |
Polypeptides sécrétés et transmembranaires, et acides nucléiques les codant
|
|
US20030133972A1
(en)
*
|
2000-10-11 |
2003-07-17 |
Targesome, Inc. |
Targeted multivalent macromolecules
|
|
ES2576678T3
(es)
|
2000-10-18 |
2016-07-08 |
Robert Sackstein |
Polipéptidos ligandos de e-selectina/l-selectina de células hematopoyéticas y métodos de uso de los mismos
|
|
US7045283B2
(en)
|
2000-10-18 |
2006-05-16 |
The Regents Of The University Of California |
Methods of high-throughput screening for internalizing antibodies
|
|
WO2002036073A2
(fr)
*
|
2000-11-02 |
2002-05-10 |
Smithkline Beecham Corporation |
Conjugues antagoniste du recepteur-lipide et vehicules d'apport contenant lesdits conjugues
|
|
DE10056136A1
(de)
*
|
2000-11-07 |
2002-05-16 |
Nemod New Modalities |
Verwendung von Schwangerschaftsproteinen, Liposomen, nativen Muzin-Fragmenten und Mimikry-Verbindungen zur Behandlung und Prophylaxe von entzündlichen Erkrankungen, zur Verhinderung der Metastasierung und zur Prophylaxe von Tumorerkrankungen
|
|
US20020127635A1
(en)
*
|
2000-11-30 |
2002-09-12 |
Balasubramanian Sathyamangalam V. |
Method of complexing a protein by the use of a dispersed system and proteins thereof
|
|
US8110218B2
(en)
*
|
2000-11-30 |
2012-02-07 |
The Research Foundation Of State University Of New York |
Compositions and methods for less immunogenic protein-lipid complexes
|
|
US7625584B2
(en)
*
|
2000-11-30 |
2009-12-01 |
The Research Foundation Of State University Of New York |
Method of complexing a protein by the use of a dispersed system and proteins thereof
|
|
US20020132982A1
(en)
*
|
2000-11-30 |
2002-09-19 |
Balasubramanian Sathyamangalam V. |
AHF associated dispersion system and method for preparation
|
|
US20060014674A1
(en)
|
2000-12-18 |
2006-01-19 |
Dennis Keith |
Methods for preparing purified lipopeptides
|
|
CN102070703B
(zh)
*
|
2000-12-18 |
2014-08-06 |
卡比斯特制药公司 |
制备纯化脂肽的方法
|
|
WO2002059145A1
(fr)
*
|
2000-12-18 |
2002-08-01 |
Cubist Pharmaceuticals, Inc. |
Procedes de preparation de lipopeptides purifies
|
|
US20040077604A1
(en)
*
|
2001-12-19 |
2004-04-22 |
Lenard Lichtenberger |
Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providingenhanced therapeutic activity
|
|
US6964849B2
(en)
|
2001-01-11 |
2005-11-15 |
Curagen Corporation |
Proteins and nucleic acids encoding same
|
|
US20040043928A1
(en)
*
|
2001-08-02 |
2004-03-04 |
Ramesh Kekuda |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
|
US20020159996A1
(en)
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
|
AR035779A1
(es)
|
2001-02-06 |
2004-07-14 |
Genetics Inst Llc |
Polipeptidos de fusion derivados de glicoproteina ib alfa de plaqueta y metodos de uso de los mismos
|
|
US7060675B2
(en)
*
|
2001-02-15 |
2006-06-13 |
Nobex Corporation |
Methods of treating diabetes mellitus
|
|
US6867183B2
(en)
*
|
2001-02-15 |
2005-03-15 |
Nobex Corporation |
Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
|
|
US7087726B2
(en)
|
2001-02-22 |
2006-08-08 |
Genentech, Inc. |
Anti-interferon-α antibodies
|
|
US20020197210A1
(en)
*
|
2001-03-08 |
2002-12-26 |
Bednarski Mark David |
Stabilized therapeutic and imaging agents
|
|
US7108863B2
(en)
*
|
2001-03-26 |
2006-09-19 |
Alza Corporation |
Liposome composition for improved intracellular delivery of a therapeutic agent
|
|
US20040126900A1
(en)
*
|
2001-04-13 |
2004-07-01 |
Barry Stephen E |
High affinity peptide- containing nanoparticles
|
|
US20030077829A1
(en)
*
|
2001-04-30 |
2003-04-24 |
Protiva Biotherapeutics Inc.. |
Lipid-based formulations
|
|
US20030203865A1
(en)
*
|
2001-04-30 |
2003-10-30 |
Pierrot Harvie |
Lipid-comprising drug delivery complexes and methods for their production
|
|
GB0111279D0
(en)
*
|
2001-05-10 |
2001-06-27 |
Nycomed Imaging As |
Radiolabelled liposomes
|
|
ATE549354T1
(de)
|
2001-05-11 |
2012-03-15 |
Amgen Inc |
Peptide und damit zusammenhängende an tall-1 bindende moleküle
|
|
EP1389182A1
(fr)
*
|
2001-05-15 |
2004-02-18 |
Transgene S.A. |
Complexes utilises pour transferer des substances utiles dans une cellule
|
|
US20030138429A1
(en)
*
|
2001-05-22 |
2003-07-24 |
Pizzo Salvatore V. |
Compositions and methods for inhibiting metastasis
|
|
US20020197253A1
(en)
*
|
2001-05-22 |
2002-12-26 |
Cheek Dennis J. |
Compositions and methods for promoting or inhibiting NDPK
|
|
WO2002096458A1
(fr)
|
2001-05-30 |
2002-12-05 |
Genentech, Inc. |
Anticorps anti-ngf pour le traitement de divers troubles
|
|
IL158819A0
(en)
*
|
2001-05-31 |
2004-05-12 |
Skyepharma Inc |
Encapsulation of nanosuspensions in liposomes and microspheres
|
|
US6828297B2
(en)
|
2001-06-04 |
2004-12-07 |
Nobex Corporation |
Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
|
US7713932B2
(en)
|
2001-06-04 |
2010-05-11 |
Biocon Limited |
Calcitonin drug-oligomer conjugates, and uses thereof
|
|
US6828305B2
(en)
*
|
2001-06-04 |
2004-12-07 |
Nobex Corporation |
Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
|
US6713452B2
(en)
|
2001-06-04 |
2004-03-30 |
Nobex Corporation |
Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
|
US6835802B2
(en)
*
|
2001-06-04 |
2004-12-28 |
Nobex Corporation |
Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
|
|
US6858580B2
(en)
*
|
2001-06-04 |
2005-02-22 |
Nobex Corporation |
Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
|
US20050107595A1
(en)
*
|
2001-06-20 |
2005-05-19 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
|
US7803915B2
(en)
*
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
|
KR100788092B1
(ko)
|
2001-06-20 |
2007-12-21 |
제넨테크, 인크. |
종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
|
|
EP2221376B1
(fr)
|
2001-06-21 |
2012-11-21 |
Isis Pharmaceuticals, Inc. |
Modulation anti-sens d'expression soluble de superoxide dismutase 1
|
|
CN1827766B
(zh)
|
2001-06-28 |
2010-08-25 |
徐荣祥 |
体外细胞的培养方法
|
|
US20040029790A1
(en)
*
|
2001-07-05 |
2004-02-12 |
Meera Patturajan |
Novel human proteins, polynucleotides encoding them and methods of using the same
|
|
US20030087274A1
(en)
*
|
2001-07-05 |
2003-05-08 |
Anderson David W. |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
|
AU2002354957A1
(en)
*
|
2001-07-19 |
2003-03-03 |
Guilford Pharmaceuticals, Inc. |
Biocompatible polymer containing composition for treatment of prostate cancers
|
|
US20030134892A1
(en)
*
|
2001-07-19 |
2003-07-17 |
Wenbin Dang |
Compositions for treatment of head and neck cancers, and methods of making and using the same
|
|
US7425545B2
(en)
|
2001-07-25 |
2008-09-16 |
Isis Pharmaceuticals, Inc. |
Modulation of C-reactive protein expression
|
|
US6964950B2
(en)
|
2001-07-25 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of C-reactive protein expression
|
|
NZ530904A
(en)
*
|
2001-07-29 |
2005-09-30 |
Yissum Res Dev Co |
Use of oligopeptides corresponding to the C-terminal portion of OGP that enhance treatments such as engraftment of bone marrow transplants and haematopoietic reconstruction
|
|
US20030096772A1
(en)
|
2001-07-30 |
2003-05-22 |
Crooke Rosanne M. |
Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
|
|
US7407943B2
(en)
|
2001-08-01 |
2008-08-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein B expression
|
|
US20040030096A1
(en)
*
|
2001-08-02 |
2004-02-12 |
Linda Gorman |
Novel human proteins, polynucleotides encoding them and methods of using the same
|
|
US7227014B2
(en)
|
2001-08-07 |
2007-06-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein (a) expression
|
|
US20030059375A1
(en)
*
|
2001-08-20 |
2003-03-27 |
Transave, Inc. |
Method for treating lung cancers
|
|
JP2005511500A
(ja)
|
2001-08-31 |
2005-04-28 |
ザ ロックフェラー ユニバーシティー |
脳におけるホスホジエステラーゼ活性およびホスホジエステラーゼ1b媒介シグナル伝達の調節
|
|
US20040235068A1
(en)
*
|
2001-09-05 |
2004-11-25 |
Levinson Arthur D. |
Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
|
|
US7166571B2
(en)
*
|
2001-09-07 |
2007-01-23 |
Biocon Limited |
Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
|
|
US7196059B2
(en)
*
|
2001-09-07 |
2007-03-27 |
Biocon Limited |
Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
|
|
US6913903B2
(en)
*
|
2001-09-07 |
2005-07-05 |
Nobex Corporation |
Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
|
|
US7312192B2
(en)
*
|
2001-09-07 |
2007-12-25 |
Biocon Limited |
Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
|
|
US7547673B2
(en)
*
|
2001-09-13 |
2009-06-16 |
The Johns Hopkins University |
Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production
|
|
MXPA04002593A
(es)
|
2001-09-18 |
2004-05-31 |
Genentech Inc |
Composiciones y metodos para el diagnostico y tratamiento de tumor.
|
|
US7981863B2
(en)
|
2001-09-19 |
2011-07-19 |
Neuronova Ab |
Treatment of Parkinson's disease with PDGF
|
|
AU2002337770B2
(en)
*
|
2001-09-28 |
2007-11-08 |
Esperion Therapeutics, Inc. |
Methods and apparatus for extrusion of vesicles at high pressure
|
|
DE10148065A1
(de)
*
|
2001-09-28 |
2003-04-17 |
Max Planck Gesellschaft |
(Ester)-Lysolecithine in Liposomen
|
|
US20030199442A1
(en)
*
|
2001-10-09 |
2003-10-23 |
Alsobrook John P. |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
|
AU2002334895B2
(en)
|
2001-10-09 |
2006-10-19 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of insulin-like growth factor binding protein 5 expression
|
|
US6750019B2
(en)
|
2001-10-09 |
2004-06-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of insulin-like growth factor binding protein 5 expression
|
|
US7332474B2
(en)
*
|
2001-10-11 |
2008-02-19 |
Amgen Inc. |
Peptides and related compounds having thrombopoietic activity
|
|
WO2004033620A2
(fr)
|
2001-11-02 |
2004-04-22 |
Insert Therapeutics, Inc. |
Procedes et compositions permettant l'utilisation therapeutique de l'interference arn
|
|
EP1441763A2
(fr)
*
|
2001-11-07 |
2004-08-04 |
Inex Pharmaceuticals Corp. |
Modeles ameliores de vaccins administrables par voie muqueuse et modes d'utilisation
|
|
US20040219201A1
(en)
*
|
2001-12-06 |
2004-11-04 |
Yechezkel Barenholz |
Tempamine compositions and methods of use
|
|
US6965025B2
(en)
|
2001-12-10 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of connective tissue growth factor expression
|
|
KR100623128B1
(ko)
|
2002-01-02 |
2006-09-14 |
제넨테크, 인크. |
종양의 진단 및 치료 방법 및 이를 위한 조성물
|
|
IL162838A0
(en)
|
2002-01-04 |
2005-11-20 |
Univ Rockefeller |
Compositions and methods for prevention and treatment peptide-of amyloid- related disorders
|
|
US20040052928A1
(en)
*
|
2002-09-06 |
2004-03-18 |
Ehud Gazit |
Peptides and methods using same for diagnosing and treating amyloid-associated diseases
|
|
US7781396B2
(en)
*
|
2002-01-31 |
2010-08-24 |
Tel Aviv University Future Technology Development L.P. |
Peptides directed for diagnosis and treatment of amyloid-associated disease
|
|
AU2003215254A1
(en)
*
|
2002-02-13 |
2003-09-04 |
Immunology Laboratories, Inc. |
Compositions and methods for treatment of microbial infections
|
|
EP1575480A4
(fr)
|
2002-02-22 |
2008-08-06 |
Genentech Inc |
Compositions et methodes de traitement de maladies relatives au systeme immunitaire
|
|
US20090042291A1
(en)
*
|
2002-03-01 |
2009-02-12 |
Xencor, Inc. |
Optimized Fc variants
|
|
US20100311954A1
(en)
*
|
2002-03-01 |
2010-12-09 |
Xencor, Inc. |
Optimized Proteins that Target Ep-CAM
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
US20030180712A1
(en)
|
2002-03-20 |
2003-09-25 |
Biostratum Ab |
Inhibition of the beta3 subunit of L-type Ca2+ channels
|
|
US20040009216A1
(en)
*
|
2002-04-05 |
2004-01-15 |
Rodrigueza Wendi V. |
Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease
|
|
KR20040101502A
(ko)
|
2002-04-16 |
2004-12-02 |
제넨테크, 인크. |
종양의 진단 및 치료 방법 및 이를 위한 조성물
|
|
CA2483476A1
(fr)
*
|
2002-04-22 |
2003-10-30 |
Absorber, Ab |
Compositions et procedes d'inhibition de l'adherence microbienne
|
|
US20040009944A1
(en)
*
|
2002-05-10 |
2004-01-15 |
Inex Pharmaceuticals Corporation |
Methylated immunostimulatory oligonucleotides and methods of using the same
|
|
US7199107B2
(en)
|
2002-05-23 |
2007-04-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of kinesin-like 1 expression
|
|
EP2305710A3
(fr)
|
2002-06-03 |
2013-05-29 |
Genentech, Inc. |
Bibliothèques de phages et anticorps synthétiques
|
|
US7601688B2
(en)
*
|
2002-06-13 |
2009-10-13 |
Biocon Limited |
Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
|
|
EP1519714B1
(fr)
|
2002-06-28 |
2010-10-20 |
Protiva Biotherapeutics Inc. |
Appareil liposomal et procedes de fabrication
|
|
EP1536843B1
(fr)
*
|
2002-07-02 |
2010-12-22 |
Board Of Regents, The University Of Texas System |
Composes et liposomes radiomarques et procedes de production et d'utilisation associes
|
|
AU2003267984A1
(en)
*
|
2002-07-03 |
2004-01-23 |
Receptor Biologix, Inc. |
Liposomal vaccine
|
|
US20040247661A1
(en)
*
|
2002-07-03 |
2004-12-09 |
Dov Michaeli |
Liposomal vaccine
|
|
US20050169979A1
(en)
*
|
2002-07-03 |
2005-08-04 |
Dov Michaeli |
Liposomal vaccine
|
|
EP2332956A1
(fr)
|
2002-07-08 |
2011-06-15 |
Genentech, Inc. |
Anticorps qui se lie á PRO71238
|
|
US7678386B2
(en)
*
|
2002-07-15 |
2010-03-16 |
Board Of Regents The University Of Texas |
Liposomes coated with selected antibodies that bind to aminophospholipids
|
|
US7622118B2
(en)
*
|
2002-07-15 |
2009-11-24 |
Board Of Regents, The University Of Texas System |
Cancer treatment methods using selected antibodies to aminophospholipids
|
|
US7615223B2
(en)
*
|
2002-07-15 |
2009-11-10 |
Board Of Regents, The University Of Texas System |
Selected immunoconjugates for binding to aminophospholipids
|
|
US7572448B2
(en)
*
|
2002-07-15 |
2009-08-11 |
Board Of Regents, The University Of Texas System |
Combined cancer treatment methods using selected antibodies to aminophospholipids
|
|
US7625563B2
(en)
*
|
2002-07-15 |
2009-12-01 |
Board Of Regents, The University Of Texas System |
Cancer treatment methods using selected immunoconjugates for binding to aminophospholipids
|
|
ATE535254T1
(de)
|
2002-07-15 |
2011-12-15 |
Genentech Inc |
Behandlung von krebs mit dem anti-erbb2- antikörper rhumab 2c4
|
|
US7714109B2
(en)
*
|
2002-07-15 |
2010-05-11 |
Board Of Regents, The University Of Texas System |
Combinations and kits for cancer treatment using selected antibodies to aminophospholipids
|
|
PT2269656E
(pt)
*
|
2002-07-15 |
2014-12-02 |
Univ Texas |
Anticorpos selecionados e peptídeos de duramicina que se ligam a fosfolipídios aniônicos e aminofosfolipídios e seus usos no tratamento de infecções virais e câncer
|
|
US7388076B2
(en)
*
|
2002-07-16 |
2008-06-17 |
University Of South Florida |
Human immunosuppressive protein
|
|
US20040161423A1
(en)
*
|
2002-07-18 |
2004-08-19 |
Sanjeev Kumar (Mendiratta) |
Polymer modified anti-angiogenic serpins
|
|
US9186322B2
(en)
*
|
2002-08-02 |
2015-11-17 |
Insmed Incorporated |
Platinum aggregates and process for producing the same
|
|
BRPI0313191A2
(pt)
*
|
2002-08-02 |
2016-11-08 |
Transave Inc |
composição e processo para produzir um agregado de platina e formulação farmacêutica
|
|
JP4459810B2
(ja)
|
2002-08-14 |
2010-04-28 |
マクロジェニクス,インコーポレーテッド |
FcγRIIB特異的抗体とその利用法
|
|
EP1393720A1
(fr)
*
|
2002-08-27 |
2004-03-03 |
Universiteit Utrecht |
Vesicules encapsulant des corticosteroides pour le traitement du cancer
|
|
JP2006508056A
(ja)
|
2002-08-28 |
2006-03-09 |
イミュネックス・コーポレーション |
心臓血管疾患を治療するための組成物および方法
|
|
AR036316A1
(es)
*
|
2002-08-29 |
2004-08-25 |
Monte Verde S A |
Una composicion farmaceutica de liposomas de tamano pequeno y metodo de preparacion
|
|
US20070231379A1
(en)
*
|
2002-08-29 |
2007-10-04 |
Slater James L |
Liposome-entrapped topoisomerase inhibitors
|
|
US8071560B2
(en)
*
|
2004-02-17 |
2011-12-06 |
University Of South Florida |
Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor
|
|
US20080214437A1
(en)
*
|
2002-09-06 |
2008-09-04 |
Mohapatra Shyam S |
Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
|
|
AU2003268531A1
(en)
|
2002-09-06 |
2004-03-29 |
University Of South Florida |
Materials and methods for treatment of allergic diseases
|
|
AU2003270439B2
(en)
|
2002-09-11 |
2009-09-24 |
Genentech, Inc. |
Novel composition and methods for the treatment of immune related diseases
|
|
EP2116551A1
(fr)
|
2002-09-11 |
2009-11-11 |
Genentech, Inc. |
Compositions et procédés pour le traitement de maladies liées au système immunitaire
|
|
NZ538719A
(en)
*
|
2002-09-13 |
2008-05-30 |
Replicor Inc |
Non-sequence complementary antiviral oligonucleotides
|
|
US20050196382A1
(en)
*
|
2002-09-13 |
2005-09-08 |
Replicor, Inc. |
Antiviral oligonucleotides targeting viral families
|
|
EP2444409A2
(fr)
|
2002-09-16 |
2012-04-25 |
Genentech, Inc. |
Compositions et procédés pour le traitement de maladies liées au système immunitaire
|
|
US6919426B2
(en)
|
2002-09-19 |
2005-07-19 |
Amgen Inc. |
Peptides and related molecules that modulate nerve growth factor activity
|
|
CA2499843A1
(fr)
|
2002-09-25 |
2004-04-08 |
Genentech, Inc. |
Nouvelles compositions et methodes de traitement du psoriasis
|
|
EP2272958A1
(fr)
|
2002-09-26 |
2011-01-12 |
ISIS Pharmaceuticals, Inc. |
Modulation de l'expression de la boîte Forkhead O1A
|
|
EP3321282A1
(fr)
|
2002-09-27 |
2018-05-16 |
Xencor, Inc. |
Variantes fc optimisées et leurs procédés de génération
|
|
US20040062748A1
(en)
*
|
2002-09-30 |
2004-04-01 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
|
|
US8129330B2
(en)
*
|
2002-09-30 |
2012-03-06 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
|
|
US7432351B1
(en)
|
2002-10-04 |
2008-10-07 |
Mayo Foundation For Medical Education And Research |
B7-H1 variants
|
|
US20060147450A1
(en)
*
|
2002-10-04 |
2006-07-06 |
Shelton David L |
Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
|
|
WO2005000194A2
(fr)
|
2002-10-08 |
2005-01-06 |
Rinat Neuroscience Corp. |
Procedes permettant de traiter des douleurs post-chirurgicales par administration d'un anticorps dirige contre le facteur de croissance neuronal, et compositions contenant cet anticorps
|
|
ES2357948T3
(es)
*
|
2002-10-08 |
2011-05-04 |
Rinat Neuroscience Corp. |
Procedimientos para tratar dolor postquirúrgico mediante la administración de un anticuerpo frente al factor de crecimiento nervioso y composiciones que contienen el mismo.
|
|
UA80447C2
(en)
|
2002-10-08 |
2007-09-25 |
|
Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
|
|
CA2501945A1
(fr)
*
|
2002-10-09 |
2004-04-22 |
Rinat Neuroscience Corp. |
Methodes de traitement de la maladie d'alzheimer au moyen d'anticorps diriges contre le peptide beta-amyloide et compositions les comprenant
|
|
JP2006515318A
(ja)
*
|
2002-10-29 |
2006-05-25 |
ファルマシア・コーポレーション |
特異的に発現する癌関連遺伝子、それによってコードされるポリペプチドおよびその使用方法
|
|
EP1576137A4
(fr)
|
2002-10-29 |
2010-06-30 |
Genentech Inc |
Compositions et methodes de traitement de maladies liees au systeme immunitaire
|
|
WO2004044139A2
(fr)
|
2002-11-05 |
2004-05-27 |
Isis Parmaceuticals, Inc. |
Oligonucleotides modifies utilises en interference d'arn
|
|
AU2003287505A1
(en)
|
2002-11-05 |
2004-06-03 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
|
EP2364716A3
(fr)
|
2002-11-08 |
2012-01-11 |
Genentech, Inc. |
Compositions et procédés pour le traitement des maladies liées aux cellules tueuses naturelles
|
|
US20040093198A1
(en)
*
|
2002-11-08 |
2004-05-13 |
Carbon Design Systems |
Hardware simulation with access restrictions
|
|
WO2004043396A2
(fr)
*
|
2002-11-09 |
2004-05-27 |
Nobex Corporation |
Promedicaments contenant du carbamate modifie et methodes de synthese de ces derniers
|
|
DK2336318T3
(da)
|
2002-11-13 |
2013-07-15 |
Genzyme Corp |
Antisense-modulering af apolipoprotein b-ekspression
|
|
WO2004044181A2
(fr)
|
2002-11-13 |
2004-05-27 |
Isis Pharmaceuticals, Inc. |
Modulation antisens de l'expression d'apolipoproteine b
|
|
US20050158375A1
(en)
*
|
2002-11-15 |
2005-07-21 |
Toshikiro Kimura |
Pharmaceutical composition containing liposomes for treating cancer
|
|
US7144999B2
(en)
|
2002-11-23 |
2006-12-05 |
Isis Pharmaceuticals, Inc. |
Modulation of hypoxia-inducible factor 1 alpha expression
|
|
EP1572116A4
(fr)
|
2002-11-26 |
2007-12-12 |
Genentech Inc |
Compositions et procedes destines au traitement de maladies de nature immune
|
|
US7648962B2
(en)
*
|
2002-11-26 |
2010-01-19 |
Biocon Limited |
Natriuretic compounds, conjugates, and uses thereof
|
|
ATE459370T1
(de)
|
2002-11-26 |
2010-03-15 |
Biocon Ltd |
Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen
|
|
US7491699B2
(en)
*
|
2002-12-09 |
2009-02-17 |
Ramot At Tel Aviv University Ltd. |
Peptide nanostructures and methods of generating and using the same
|
|
KR20050090987A
(ko)
*
|
2002-12-19 |
2005-09-14 |
알자 코포레이션 |
혈관신생 조직 성장 치료 방법
|
|
CA2511598C
(fr)
*
|
2002-12-24 |
2016-09-13 |
Rinat Neuroscience Corp. |
Anticorps anti-ngf et procedes d'utilisation de ces anticorps
|
|
US9498530B2
(en)
|
2002-12-24 |
2016-11-22 |
Rinat Neuroscience Corp. |
Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
|
|
US7569364B2
(en)
|
2002-12-24 |
2009-08-04 |
Pfizer Inc. |
Anti-NGF antibodies and methods using same
|
|
US8980310B2
(en)
*
|
2002-12-31 |
2015-03-17 |
Bharat Serums and Vaccines, Ltd. |
Non-pegylated long-circulating liposomes
|
|
AU2003303368B2
(en)
|
2002-12-31 |
2010-06-17 |
Zydus Bsv Pharma Private Limited |
Non-pegylated long-circulating liposomes
|
|
EP1583713B1
(fr)
*
|
2003-01-07 |
2009-03-25 |
Ramot at Tel Aviv University Ltd. |
Nanostructures de peptides encapsulant une matiere etrangere ainsi que procede de fabrication correspondant
|
|
US7169892B2
(en)
|
2003-01-10 |
2007-01-30 |
Astellas Pharma Inc. |
Lipid-peptide-polymer conjugates for long blood circulation and tumor specific drug delivery systems
|
|
WO2004063216A1
(fr)
*
|
2003-01-10 |
2004-07-29 |
Yamanouchi Pharmaceutical Co., Ltd. |
Conjugue de retention dans le sang et apport de medicament specifique de tissu cancereux
|
|
CA2515484C
(fr)
|
2003-02-11 |
2011-09-20 |
Antisense Therapeutics Ltd |
Modulation de l'expression du recepteur du facteur de croissance i analogue a l'insuline
|
|
PL379983A1
(pl)
|
2003-02-19 |
2006-11-27 |
Rinat Neuroscience Corp. |
Sposoby leczenia bólu polegające na podaniu antagonisty czynnika wzrostu nerwów i niesteroidowego leku przeciwzapalnego oraz zawierające je kompozycje
|
|
US7803781B2
(en)
|
2003-02-28 |
2010-09-28 |
Isis Pharmaceuticals, Inc. |
Modulation of growth hormone receptor expression and insulin-like growth factor expression
|
|
US7968115B2
(en)
|
2004-03-05 |
2011-06-28 |
Board Of Regents, The University Of Texas System |
Liposomal curcumin for treatment of cancer
|
|
US20040185559A1
(en)
|
2003-03-21 |
2004-09-23 |
Isis Pharmaceuticals Inc. |
Modulation of diacylglycerol acyltransferase 1 expression
|
|
WO2004087097A2
(fr)
*
|
2003-03-31 |
2004-10-14 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Ensembles de lipides contenant des amphiphiles de formation non liposomique
|
|
KR20060034215A
(ko)
|
2003-03-31 |
2006-04-21 |
알자 코포레이션 |
비대칭 지질 코팅을 가지는 지질 입자 및 그 제조 방법
|
|
HRP20050934B1
(hr)
|
2003-04-04 |
2014-09-26 |
Genentech, Inc. |
Formulacije s visokom koncentracijom antitijela i proteina
|
|
MXPA05010778A
(es)
|
2003-04-09 |
2005-12-12 |
Genentech Inc |
Terapia para enfermedad autoinmune en un paciente con una respuesta inadecuada a un inhibidor tnf-alfa.
|
|
CN1774281B
(zh)
*
|
2003-04-15 |
2010-10-13 |
奥珀百思控股公司 |
包含蛋白质和/或多肽以及胶体颗粒的药物组合物
|
|
WO2004094457A2
(fr)
*
|
2003-04-16 |
2004-11-04 |
Arizona Board Of Regents, Acting For And On Behalf Of, Arizona State University |
Composition peptidomimetique rgd stable
|
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
|
WO2004093788A2
(fr)
*
|
2003-04-17 |
2004-11-04 |
The Trustees Of Columbia University In The City Ofnew York |
Desmogleine 4, nouveau gene de la croissance des cheveux
|
|
US7399853B2
(en)
|
2003-04-28 |
2008-07-15 |
Isis Pharmaceuticals |
Modulation of glucagon receptor expression
|
|
ATE478093T1
(de)
|
2003-05-12 |
2010-09-15 |
Affymax Inc |
Neue poly(ethylenglycol) modifizierte erythropoietinagonisten und deren verwendungen
|
|
NZ543934A
(en)
|
2003-05-12 |
2008-06-30 |
Affymax Inc |
Novel spacer moiety for poly (ethylene glycol)-modified peptide-based compounds
|
|
RS20150135A1
(sr)
|
2003-05-30 |
2015-08-31 |
Genentech Inc. |
Tretman sa anti-vegf antitelima
|
|
WO2005000896A2
(fr)
*
|
2003-05-30 |
2005-01-06 |
Genentech, Inc. |
Polypeptides se liant a un anticorps anti-facteur tissulaire, et ses utilisations
|
|
AU2004253455B2
(en)
|
2003-06-03 |
2011-03-03 |
Eli Lilly And Company |
Modulation of survivin expression
|
|
ATE425463T1
(de)
|
2003-06-06 |
2009-03-15 |
Genentech Inc |
Modulation der wechselwirkung zwischen hgf-beta- kette und c-met
|
|
MXPA05013509A
(es)
|
2003-06-11 |
2006-04-05 |
Wyeth Corp |
Polipeptidos de fusion de variante ib alfa de glucoproteina de plaquetas y metodos y uso de los mismos.
|
|
US7939058B2
(en)
*
|
2003-07-03 |
2011-05-10 |
University Of Southern California |
Uses of IL-12 in hematopoiesis
|
|
WO2005007812A2
(fr)
|
2003-07-03 |
2005-01-27 |
University Of Medicine And Dentistry Of New Jersey |
Genes utiles en tant qu'outils de diagnostic pour l'autisme
|
|
MX341074B
(es)
|
2003-07-08 |
2016-08-05 |
Genentech Inc |
Polipeptidos heterologos il-17 a/f y usos terapeuticos de los mismos.
|
|
ES2559828T3
(es)
*
|
2003-07-16 |
2016-02-16 |
Protiva Biotherapeutics Inc. |
ARN de interferencia encapsulado en lípidos
|
|
CN100431525C
(zh)
*
|
2003-07-17 |
2008-11-12 |
台湾东洋药品工业股份有限公司 |
脂质体悬浮液制造方法及含该法所制脂质体悬浮液的产物
|
|
KR20090077984A
(ko)
*
|
2003-07-31 |
2009-07-16 |
더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 |
인지질과 소염성 약제의 멸균 제제
|
|
EP2530157B1
(fr)
|
2003-07-31 |
2016-09-28 |
Regulus Therapeutics Inc. |
Composés oligomères et compositions à utiliser dans la modulation de miARNs
|
|
WO2005019258A2
(fr)
|
2003-08-11 |
2005-03-03 |
Genentech, Inc. |
Compositions et methodes de traitement de maladies relatives au systeme immunitaire
|
|
US20050054614A1
(en)
*
|
2003-08-14 |
2005-03-10 |
Diacovo Thomas G. |
Methods of inhibiting leukocyte accumulation
|
|
US20050043239A1
(en)
*
|
2003-08-14 |
2005-02-24 |
Jason Douangpanya |
Methods of inhibiting immune responses stimulated by an endogenous factor
|
|
US7825235B2
(en)
|
2003-08-18 |
2010-11-02 |
Isis Pharmaceuticals, Inc. |
Modulation of diacylglycerol acyltransferase 2 expression
|
|
US8986731B2
(en)
*
|
2003-08-26 |
2015-03-24 |
Biolitec Pharma Marketing Ltd |
Pegylated liposomal formulations of hydrophobic photosensitizers for photodynamic therapy
|
|
ATE422880T1
(de)
*
|
2003-08-26 |
2009-03-15 |
Smithkline Beecham Corp |
Heterofunktionelle copolymere von glycerol und polyethylenglykol, ihre konjugate und zusammensetzungen
|
|
US8846079B1
(en)
|
2004-12-01 |
2014-09-30 |
Vgsk Technologies, Inc. |
Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal
|
|
US11324698B2
(en)
|
2003-08-28 |
2022-05-10 |
Vgsk Technologies, Inc. |
Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal
|
|
US20060115523A1
(en)
*
|
2004-12-01 |
2006-06-01 |
Konduri Kameswari S |
Sterically stabilized liposome and triamcinolone composition for treating the respiratory tract of a mammal
|
|
CN1867580B
(zh)
*
|
2003-09-03 |
2010-09-29 |
协和发酵麒麟株式会社 |
被甘油衍生物修饰的化合物
|
|
US20050233435A1
(en)
*
|
2003-09-04 |
2005-10-20 |
Nyu Medical Center |
Plasmodium axenic liver stages as a noninfectious whole organism malaria vaccine
|
|
US20070123480A1
(en)
*
|
2003-09-11 |
2007-05-31 |
Replicor Inc. |
Oligonucleotides targeting prion diseases
|
|
NZ581166A
(en)
*
|
2003-09-15 |
2011-06-30 |
Protiva Biotherapeutics Inc |
Polyethyleneglycol-modified lipid compounds and uses thereof
|
|
EA009670B1
(ru)
|
2003-09-18 |
2008-02-28 |
Ай Эс Ай Эс ФАРМАСЬЮТИКАЛЗ, ИНК. |
МОДУЛИРОВАНИЕ ЭКСПРЕССИИ eIF4E
|
|
CA2540407A1
(fr)
*
|
2003-09-25 |
2005-03-31 |
Tel Aviv University Future Technology Development L.P. |
Compositions et methodes d'utilisation de ces compositions pour le traitement des maladies associees a la substance amyloide
|
|
US8101720B2
(en)
*
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
|
WO2005031362A2
(fr)
*
|
2003-10-02 |
2005-04-07 |
Ramot At Tel Aviv University Ltd. |
Nouveaux agents antibacteriens et procedes permettant de les identifier et de les utiliser
|
|
WO2005035548A1
(fr)
|
2003-10-10 |
2005-04-21 |
Meditech Research Limited |
Modulation de synthese et de degradation d'hyaluronan dans le traitement de maladie
|
|
WO2005034979A2
(fr)
*
|
2003-10-11 |
2005-04-21 |
Inex Pharmaceuticals Corporation |
Procedes et compositions permettant de renforcer l'immunite innee et la cytotoxicite cellulaire dependant des anticorps
|
|
TW200517114A
(en)
|
2003-10-15 |
2005-06-01 |
Combinatorx Inc |
Methods and reagents for the treatment of immunoinflammatory disorders
|
|
CA2542804A1
(fr)
*
|
2003-10-24 |
2005-05-06 |
Alza Corporation |
Preparation de particules lipidiques
|
|
WO2005041870A2
(fr)
*
|
2003-10-24 |
2005-05-12 |
Ader Enterprises, Inc. |
Composition et procede pour le traitement d'une maladie de l'oeil
|
|
WO2005040163A1
(fr)
*
|
2003-10-28 |
2005-05-06 |
Dr. Reddy's Laboratories Ltd |
Composes heterocycliques bloquant les effets des produits terminaux avances de glycation
|
|
US20050191653A1
(en)
|
2003-11-03 |
2005-09-01 |
Freier Susan M. |
Modulation of SGLT2 expression
|
|
ATE434431T1
(de)
*
|
2003-11-14 |
2009-07-15 |
Het Nl Kanker I The Netherland |
Pharmazeutische formulierungen mit kurzketten- sphingolipiden und ihre verwendung
|
|
US20050129753A1
(en)
*
|
2003-11-14 |
2005-06-16 |
Gabizon Alberto A. |
Method for drug loading in liposomes
|
|
DE602004024921D1
(de)
|
2003-11-17 |
2010-02-11 |
Genentech Inc |
Zusammensetzungen und verfahren zur behandlung von tumoren hämatopoetischen ursprungs
|
|
CN1914226B
(zh)
*
|
2003-11-25 |
2012-02-01 |
达纳-法伯癌症研究院有限公司 |
SARS-CoV抗体及其使用方法
|
|
EP1701979A2
(fr)
*
|
2003-12-03 |
2006-09-20 |
Xencor, Inc. |
Proteines optimisees qui ciblent le recepteur du facteur de croissance epidermique
|
|
US7312320B2
(en)
|
2003-12-10 |
2007-12-25 |
Novimmune Sa |
Neutralizing antibodies and methods of use thereof
|
|
US9050378B2
(en)
*
|
2003-12-10 |
2015-06-09 |
Board Of Regents, The University Of Texas System |
N2S2 chelate-targeting ligand conjugates
|
|
CA2548282A1
(fr)
|
2003-12-11 |
2005-06-30 |
Genentech, Inc. |
Methodes et compositions pour inhiber une dimerisation et une activation de c-met
|
|
WO2005062955A2
(fr)
*
|
2003-12-23 |
2005-07-14 |
Rinat Neuroscience Corp. |
Anticorps anti-trkc agonistes et procedes d'utilisation
|
|
EP2311873B1
(fr)
|
2004-01-07 |
2018-08-29 |
Novartis Vaccines and Diagnostics, Inc. |
Anticorps monoclonal spécifique de m-csf et ses utilisations
|
|
EP1706149A2
(fr)
*
|
2004-01-15 |
2006-10-04 |
Alza Corporation |
Composition de liposomes pour l'administration d'agents therapeutiques
|
|
WO2005071080A2
(fr)
|
2004-01-20 |
2005-08-04 |
Isis Pharmaceuticals, Inc. |
Modulation de l'expression du récepteur glucocorticoïde
|
|
US7468431B2
(en)
|
2004-01-22 |
2008-12-23 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E-BP2 expression
|
|
US20050181035A1
(en)
*
|
2004-02-17 |
2005-08-18 |
Dow Steven W. |
Systemic immune activation method using non CpG nucleic acids
|
|
AU2005227870A1
(en)
*
|
2004-02-17 |
2005-10-13 |
University Of South Florida |
Materials and methods for treatment of inflammatory and cell proliferation disorders
|
|
DE602005018325D1
(de)
|
2004-02-19 |
2010-01-28 |
Genentech Inc |
Antikörper mit korrigierten cdr
|
|
US8784881B2
(en)
|
2004-03-05 |
2014-07-22 |
Board Of Regents, The University Of Texas System |
Liposomal curcumin for treatment of diseases
|
|
US8569474B2
(en)
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
|
EP2365077B1
(fr)
*
|
2004-03-12 |
2013-05-08 |
Alnylam Pharmaceuticals, Inc. |
Agents ARNi ciblant le facteur de croissance de l'endothélium vasculaire (VEGF)
|
|
EP1579850A3
(fr)
*
|
2004-03-15 |
2009-12-16 |
Nipro Corporation |
Préparation pharmaceutique contenant des liposomes pour le traitement du cancer
|
|
EP1730309B1
(fr)
|
2004-03-15 |
2016-05-04 |
Ionis Pharmaceuticals, Inc. |
Compositions et methodes pour optimiser le clivage d'arn par rnase h
|
|
EP1729786A4
(fr)
*
|
2004-03-18 |
2008-03-26 |
Transave Inc |
Administration de cisplatine par inhalation
|
|
US20070065522A1
(en)
*
|
2004-03-18 |
2007-03-22 |
Transave, Inc. |
Administration of high potency platinum compound formulations by inhalation
|
|
US8241663B2
(en)
*
|
2004-03-26 |
2012-08-14 |
Terumo Kabushiki Kaisha |
Liposome preparation
|
|
ES2707393T3
(es)
*
|
2004-03-26 |
2019-04-03 |
Curis Inc |
Moduladores de interferencia de ARN de señalización de hedgehog y usos de los mismos
|
|
US20050244869A1
(en)
*
|
2004-04-05 |
2005-11-03 |
Brown-Driver Vickie L |
Modulation of transthyretin expression
|
|
DK2206728T3
(en)
|
2004-04-07 |
2018-04-23 |
Rinat Neuroscience Corp |
METHODS OF TREATING BONE CANCER PAIN BY SUBMITTING A NERVOUS FACTOR-ANTAGONISTIC ANTIBODY
|
|
US7794713B2
(en)
|
2004-04-07 |
2010-09-14 |
Lpath, Inc. |
Compositions and methods for the treatment and prevention of hyperproliferative diseases
|
|
EP1742660A2
(fr)
*
|
2004-04-16 |
2007-01-17 |
Genentech, Inc. |
Traitement de troubles
|
|
US20150017671A1
(en)
|
2004-04-16 |
2015-01-15 |
Yaping Shou |
Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
|
|
CA2821167C
(fr)
*
|
2004-05-03 |
2016-06-28 |
Merrimack Pharmaceuticals, Inc. |
Liposomes pour l'administration de drogues contenant des polyols anioniques ou des sucres anioniques
|
|
US8658203B2
(en)
|
2004-05-03 |
2014-02-25 |
Merrimack Pharmaceuticals, Inc. |
Liposomes useful for drug delivery to the brain
|
|
HRP20161751T1
(hr)
|
2004-05-13 |
2017-04-07 |
Icos Corporation |
Kinazolinoni kao inhibitori humane fosfatidilinozitol 3-kinaze delta
|
|
EP1750673B1
(fr)
*
|
2004-05-17 |
2009-12-02 |
Tekmira Pharmaceuticals Corporation |
Formulations liposomales comprenant de la dihydrosphingomyéline, et procedés d'utilisation correspondants
|
|
WO2005118647A2
(fr)
*
|
2004-05-18 |
2005-12-15 |
Genentech, Inc. |
Principaux variants de proteines de coque pour affichage c-terminal et bi-terminal
|
|
US20050260260A1
(en)
*
|
2004-05-19 |
2005-11-24 |
Edward Kisak |
Liposome compositions for the delivery of macromolecules
|
|
AU2005245018A1
(en)
*
|
2004-05-21 |
2005-12-01 |
Transave, Inc. |
Treatment of lung diseases and pre-lung disease conditions
|
|
EP1749000A4
(fr)
*
|
2004-05-25 |
2009-12-30 |
Metabolex Inc |
Triazoles substitués bicyliques comme modulateurs de ppar et méthodes de préparation
|
|
JP2008500338A
(ja)
*
|
2004-05-25 |
2008-01-10 |
イコス・コーポレイション |
造血細胞の異常増殖を治療及び/又は予防する方法
|
|
CN1997633A
(zh)
*
|
2004-05-25 |
2007-07-11 |
麦它波莱克斯股份有限公司 |
作为ppar调节剂的取代的三唑及其制备方法
|
|
JP5266492B2
(ja)
*
|
2004-05-28 |
2013-08-21 |
ヒューマン バイオモレキュラル リサーチ インスティテュート |
代謝安定性鎮痛薬、疼痛薬物療法及び他の物質の合成
|
|
US20090048192A1
(en)
*
|
2004-06-03 |
2009-02-19 |
Isis Pharmaceuticals, Inc. |
Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
|
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
|
EP1766052A4
(fr)
*
|
2004-06-03 |
2009-12-16 |
Isis Pharmaceuticals Inc |
Compositions chimeriques oligomeres a breche
|
|
WO2005121372A2
(fr)
*
|
2004-06-03 |
2005-12-22 |
Isis Pharmaceuticals, Inc. |
Compositions a double brin comprenant des brins differentiellement modifies utilises dans la modulation genetique
|
|
AU2005249566B2
(en)
|
2004-06-04 |
2010-11-11 |
Genentech, Inc. |
Method for treating multiple sclerosis
|
|
US7745651B2
(en)
|
2004-06-07 |
2010-06-29 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods of use
|
|
WO2005121348A1
(fr)
*
|
2004-06-07 |
2005-12-22 |
Protiva Biotherapeutics, Inc. |
Arn interferant encapsule dans des lipides
|
|
CA2579756C
(fr)
*
|
2004-06-19 |
2013-04-30 |
Human Biomolecular Research Institute |
Modulateurs de neurotransmetteurs du systeme nerveux central
|
|
CA2571243A1
(fr)
|
2004-06-21 |
2006-01-05 |
The Board Of Trustees Of The Leland Stanford Junior University |
Genes et voies exprimes de maniere differentielle dans des troubles bipolaires et/ou troubles depressifs majeurs
|
|
AU2005259799A1
(en)
|
2004-07-02 |
2006-01-12 |
Protiva Biotherapeutics, Inc. |
Immunostimulatory siRNA molecules and uses therefor
|
|
US20060019893A1
(en)
*
|
2004-07-02 |
2006-01-26 |
Genentech, Inc. |
Factor VIIa variants
|
|
JP2008505928A
(ja)
*
|
2004-07-08 |
2008-02-28 |
アムジェン インコーポレーテッド |
治療用ペプチド
|
|
US20090156471A1
(en)
*
|
2004-07-15 |
2009-06-18 |
Ramot At Tel Aviv University Ltd. |
Use of anti-amyloid agents for treating and typing pathogen infections
|
|
DK2471813T3
(en)
|
2004-07-15 |
2015-03-02 |
Xencor Inc |
Optimized Fc variants
|
|
WO2006007712A1
(fr)
*
|
2004-07-19 |
2006-01-26 |
Protiva Biotherapeutics, Inc. |
Methodes permettant de distribuer des agents therapeutiques comprenant des conjugues de lipide-polyethylene glycol
|
|
CN103223160B
(zh)
*
|
2004-07-19 |
2015-02-18 |
比奥孔有限公司 |
胰岛素-低聚物共轭物,制剂及其用途
|
|
SI1771474T1
(sl)
|
2004-07-20 |
2010-06-30 |
Genentech Inc |
Inhibitorji angiopoetinu podobnega proteina kombinacije in njihova uporaba
|
|
MX2007001064A
(es)
|
2004-07-26 |
2007-04-12 |
Genentech Inc |
Metodos y composiciones para modular la activacion del factor de crecimiento de hepatocitos.
|
|
CA2575663C
(fr)
*
|
2004-07-30 |
2013-04-23 |
Rinat Neuroscience Corp. |
Anticorps anti peptide amyloide beta, et leurs procedes d'utilisation
|
|
US9132116B2
(en)
*
|
2004-08-02 |
2015-09-15 |
Willowcroft Pharm Inc. |
Mast cell stabilizers to prevent or treat laminitis
|
|
EP1781310B1
(fr)
|
2004-08-02 |
2015-10-14 |
Ramot at Tel Aviv University Ltd. |
Articles de nanostructures a base de peptides et leur procede de formation
|
|
ES2356748T3
(es)
|
2004-08-17 |
2011-04-12 |
Tyco Healthcare Group Lp |
Barrera anti-adhesión.
|
|
JP2006056807A
(ja)
*
|
2004-08-18 |
2006-03-02 |
Konica Minolta Medical & Graphic Inc |
光線力学療法製剤
|
|
ATE539745T1
(de)
|
2004-08-19 |
2012-01-15 |
Univ Tel Aviv Future Tech Dev |
Zusammensetzungen zur behandlung von amyloid- assoziierten erkrankungen
|
|
JP4715133B2
(ja)
*
|
2004-08-26 |
2011-07-06 |
コニカミノルタエムジー株式会社 |
抗腫瘍リポソーム製剤およびその製造方法
|
|
JP2006069929A
(ja)
*
|
2004-08-31 |
2006-03-16 |
Konica Minolta Medical & Graphic Inc |
真菌症治療製剤およびその製造方法
|
|
US7786086B2
(en)
*
|
2004-09-08 |
2010-08-31 |
Ramot At Tel-Aviv University Ltd. |
Peptide nanostructures containing end-capping modified peptides and methods of generating and using the same
|
|
US7884086B2
(en)
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
|
WO2006027787A1
(fr)
*
|
2004-09-09 |
2006-03-16 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Compositions liposomales a base de glucocorticoides et de derives de glucocorticoides
|
|
EP1793805A1
(fr)
*
|
2004-09-09 |
2007-06-13 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Formules liposomales comprenant une base faible amphipathique telle que la tempamine pour le traitement des affections neurodegeneratives
|
|
US6998028B1
(en)
*
|
2004-09-24 |
2006-02-14 |
Superpower, Inc. |
Methods for forming superconducting conductors
|
|
DK1797127T3
(en)
|
2004-09-24 |
2017-10-02 |
Amgen Inc |
Modified Fc molecules
|
|
CA2581896C
(fr)
|
2004-09-29 |
2015-11-10 |
Mount Sinai School Of Medicine Of New York University |
Compositions et methodes modulant la fsh et le recepteur de la fsh, inhibant la resorption osseuse osteoclastique et les pertes osseuses de l'osteoporose
|
|
ATE514776T1
(de)
|
2004-10-05 |
2011-07-15 |
California Inst Of Techn |
Aptamer-regulierte nukleinsäuren und verwendungen davon
|
|
ZA200702335B
(en)
|
2004-10-05 |
2009-05-27 |
Genentech Inc |
Method for treating vasculitis
|
|
HUE039237T2
(hu)
|
2004-10-06 |
2018-12-28 |
Mayo Found Medical Education & Res |
B7-H1 és PD-1 vesesejt karcinoma kezelésében
|
|
TW200612993A
(en)
*
|
2004-10-08 |
2006-05-01 |
Alza Corp |
Lipopolymer conjugates
|
|
CA2582242A1
(fr)
*
|
2004-10-08 |
2006-04-20 |
Alza Corporation |
Procede d'insertion d'un fragment associe aux lipides dans un ensemble lipidique preforme en utilisant des micro-ondes
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
KR101287918B1
(ko)
*
|
2004-10-26 |
2013-07-19 |
오르토 바이오테크 프로덕츠 엘.피. |
엑티나시딘 743과 조합된 페길화된 리포좀 독소루비신
|
|
CA2584583A1
(fr)
*
|
2004-10-28 |
2006-05-11 |
Alza Corporation |
Formulations de liposomes lyophilises et methode associee
|
|
NZ554761A
(en)
|
2004-10-29 |
2010-01-29 |
Pharma Mar Sa |
Formulations comprising ecteinascidin and a disaccharide
|
|
TW200618820A
(en)
*
|
2004-11-05 |
2006-06-16 |
Alza Corp |
Liposome formulations of boronic acid compounds
|
|
US20090285878A1
(en)
|
2004-11-05 |
2009-11-19 |
Tekmira Pharmaceuticals Corporation |
Compositions and methods for stabilizing liposomal drug formulations
|
|
EP1811963A4
(fr)
*
|
2004-11-08 |
2010-01-06 |
Transave Inc |
Methodes de traitement du cancer avec des formulations de composes de platine a base lipipique administrees par voie intraperitoneale
|
|
WO2006060148A2
(fr)
*
|
2004-11-11 |
2006-06-08 |
Affymax, Inc. |
Nouveaux peptides qui se lient au recepteur d'erythropoietine
|
|
AU2005303389A1
(en)
*
|
2004-11-15 |
2006-05-18 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Combination therapy associating preferably a ceramide with a cytotoxic drug
|
|
EP1828219A4
(fr)
*
|
2004-11-17 |
2008-07-23 |
Protiva Biotherapeutics Inc |
Silence arnsi de l'apolipoproteine b
|
|
JP5110880B2
(ja)
*
|
2004-11-18 |
2012-12-26 |
テルモ株式会社 |
医薬組成物、製剤および組み合わせ製剤
|
|
CA2590768A1
(fr)
*
|
2004-12-14 |
2006-06-22 |
Alnylam Pharmaceuticals, Inc. |
Modulation et utilisations de l'arni de mll-af4
|
|
DK1841793T3
(da)
|
2005-01-07 |
2010-07-19 |
Diadexus Inc |
Ovr110-antistofsammensætninger og fremgangsmåder til anvendelse deraf
|
|
US20080207505A1
(en)
*
|
2005-01-12 |
2008-08-28 |
James Kenneth D |
Bna Conjugates and Methods of Use
|
|
CN102580084B
(zh)
|
2005-01-21 |
2016-11-23 |
健泰科生物技术公司 |
Her抗体的固定剂量给药
|
|
US9937127B2
(en)
*
|
2005-01-28 |
2018-04-10 |
Kyowa Hakko Kirin Co., Ltd. |
Method of producing fine particles surface-modified with water-soluble substance
|
|
EP2042186A1
(fr)
|
2005-01-31 |
2009-04-01 |
Vaxinnate Corporation |
Nouveaux polypeptides se fixant au récepteur 2 (TLR2) de type Toll
|
|
US8029783B2
(en)
|
2005-02-02 |
2011-10-04 |
Genentech, Inc. |
DR5 antibodies and articles of manufacture containing same
|
|
ES2852549T3
(es)
|
2005-02-09 |
2021-09-13 |
Sarepta Therapeutics Inc |
Composición antisentido para tratamiento de la atrofia muscular
|
|
KR101289537B1
(ko)
|
2005-02-15 |
2013-07-31 |
듀크 유니버시티 |
항-cd19 항체 및 종양학에서 이의 용도
|
|
CA2598409A1
(fr)
*
|
2005-02-17 |
2006-08-24 |
Icos Corporation |
Procede d'inhibition d'accumulation de leucocytes
|
|
WO2006089141A2
(fr)
|
2005-02-18 |
2006-08-24 |
Dana-Farber Cancer Institute |
Anticorps contre cxcr4 et leurs procédés d'utilisation
|
|
CN103027893B
(zh)
*
|
2005-02-18 |
2014-11-12 |
国立大学法人德岛大学 |
含聚氧化烯链的脂质衍生物及含有该衍生物的脂质膜结构体
|
|
MX2007009889A
(es)
|
2005-02-23 |
2007-09-07 |
Genentech Inc |
Alargar el tiempo hasta la progresion de la enfermedad o la supervivencia de los pacientes de cancer.
|
|
TW200714289A
(en)
*
|
2005-02-28 |
2007-04-16 |
Genentech Inc |
Treatment of bone disorders
|
|
TW200642695A
(en)
*
|
2005-03-08 |
2006-12-16 |
Genentech Inc |
Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs)
|
|
RU2007137489A
(ru)
|
2005-03-10 |
2009-04-20 |
Дженентек, Инк. (Us) |
Способы и композиции для модуляции целостности сосудов
|
|
JP2006248978A
(ja)
*
|
2005-03-10 |
2006-09-21 |
Mebiopharm Co Ltd |
新規なリポソーム製剤
|
|
EP1861072A2
(fr)
*
|
2005-03-14 |
2007-12-05 |
Massachusetts Institute Of Technology |
Nanocellules pour le diagnostic et le traitement de maladies et troubles
|
|
EP1865954A4
(fr)
|
2005-03-21 |
2010-12-15 |
Metabolex Inc |
Methodes pour eviter un oedeme dans le traitement ou la prevention de maladies sensibles a ppar gamma, telles que le cancer
|
|
CN1840193B
(zh)
*
|
2005-03-29 |
2010-05-12 |
中国科学院生物物理研究所 |
聚乙二醇化磷脂包载的蒽环类抗肿瘤抗生素的纳米胶束制剂
|
|
JP2008537551A
(ja)
|
2005-03-31 |
2008-09-18 |
カランド ファーマシューティカルズ, インコーポレイテッド |
リボヌクレオチドレダクターゼサブユニット2の阻害剤およびその使用
|
|
UY29504A1
(es)
*
|
2005-04-29 |
2006-10-31 |
Rinat Neuroscience Corp |
Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
|
|
EP1885755A4
(fr)
|
2005-05-05 |
2009-07-29 |
Univ Duke |
Traitements des maladies auto-immunes par anticorps anti-cd19
|
|
US7531637B2
(en)
|
2005-05-06 |
2009-05-12 |
Zymogenetics, Inc. |
IL-31 monoclonal antibodies
|
|
EP1899364B2
(fr)
|
2005-05-17 |
2024-10-30 |
University of Connecticut |
Compositions et methodes d'immunomodulation d'un organisme
|
|
US7550433B2
(en)
|
2005-06-03 |
2009-06-23 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
|
US7919461B2
(en)
*
|
2005-06-03 |
2011-04-05 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
|
US8324159B2
(en)
*
|
2005-06-03 |
2012-12-04 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
|
AU2006255686A1
(en)
|
2005-06-06 |
2006-12-14 |
Genentech, Inc. |
Transgenic models for different genes and their use for gene characterization
|
|
US20070014845A1
(en)
*
|
2005-07-01 |
2007-01-18 |
Yuanpeng Zhang |
Liposomal delivery vehicle for hydrophobic drugs
|
|
WO2007008943A2
(fr)
|
2005-07-08 |
2007-01-18 |
Xencor, Inc. |
Proteines optimisees qui ciblent la molecule ep-cam
|
|
BRPI0613770A2
(pt)
|
2005-07-22 |
2009-05-19 |
Y S Therapeutics Co Ltd |
anticorpos anti-cd26 e métodos de uso destes
|
|
EP2311876A3
(fr)
*
|
2005-07-28 |
2011-04-27 |
Novartis AG |
Anticorps monoclonal spécifique du M-CSF et ses utilisations
|
|
WO2007016240A2
(fr)
*
|
2005-07-28 |
2007-02-08 |
Novartis Ag |
Utilisation d'anticorps anti-m-csf
|
|
US8998881B2
(en)
|
2005-08-10 |
2015-04-07 |
Alza Corporation |
Method for delivering drugs to tissue under microjet propulsion
|
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
|
EP1922410A2
(fr)
|
2005-08-15 |
2008-05-21 |
Genentech, Inc. |
Disruptions et compositions géniques et procédés associés
|
|
US20070054873A1
(en)
*
|
2005-08-26 |
2007-03-08 |
Protiva Biotherapeutics, Inc. |
Glucocorticoid modulation of nucleic acid-mediated immune stimulation
|
|
US7700567B2
(en)
|
2005-09-29 |
2010-04-20 |
Supergen, Inc. |
Oligonucleotide analogues incorporating 5-aza-cytosine therein
|
|
US10004828B2
(en)
*
|
2005-10-11 |
2018-06-26 |
Romat at Tel-Aviv University Ltd. |
Self-assembled Fmoc-ff hydrogels
|
|
TW200732350A
(en)
*
|
2005-10-21 |
2007-09-01 |
Amgen Inc |
Methods for generating monovalent IgG
|
|
US7875602B2
(en)
*
|
2005-10-21 |
2011-01-25 |
Sutter West Bay Hospitals |
Camptothecin derivatives as chemoradiosensitizing agents
|
|
DK2481756T3
(en)
|
2005-10-31 |
2017-10-09 |
Oncomed Pharm Inc |
Compositions and Methods for Diagnosing and Treating Cancer
|
|
GB0522082D0
(en)
|
2005-10-31 |
2005-12-07 |
Pharma Mar Sa |
Formulations
|
|
US20070197460A1
(en)
|
2005-11-01 |
2007-08-23 |
Alnylam Pharmaceuticals, Inc. |
Rnai inhibition of influenza virus replication
|
|
CN101346393B
(zh)
*
|
2005-11-02 |
2015-07-22 |
普洛体维生物治疗公司 |
修饰的siRNA分子及其应用
|
|
US7879212B2
(en)
*
|
2005-11-03 |
2011-02-01 |
Ramot At Tel-Aviv University Ltd. |
Peptide nanostructure-coated electrodes
|
|
DE102005053066A1
(de)
|
2005-11-04 |
2007-05-10 |
Basf Ag |
Verwendung von Copolymeren als Solubilisatoren für in Wasser schwerlöslichen Verbindungen
|
|
US20070190180A1
(en)
*
|
2005-11-08 |
2007-08-16 |
Pilkiewicz Frank G |
Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
|
|
US20070190181A1
(en)
*
|
2005-11-08 |
2007-08-16 |
Pilkiewicz Frank G |
Methods of treating cancer with lipid-based platinum compound forumulations administered intravenously
|
|
US9107824B2
(en)
|
2005-11-08 |
2015-08-18 |
Insmed Incorporated |
Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
|
|
WO2007056264A2
(fr)
*
|
2005-11-08 |
2007-05-18 |
Transave, Inc. |
Methodes de traitement anticancereux avec des formulations d'un compose de platine a base de lipides d'une haute activite administrees par voie intraperitoneale
|
|
US20090019557A1
(en)
|
2005-11-12 |
2009-01-15 |
Huda Akil |
Fgf2-related methods for diagnosing and treating depression
|
|
WO2007054809A2
(fr)
|
2005-11-14 |
2007-05-18 |
Rinat Neuroscience Corp. |
Anticorps antagonistes orientes contre un peptide lie au gene de la calcitonine, et procedes d'utilisation correspondants
|
|
TW200736277A
(en)
|
2005-11-14 |
2007-10-01 |
Amgen Inc |
RANKL antibody-PTH/PTHrP chimeric molecules
|
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
|
AP2809A
(en)
|
2005-11-18 |
2013-12-31 |
Glenmark Pharmaceuticals Sa |
Anti-Alpha2 Integrin antibodies and their uses
|
|
WO2007062380A2
(fr)
|
2005-11-21 |
2007-05-31 |
Isis Pharmaceuticals, Inc. |
MODULATION DE L'EXPRESSION D’eIF4E-BP2
|
|
JP2009516514A
(ja)
|
2005-11-21 |
2009-04-23 |
ジェネンテック・インコーポレーテッド |
新規遺伝子破壊、それらに関する組成物および方法
|
|
WO2007064658A2
(fr)
*
|
2005-11-30 |
2007-06-07 |
Transave, Inc. |
Procedes efficaces et sans risques d'administation d'agents therapeutiques
|
|
US8466263B2
(en)
*
|
2005-12-02 |
2013-06-18 |
Dana-Farber Cancer Institute, Inc. |
Carbonic anhydrase IX (G250) anitbodies
|
|
EP1954719A2
(fr)
|
2005-12-02 |
2008-08-13 |
Genentech Inc. |
Compositions et methodes de traitement de maladies et troubles associes e la signalisation de la cytokine
|
|
EP1962796A2
(fr)
*
|
2005-12-08 |
2008-09-03 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Procedes permettant d agir par rayonnements ultrasonores sur des compositions de liposomes
|
|
JP2009523119A
(ja)
*
|
2005-12-09 |
2009-06-18 |
ビーエーエスエフ ソシエタス・ヨーロピア |
水に溶けにくい化合物のための可溶化剤としてのポリビニルラクタム−ポリオキシアルキレンブロックコポリマーの使用
|
|
US9149543B2
(en)
|
2005-12-15 |
2015-10-06 |
The Trustees Of The University Of Pennsylvania |
Methods and models for rapid, widespread delivery of genetic material to the CNS using non-viral, cationic lipid-mediated vectors
|
|
WO2007082144A2
(fr)
*
|
2006-01-05 |
2007-07-19 |
Mayo Foundation For Medical Education And Research |
Methode permettant de detecter un cancer a l'aide de b7-h1 et de survivine
|
|
KR20080083187A
(ko)
|
2006-01-05 |
2008-09-16 |
노바르티스아게 |
암 전이 및 암 전이와 관련된 골 소실의 예방 및 치료 방법
|
|
US20090215084A1
(en)
*
|
2006-01-05 |
2009-08-27 |
Mayo Foundation For Medical Education And Research |
B7-h1 and b7-h4 in cancer
|
|
WO2007089611A2
(fr)
|
2006-01-26 |
2007-08-09 |
Isis Pharmaceuticals Inc. |
Compositions et leurs utilisations dirigées contre la huntingtine
|
|
JP5199886B2
(ja)
*
|
2006-01-26 |
2013-05-15 |
レコファーマ アーベー |
ウイルスの接着を阻害するための組成物および方法
|
|
US7829097B2
(en)
*
|
2006-02-06 |
2010-11-09 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Use of HMGB1 for protection against ischemia reperfusion injury
|
|
EP1988768A2
(fr)
|
2006-02-17 |
2008-11-12 |
Genentech, Inc. |
Nouvelles disruption géniques, compositions et procédés associés
|
|
EP2540741A1
(fr)
|
2006-03-06 |
2013-01-02 |
Aeres Biomedical Limited |
Anticorps humanisés anti CD22 et leur utilisation dans le traitement de l'oncologie, la transplantation et les maladies auto-immunes
|
|
US20070218116A1
(en)
*
|
2006-03-14 |
2007-09-20 |
Schwendener Reto A |
Compositions and methods for the treatment of tumors and tumor metastases
|
|
US9119782B2
(en)
*
|
2006-03-20 |
2015-09-01 |
Mary P. McCourt |
Drug delivery means
|
|
EP1989231B1
(fr)
|
2006-03-21 |
2015-05-20 |
Genentech, Inc. |
Thérapie combinatoire engageant des antagonistes alpha5beta1
|
|
WO2007109376A2
(fr)
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Thérapeutique anticorps antigène de cellules anti-tumorales
|
|
EA014886B1
(ru)
|
2006-03-31 |
2011-02-28 |
Элнилэм Фармасьютикалз, Инк. |
КОМПОЗИЦИИ И СПОСОБЫ ИНГИБИРОВАНИЯ ЭКСПРЕССИИ ГЕНА Eg5
|
|
CA2647277A1
(fr)
|
2006-04-05 |
2007-11-08 |
Genentech, Inc. |
Methode d'utilisation du boc/cdo pour moduler l'emission des signaux du hedgehog
|
|
EP2082645A1
(fr)
|
2006-04-19 |
2009-07-29 |
Genentech, Inc. |
Nouvelle dislocation de gènes, compositions et procédés correspondants
|
|
US8758723B2
(en)
|
2006-04-19 |
2014-06-24 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods for cellular imaging and therapy
|
|
WO2007124361A2
(fr)
*
|
2006-04-20 |
2007-11-01 |
Mayo Foundation For Medical Education And Research |
B7-h1 soluble
|
|
EP2636743A1
(fr)
|
2006-04-21 |
2013-09-11 |
Intervet International B.V. |
Espèces de pestivirus
|
|
US7691824B2
(en)
|
2006-04-28 |
2010-04-06 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a gene from the JC virus
|
|
US8298818B2
(en)
*
|
2006-04-28 |
2012-10-30 |
University Of Florida Research Foundation, Inc. |
Self-complementary adeno-associated virus having a truncated CMV-chicken β-actin promoter
|
|
US8697120B2
(en)
*
|
2006-05-01 |
2014-04-15 |
Johns Hopkins University |
Method and use of nano-scale devices for reduction of tissue injury in ischemic and reperfusion injury
|
|
EP2013344B1
(fr)
*
|
2006-05-03 |
2012-08-29 |
Baltic Technology Development, Ltd. |
Agents antisens combinant un oligonucléotide modifié par une base fortement liée et une nucléase artificielle
|
|
WO2007133627A2
(fr)
*
|
2006-05-10 |
2007-11-22 |
Alza Corporation |
Procédé de fabrication de conjugués de liposomes avec des ligands sensibles à la température
|
|
JP5282031B2
(ja)
*
|
2006-05-15 |
2013-09-04 |
ドミトリィ ビー カーポティン |
有機物を含む磁性微粒子
|
|
US20080014205A1
(en)
|
2006-05-15 |
2008-01-17 |
Lawrence Horowitz |
Neutralizing Antibodies to Influenza Viruses
|
|
AU2007253803B2
(en)
|
2006-05-19 |
2012-05-24 |
Alnylam Pharmaceuticals, Inc. |
RNAi modulation of Aha and therapeutic uses thereof
|
|
WO2007137163A2
(fr)
*
|
2006-05-19 |
2007-11-29 |
Georgia Tech Research Corporation |
Ligand des transporteurs abc
|
|
CA2653451C
(fr)
|
2006-05-22 |
2015-12-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions et methodes inhibant l'expression du gene ikk-b
|
|
US20090209625A1
(en)
*
|
2006-05-23 |
2009-08-20 |
Sanjay Bhanot |
Modulation of chrebp expression
|
|
US8598333B2
(en)
*
|
2006-05-26 |
2013-12-03 |
Alnylam Pharmaceuticals, Inc. |
SiRNA silencing of genes expressed in cancer
|
|
US7862812B2
(en)
|
2006-05-31 |
2011-01-04 |
Lpath, Inc. |
Methods for decreasing immune response and treating immune conditions
|
|
US7915399B2
(en)
*
|
2006-06-09 |
2011-03-29 |
Protiva Biotherapeutics, Inc. |
Modified siRNA molecules and uses thereof
|
|
US7981425B2
(en)
*
|
2006-06-19 |
2011-07-19 |
Amgen Inc. |
Thrombopoietic compounds
|
|
KR101376634B1
(ko)
|
2006-06-19 |
2014-03-27 |
더 존스 홉킨스 유니버시티 |
리포좀아제에 의한 치료제의 종양특이적 전달
|
|
PT2029173T
(pt)
|
2006-06-26 |
2016-11-02 |
Macrogenics Inc |
Anticorpos específicos fc rib e seus métodos de uso
|
|
US20080096900A1
(en)
|
2006-06-26 |
2008-04-24 |
Amgen Inc. |
Methods for treating atherosclerosis
|
|
JP5072275B2
(ja)
*
|
2006-07-03 |
2012-11-14 |
テルモ株式会社 |
閉鎖小胞の分離方法、製剤の製造方法および評価方法
|
|
EP2471809B1
(fr)
|
2006-07-11 |
2015-09-02 |
University Of Medicine And Dentistry Of New Jersey |
Protéines, acides nucléiques codant pour celles-ci et procédés d'utilisation correspondants
|
|
US8324158B2
(en)
*
|
2006-07-14 |
2012-12-04 |
Georgia Tech Research Corporation |
Methods for inhibiting CLC-2 channel with GATX2
|
|
US8343539B2
(en)
|
2006-07-14 |
2013-01-01 |
Regents Of The University Of Minnesota |
Compounds that bind α5β1 integrin and methods of use
|
|
AU2007275654A1
(en)
|
2006-07-19 |
2008-01-24 |
The Trustees Of The University Of Pennsylvania |
WSX-1/p28 as a target for anti-inflammatory responses
|
|
WO2008011473A2
(fr)
|
2006-07-19 |
2008-01-24 |
Isis Pharmaceuticals, Inc. |
Compositions et leurs utilisations liées à l'hbxip
|
|
JP4936312B2
(ja)
*
|
2006-07-20 |
2012-05-23 |
株式会社島津製作所 |
新規な両親媒性物質、それを用いた薬剤搬送システム及び分子イメージングシステム
|
|
WO2008013918A2
(fr)
*
|
2006-07-26 |
2008-01-31 |
Myelin Repair Foundation, Inc. |
Régulation du cycle cellulaire et différenciation
|
|
WO2008019326A2
(fr)
*
|
2006-08-04 |
2008-02-14 |
Novartis Ag |
Anticorps spécifique de ephb3 et ses utilisations
|
|
CA2660286A1
(fr)
|
2006-08-09 |
2008-02-21 |
Homestead Clinical Corporation |
Proteines specifiques d'organes et procedes d'utilisation
|
|
HRP20140331T1
(hr)
|
2006-08-14 |
2014-05-09 |
Xencor, Inc. |
Optimizirana antitijela usmjerena na cd19
|
|
PL2059535T3
(pl)
*
|
2006-08-18 |
2014-04-30 |
Novartis Ag |
Przeciwciało specyficzne względem PRLR i jego zastosowanie
|
|
EP2061900A2
(fr)
|
2006-08-25 |
2009-05-27 |
Oncotherapy Science, Inc. |
Marqueurs pronostiques et cibles thérapeutiques s'appliquant au cancer du poumon
|
|
WO2008027338A2
(fr)
|
2006-08-28 |
2008-03-06 |
Kyowa Hakko Kirin Co., Limited |
Anticorps monoclonaux humains anti-hlight humain
|
|
CN101505785A
(zh)
|
2006-08-29 |
2009-08-12 |
健泰科生物技术公司 |
替奈普酶用于治疗急性缺血性中风的用途
|
|
SI2594586T1
(sl)
|
2006-09-01 |
2014-11-28 |
Zymogenetics, Inc. |
IL-31 monoklonska protitelesa in metode uporabe
|
|
CA2600220C
(fr)
*
|
2006-09-07 |
2014-12-09 |
Canadian Blood Services |
Particules lipidiques reticulees en surface et methodes de production et utilisations connexes
|
|
SI2066694T1
(sl)
|
2006-09-29 |
2016-02-29 |
Oncomed Pharmaceuticals, Inc. |
Sestavki in postopki za diagnosticiranje in zdravljenje raka
|
|
US9505821B2
(en)
|
2006-10-03 |
2016-11-29 |
Rutgers, The State University Of New Jersey |
ATAP peptides, nucleic acids encoding the same and associated methods of use
|
|
US10925977B2
(en)
|
2006-10-05 |
2021-02-23 |
Ceil>Point, LLC |
Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
|
|
TW200833840A
(en)
|
2006-10-25 |
2008-08-16 |
Amgen Inc |
Toxin peptide therapeutic agents
|
|
MX2009004532A
(es)
|
2006-10-27 |
2009-09-04 |
Lpath Inc |
Composiciones y metodos para unir esfingosina-1-fosfato.
|
|
WO2008055072A2
(fr)
|
2006-10-27 |
2008-05-08 |
Lpath, Inc. |
Compositions et procédés pour traiter des maladies et des troubles oculaires
|
|
WO2008058291A2
(fr)
|
2006-11-09 |
2008-05-15 |
California Institute Of Technology |
Ribosymes modulaires régulés par les aptamères
|
|
WO2008055314A1
(fr)
|
2006-11-10 |
2008-05-15 |
Dimerix Bioscience Pty Ltd |
Hétéro-dimères/-oligomères de récepteur à hormone de libération de la thyrotropine et de récepteur à orexine
|
|
AU2007323836B2
(en)
*
|
2006-11-13 |
2013-04-18 |
Icos Corporation |
Thienopyrimidinones for treatment of inflammatory disorders and cancers
|
|
CA2670696A1
(fr)
|
2006-11-27 |
2008-06-05 |
Diadexus, Inc. |
Compositions d'anticorps ovr110 et leurs procedes d'utilisation
|
|
BRPI0720437A2
(pt)
|
2006-12-07 |
2014-01-07 |
Novartis Ag |
Anticorpos antafonísticos contra ephb3
|
|
EP1932517A3
(fr)
*
|
2006-12-11 |
2008-07-16 |
Universiteit Utrecht Holding B.V. |
Liposomes contenant des dérivés de polyphénols et son procédé de post-chargement
|
|
WO2008076964A1
(fr)
*
|
2006-12-18 |
2008-06-26 |
The Johns Hopkins University |
Agents thérapeutiques pour le traitement du cancer utilisant du 3-bromopyruvate et d'autres inhibiteurs sélectifs de la production d'atp
|
|
US8834920B2
(en)
|
2006-12-21 |
2014-09-16 |
Alza Corporation |
Liposome composition for targeting egfr receptor
|
|
WO2008079976A2
(fr)
|
2006-12-21 |
2008-07-03 |
Centocor, Inc. |
Constructions dimères de récepteur egf à haute affinité et utilisations correspondantes
|
|
US8536113B2
(en)
*
|
2006-12-21 |
2013-09-17 |
Janssen Biotech, Inc. |
EGFR binding peptides and uses thereof
|
|
WO2008094370A2
(fr)
|
2006-12-22 |
2008-08-07 |
University Of Utah Research Foundation |
Procédé de détection de maladies et états pathologiques oculaires et traitement de ceux-ci
|
|
WO2008083169A2
(fr)
*
|
2006-12-26 |
2008-07-10 |
The Johns Hopkins University |
Compositions et procédés pour le traitement de troubles immunologiques
|
|
US20090142342A1
(en)
*
|
2006-12-27 |
2009-06-04 |
Johns Hopkins University |
B7-h4 receptor agonist compositions and methods for treating inflammation and auto-immune diseases
|
|
US7989173B2
(en)
|
2006-12-27 |
2011-08-02 |
The Johns Hopkins University |
Detection and diagnosis of inflammatory disorders
|
|
EP2109455A2
(fr)
*
|
2006-12-27 |
2009-10-21 |
The Johns Hopkins University |
Compositions et procédés pour la stimulation d'une réaction immunitaire
|
|
US7638541B2
(en)
|
2006-12-28 |
2009-12-29 |
Metabolex Inc. |
5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
|
|
EP2118118B1
(fr)
*
|
2007-01-19 |
2017-09-27 |
Exiqon A/S |
Apport cellulaire médié d'oligonucléotides de lna
|
|
WO2008091655A2
(fr)
*
|
2007-01-23 |
2008-07-31 |
The Regents Of The University Of California |
Procédés, compositions et dispositif de chauffage et libération dirigés et contrôlés d'agents
|
|
EP2641971A1
(fr)
|
2007-01-29 |
2013-09-25 |
Isis Pharmaceuticals, Inc. |
Composés et procédés pour moduler lýexpression d'une protéine
|
|
WO2008094275A1
(fr)
|
2007-01-30 |
2008-08-07 |
New York University |
Peptides destinés à être utilisés dans un traitement d'états associés à de l'oxyde nitrique
|
|
JP5761915B2
(ja)
|
2007-02-22 |
2015-08-12 |
ジェネンテック, インコーポレイテッド |
炎症性腸疾患の検出方法
|
|
ES2477497T3
(es)
*
|
2007-03-02 |
2014-07-17 |
Genentech, Inc. |
Predicción de la respuesta a un inhibidor de la dimerización de HER basado en la expresión de HER3 bajo
|
|
AU2008227852B2
(en)
*
|
2007-03-19 |
2011-02-24 |
Fresenius Kabi Oncology Ltd. |
Proliposomal and liposomal compositions
|
|
JP4510842B2
(ja)
*
|
2007-03-26 |
2010-07-28 |
キヤノン株式会社 |
ポリヒドロキシアルカノエート被覆リポソーム
|
|
EP2147102B1
(fr)
|
2007-03-29 |
2014-01-15 |
Alnylam Pharmaceuticals Inc. |
Compositions et procédés pour inhiber l'expression d'un gène à partir du virus ébola
|
|
EP2164868B1
(fr)
|
2007-05-04 |
2015-03-25 |
Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA |
Domaines variables transgéniques d'anticorps de lapin et leurs utilisations
|
|
EP2703011A3
(fr)
|
2007-05-07 |
2014-03-26 |
MedImmune, LLC |
Anticorps anti-ICOS et leur utilisation dans le traitement de l'oncologie, la transplantation et les maladies auto-immunes
|
|
US20090196913A1
(en)
*
|
2007-05-11 |
2009-08-06 |
Ken Shi Kun Huang |
Anti-Alpha-V Immunoliposome Composition, Methods, and Uses
|
|
US20090175784A1
(en)
|
2007-05-11 |
2009-07-09 |
Joshua Goldstein |
Anti-Alpha V Immunoliposome Composition, Methods, and Uses
|
|
US20090163698A1
(en)
*
|
2007-05-11 |
2009-06-25 |
John Joseph Grigsby |
Method for Preparing Antibody Conjugates
|
|
JP2010526868A
(ja)
|
2007-05-14 |
2010-08-05 |
ノビミューン エスアー |
改変されたエフェクター機能を有するFc受容体結合ポリペプチド
|
|
EP2650018A3
(fr)
|
2007-05-14 |
2014-09-03 |
The University of Chicago |
Produits de fusion anticorps-LIGHT pour les thérapies du cancer
|
|
EP2738257A1
(fr)
|
2007-05-22 |
2014-06-04 |
Amgen Inc. |
Compositions et procédés pour produire des protéines de fusion bioactives
|
|
WO2008148023A2
(fr)
*
|
2007-05-23 |
2008-12-04 |
Medical College Of Georgia Research Institute, Inc. |
Compositions et procédés pour traiter des troubles neurologiques
|
|
JP2010527618A
(ja)
|
2007-05-24 |
2010-08-19 |
アメリカ合衆国 |
ヌクレオシドサルベージ経路を通しての核内タンパク質伝達
|
|
US9163091B2
(en)
*
|
2007-05-30 |
2015-10-20 |
Lpath, Inc. |
Compositions and methods for binding lysophosphatidic acid
|
|
DK2164992T3
(en)
|
2007-05-30 |
2016-08-15 |
Lpath Inc |
COMPOSITIONS AND METHODS FOR BONDING OF LYTHOPHOSPHATIC ACID
|
|
EP3392273A1
(fr)
|
2007-05-30 |
2018-10-24 |
Xencor, Inc. |
Procédés et compositions pour inhiber des cellules exprimant cd32b
|
|
AR066984A1
(es)
|
2007-06-15 |
2009-09-23 |
Novartis Ag |
Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
|
|
TW200916094A
(en)
*
|
2007-06-27 |
2009-04-16 |
Poniard Pharmaceuticals Inc |
Stabilized picoplatin dosage form
|
|
JP2010533649A
(ja)
|
2007-07-13 |
2010-10-28 |
ザ ジョンズ ホプキンス ユニバーシティー |
B7−dc改変体
|
|
RS53595B1
(sr)
|
2007-07-16 |
2015-02-27 |
Genentech, Inc. |
Anti-cd79b antitela i imunokonjugati i metode upotrebe
|
|
WO2009011855A2
(fr)
*
|
2007-07-16 |
2009-01-22 |
California Institute Of Technology |
Sélection de domaines de capteur à base d'acide nucléique dans une plate-forme d'échange d'acide nucléique
|
|
ES2528922T3
(es)
|
2007-07-16 |
2015-02-13 |
Genentech, Inc. |
Anticuerpos anti-CD79b humanizados e inmunoconjugados y métodos de uso
|
|
CN101754962B
(zh)
|
2007-07-19 |
2013-12-25 |
赛马拜制药公司 |
作为rup3或gpr119受体的激动剂治疗糖尿病和代谢性病症的n-氮杂环状经取代吡咯、吡唑、咪唑、三唑和四唑衍生物
|
|
EP2173781A1
(fr)
*
|
2007-07-26 |
2010-04-14 |
Basf Se |
Procédé de fabrication de copolymères à base de polyéthers sous forme solide pouvant être obtenus par polymérisation-greffage en solution
|
|
PL2489731T3
(pl)
|
2007-07-26 |
2015-01-30 |
Amgen Inc |
Zmodyfikowane enzymy acylotransferaza lecytyna-cholesterol
|
|
US7666973B2
(en)
|
2007-07-30 |
2010-02-23 |
Tyco Healthcare Group Lp |
Carbonate copolymers
|
|
EP2185198B1
(fr)
|
2007-08-02 |
2015-01-14 |
Gilead Biologics, Inc. |
Inhibiteurs/anticorps dirigés contre lox et loxl2, et procédés d'utilisation associés
|
|
CA2695991A1
(fr)
*
|
2007-08-09 |
2009-02-12 |
Daiichi Sankyo Company, Limited |
Immunoliposome induisant l'apoptose dans une cellule exprimant un recepteur comportant le domaine apoptotique
|
|
US20090048423A1
(en)
*
|
2007-08-15 |
2009-02-19 |
Tyco Healthcare Group Lp |
Phospholipid Copolymers
|
|
US8268958B2
(en)
|
2007-08-15 |
2012-09-18 |
Tyco Healthcare Group Ip |
Phospholipid copolymers
|
|
US20120165387A1
(en)
|
2007-08-28 |
2012-06-28 |
Smolke Christina D |
General composition framework for ligand-controlled RNA regulatory systems
|
|
US8367815B2
(en)
*
|
2007-08-28 |
2013-02-05 |
California Institute Of Technology |
Modular polynucleotides for ligand-controlled regulatory systems
|
|
EP2197890A1
(fr)
*
|
2007-09-07 |
2010-06-23 |
Gencia Corporation |
Compositions mitochondriales et leurs utilisations
|
|
US8865667B2
(en)
*
|
2007-09-12 |
2014-10-21 |
California Institute Of Technology |
Higher-order cellular information processing devices
|
|
CA2700378A1
(fr)
*
|
2007-09-21 |
2009-03-29 |
Cytimmune Sciences, Inc. |
Procedes et compositions de metal colloidal nanotherapeutiques
|
|
US20110014118A1
(en)
*
|
2007-09-21 |
2011-01-20 |
Lawrence Tamarkin |
Nanotherapeutic colloidal metal compositions and methods
|
|
JP5731198B2
(ja)
*
|
2007-09-27 |
2015-06-10 |
イムノバクシーン・テクノロジーズ・インコーポレイテッドImmunovaccine Technologies Inc. |
インビボでのポリヌクレオチドの送達のための連続疎水相を含む担体におけるリポソームの使用
|
|
EP2197917A1
(fr)
|
2007-09-28 |
2010-06-23 |
Universitätsspital Basel |
Immunoliposomes utilisés pour le traitement du cancer
|
|
EP2205741A2
(fr)
|
2007-10-02 |
2010-07-14 |
Amgen Inc. |
Accroissement de l'érythropoïétine utilisant des acides nucléiques hybridables à de l'arnmi et leurs précurseurs
|
|
US20100209452A1
(en)
*
|
2007-10-03 |
2010-08-19 |
Immunovaccine Technologies, Inc |
Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
|
|
PT2203181T
(pt)
*
|
2007-10-16 |
2018-05-10 |
Biocon Ltd |
Uma composição farmacêutica sólida para administração por via oral e o seu processo de fabrico
|
|
US8361465B2
(en)
*
|
2007-10-26 |
2013-01-29 |
Lpath, Inc. |
Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
|
|
HUE025787T2
(en)
|
2007-11-05 |
2016-05-30 |
Medimmune Llc |
Method for treating scleroderma
|
|
US20110152346A1
(en)
*
|
2007-11-05 |
2011-06-23 |
Baltic Technology Development Ltd. |
Use of Oligonucleotides with Modified Bases in Hybridization of Nucleic Acids
|
|
WO2009062102A2
(fr)
|
2007-11-07 |
2009-05-14 |
Genentech, Inc. |
Compositions et procédés de traitement de troubles microbiens
|
|
MX2010005244A
(es)
|
2007-11-12 |
2010-10-25 |
Theraclone Sciences Inc |
Composiciones y métodos para la terapia y el diagnóstico de influenza.
|
|
WO2010135521A2
(fr)
|
2009-05-20 |
2010-11-25 |
Theraclone Sciences, Inc. |
Compositions et procédés pour le traitement et le diagnostic de la grippe
|
|
US20110033476A1
(en)
*
|
2007-11-12 |
2011-02-10 |
Theraclone Sciences Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
|
US8598165B2
(en)
|
2007-11-26 |
2013-12-03 |
University Of Kansas |
Morpholines as selective inhibitors of cytochrome P450 2A13
|
|
EP3524619A1
(fr)
|
2007-12-06 |
2019-08-14 |
Dana-Farber Cancer Institute, Inc. |
Anticorps dirigés contre le virus de la grippe et leurs procédés d'utilisation
|
|
WO2009071696A2
(fr)
|
2007-12-07 |
2009-06-11 |
Zymogenetics, Inc. |
Molécules d'anticorps humanisés spécifiques pour il-31
|
|
US9029524B2
(en)
*
|
2007-12-10 |
2015-05-12 |
California Institute Of Technology |
Signal activated RNA interference
|
|
US7871985B2
(en)
|
2007-12-10 |
2011-01-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of factor VII gene
|
|
JP5737944B2
(ja)
|
2007-12-17 |
2015-06-17 |
ファイザー・リミテッドPfizer Limited |
間質性膀胱炎の治療
|
|
WO2009086514A1
(fr)
|
2007-12-28 |
2009-07-09 |
Dana-Farber Cancer Institute, Inc. |
Anticorps monoclonaux humanisés et procédés d'utilisation
|
|
US20110117125A1
(en)
|
2008-01-02 |
2011-05-19 |
Tekmira Pharmaceuticals Corporation |
Compositions and methods for the delivery of nucleic acids
|
|
US20090181094A1
(en)
*
|
2008-01-15 |
2009-07-16 |
Eric Yueh-Lang Sheu |
Molecular Cage for Sustained Release Control of Pharmaceutical and Cosmetic Agents
|
|
AR070141A1
(es)
*
|
2008-01-23 |
2010-03-17 |
Glenmark Pharmaceuticals Sa |
Anticuerpos humanizados especificos para el factor von willebrand
|
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
|
IL287292B
(en)
|
2008-01-31 |
2022-09-01 |
Genentech Inc |
Cycteine engineering anti-cd79b antibodies and antibody-drug conjugates
|
|
WO2009111315A2
(fr)
*
|
2008-02-29 |
2009-09-11 |
Mayo Foundation For Medical Education And Research |
Méthodes de réduction de l’inflammation granulomateuse
|
|
CN105267233B
(zh)
*
|
2008-03-05 |
2019-07-26 |
阿尔尼拉姆医药品有限公司 |
用于抑制Eg5和VEGF基因表达的组合物和方法
|
|
EP2257571B1
(fr)
|
2008-03-10 |
2015-03-04 |
Theraclone Sciences, Inc. |
Compositions et procédés pour le diagnostic et le traitement d'une infection à cytomégalovirus
|
|
EP2105145A1
(fr)
*
|
2008-03-27 |
2009-09-30 |
ETH Zürich |
Procédé pour la libération spécifique dans les muscles d'oligonucléotides conjugués avec des lipides
|
|
EP2698380A1
(fr)
|
2008-03-28 |
2014-02-19 |
Sea Lane Biotechnologies, LLC |
Neutralisation de molécules pour antigènes viraux
|
|
JP5711655B2
(ja)
*
|
2008-03-31 |
2015-05-07 |
シマベイ セラピューティクス, インコーポレーテッド |
オキシメチレンアリール化合物およびその使用
|
|
AU2009232355A1
(en)
|
2008-04-04 |
2009-10-08 |
Calando Pharmaceuticals, Inc. |
Compositions and use of EPAS1 inhibitors
|
|
JP5770624B2
(ja)
|
2008-04-09 |
2015-08-26 |
ジェネンテック, インコーポレイテッド |
免疫関連疾患の治療のための新規組成物と方法
|
|
EP3023502A1
(fr)
|
2008-04-10 |
2016-05-25 |
Cell Signaling Technology, Inc. |
Compositions et procédés pour détecter des mutations egfr dans le cancer
|
|
PL2279254T3
(pl)
|
2008-04-15 |
2017-11-30 |
Protiva Biotherapeutics Inc. |
Nowe preparaty lipidowe do dostarczania kwasów nukleinowych
|
|
WO2009134917A2
(fr)
*
|
2008-04-29 |
2009-11-05 |
Wyeth |
Méthodes de traitement d’une inflammation
|
|
US8324366B2
(en)
|
2008-04-29 |
2012-12-04 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for delivering RNAI using lipoproteins
|
|
CA2722127A1
(fr)
*
|
2008-05-09 |
2009-11-12 |
Recopharma Ab |
Compositions et methodes pour inhiber la toxine shiga et la toxine de type shiga
|
|
US20090280134A1
(en)
*
|
2008-05-09 |
2009-11-12 |
Recopharma Ab |
Compositions and methods for inhibiting toxin a from clostridium difficile
|
|
SI2279004T1
(sl)
|
2008-05-16 |
2015-05-29 |
F. Hoffmann-La Roche Ag |
Uporaba biomarkerjev za ocenjevanje zdravljenja gastrointestinalnih vnetnih motenj z antagonisti beta7 integrina
|
|
US8093018B2
(en)
|
2008-05-20 |
2012-01-10 |
Otsuka Pharmaceutical Co., Ltd. |
Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
|
|
CN102036658A
(zh)
*
|
2008-05-23 |
2011-04-27 |
香港大学 |
治疗流感的联合疗法
|
|
AU2009253780B2
(en)
*
|
2008-06-05 |
2014-08-14 |
Immunovaccine Technologies Inc. |
Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
|
|
WO2009148121A1
(fr)
|
2008-06-05 |
2009-12-10 |
株式会社 島津製作所 |
Nouvel ensemble moleculaire, sonde moleculaire d’imagerie moleculaire et sonde moleculaire de systeme d’administration de medicament, systeme d’imagerie moleculaire et systeme d’administration de medicament associes
|
|
US8173621B2
(en)
*
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
|
WO2009150623A1
(fr)
|
2008-06-13 |
2009-12-17 |
Pfizer Inc |
Traitement de la prostatite chronique
|
|
US20110104074A1
(en)
*
|
2008-06-18 |
2011-05-05 |
University Of Louisville Research Foundation, Inc. |
Methods for targeted cancer treatment and detection
|
|
US20100003315A1
(en)
*
|
2008-07-02 |
2010-01-07 |
Willeford Kenneth L |
Method and Composition for the Treatment of Skin Conditions
|
|
CA2729306C
(fr)
|
2008-07-08 |
2015-08-18 |
Oncomed Pharmaceuticals, Inc. |
Agents de liaison de notch et antagonistes de notch ainsi que procedes d'utilisation correspondants
|
|
US8834875B2
(en)
|
2010-01-13 |
2014-09-16 |
Oncomed Pharmaceuticals, Inc. |
Notch1 binding agents and methods of use thereof
|
|
WO2010006282A2
(fr)
|
2008-07-10 |
2010-01-14 |
Serina Therapeutics, Inc. |
Polyoxazolines avec groupes terminaux inertes, polyoxazolines préparées à partir de groupes initiateurs protégés, et composés en rapport
|
|
US20100008900A1
(en)
*
|
2008-07-14 |
2010-01-14 |
The University Of Hong Kong |
Annexin ii compositions for treating or monitoring inflammation or immune-mediated disorders
|
|
US8815818B2
(en)
|
2008-07-18 |
2014-08-26 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell delivery of RNAI
|
|
US20110237646A1
(en)
*
|
2008-08-07 |
2011-09-29 |
Isis Pharmaceuticals, Inc. |
Modulation of transthyretin expression for the treatment of cns related disorders
|
|
US8652843B2
(en)
|
2008-08-12 |
2014-02-18 |
Oncomed Pharmaceuticals, Inc. |
DDR1-binding agents and methods of use thereof
|
|
US10457639B2
(en)
|
2008-08-15 |
2019-10-29 |
Georgetown University |
Fluorescent regulators of RASSF1A expression and human cancer cell proliferation
|
|
WO2010021750A2
(fr)
|
2008-08-21 |
2010-02-25 |
The Johns Hopkins University |
Procédés et compositions pour l'administration de 3-halopyruvate et de composés associés pour le traitement du cancer
|
|
RS54413B1
(sr)
*
|
2008-08-22 |
2016-04-28 |
Sanofi |
[4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoksi-etil)-4trifluorometoksi-1h-indol-3-il]metanon kao inhibitor triptaze iz mastocita
|
|
RS54233B1
(sr)
|
2008-08-25 |
2015-12-31 |
Amplimmune Inc. |
Kompozicije pd-1 antagonista i postupci za njihovu primenu
|
|
WO2010027818A2
(fr)
|
2008-08-25 |
2010-03-11 |
Dana-Farber Cancer Institute, Inc. |
Epitope conservé d'hémagglutinine, anticorps contre l'épitope et procédés d'utilisation
|
|
MX2011002250A
(es)
*
|
2008-08-25 |
2011-08-17 |
Amplimmune Inc |
Antagonistas de muerte celular programada-1 y métodos de uso de los mismos.
|
|
CN103429270B
(zh)
|
2008-08-25 |
2016-11-23 |
埃克斯雷德制药有限公司 |
阻止结缔组织生长因子的反义核苷酸及其用途
|
|
US8318693B2
(en)
|
2008-09-02 |
2012-11-27 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of mutant EGFR gene
|
|
CN102149728B
(zh)
|
2008-09-10 |
2014-10-15 |
霍夫曼-拉罗奇有限公司 |
抑制眼部血管生成的方法
|
|
TWI445716B
(zh)
|
2008-09-12 |
2014-07-21 |
Rinat Neuroscience Corp |
Pcsk9拮抗劑類
|
|
TW201438738A
(zh)
|
2008-09-16 |
2014-10-16 |
Genentech Inc |
治療進展型多發性硬化症之方法
|
|
CN102405286A
(zh)
|
2008-09-22 |
2012-04-04 |
阿克赛医药公司 |
减小大小的自递送RNAi化合物
|
|
CA2739170A1
(fr)
|
2008-09-25 |
2010-04-01 |
Alnylam Pharmaceuticals, Inc. |
Compositions a base de preparation lipidique et methodes destinees a inhiber l'expression d'un gene de serum amyloide a
|
|
CA2740125A1
(fr)
|
2008-10-09 |
2010-04-15 |
Northeastern University |
Nanosystemes polymeres multifonctionnels a auto-assemblage
|
|
WO2010042877A1
(fr)
|
2008-10-09 |
2010-04-15 |
Tekmira Pharmaceuticals Corporation |
Lipides aminés améliorés et procédés d'administration d'acides nucléiques
|
|
HUE026604T2
(hu)
|
2008-10-20 |
2016-06-28 |
Alnylam Pharmaceuticals Inc |
Transztiretin-expresszió gátlására szolgáló készítmények és eljárások
|
|
JP5382380B2
(ja)
*
|
2008-10-21 |
2014-01-08 |
インターナショナル ワクチン インスティテュート |
新規のシゲラタンパク質抗原及び方法
|
|
NZ592603A
(en)
|
2008-10-21 |
2013-02-22 |
Metabolex Inc |
Aryl gpr120 receptor agonists and uses thereof
|
|
US8871202B2
(en)
|
2008-10-24 |
2014-10-28 |
Lpath, Inc. |
Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
|
|
WO2010052556A1
(fr)
*
|
2008-11-06 |
2010-05-14 |
Glenmark Pharmaceuticals S.A. |
Traitement utilisant des anticorps anti-intégrine alpha 2
|
|
EP3757090B1
(fr)
|
2008-11-10 |
2024-06-12 |
Arbutus Biopharma Corporation |
Nouveaux lipides et compositions d'administration d'agents thérapeutiques
|
|
PT2355828T
(pt)
|
2008-11-13 |
2018-07-02 |
Gilead Calistoga Llc |
Terapias para malignidades hematológicas
|
|
US9492449B2
(en)
|
2008-11-13 |
2016-11-15 |
Gilead Calistoga Llc |
Therapies for hematologic malignancies
|
|
US20100143351A1
(en)
|
2008-11-22 |
2010-06-10 |
Genentech, Inc. |
Anti-Angiogenesis Therapy for the Treatment of Breast Cancer
|
|
US20110230399A1
(en)
*
|
2008-11-25 |
2011-09-22 |
Bowen Richard L |
Methods for Treating Obesity Related Disease
|
|
US20110160222A1
(en)
*
|
2008-11-26 |
2011-06-30 |
Metabolex, Inc. |
Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
|
|
CN102317458B
(zh)
|
2008-12-04 |
2018-01-02 |
库尔纳公司 |
通过红细胞生成素(epo)天然反义转录物的抑制对epo相关疾病的治疗
|
|
KR101866152B1
(ko)
|
2008-12-04 |
2018-06-08 |
큐알엔에이, 인크. |
종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
|
|
JP6099868B2
(ja)
|
2008-12-04 |
2017-03-22 |
クルナ・インコーポレーテッド |
サーチュイン1(sirt1)に対する天然アンチセンス転写物の抑制によるサーチュイン1関連疾患の治療
|
|
AU2009324534B2
(en)
|
2008-12-10 |
2015-07-30 |
Alnylam Pharmaceuticals, Inc. |
GNAQ targeted dsRNA compositions and methods for inhibiting expression
|
|
WO2010068680A1
(fr)
|
2008-12-10 |
2010-06-17 |
Mount Sinai School Of Medicine Of New York University |
Adjuvants spécifiques du lignage 17 du type lymphocytes t, compositions et méthodes
|
|
AR074760A1
(es)
|
2008-12-18 |
2011-02-09 |
Metabolex Inc |
Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
|
|
TW201034675A
(en)
|
2008-12-18 |
2010-10-01 |
Sanofi Aventis |
Method for treating macular degeneration
|
|
CN102264398B
(zh)
*
|
2008-12-22 |
2013-12-18 |
克雷毕里斯股份有限公司 |
合成吲哚并咔唑化合物的聚合物缀合物
|
|
WO2010075249A2
(fr)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
Méthode de traitement de la polyarthrite rhumatoïde avec des antagonistes de cellules b
|
|
CL2009002207A1
(es)
*
|
2008-12-23 |
2011-02-18 |
Gilead Pharmasset Llc |
Compuestos derivados de 3-hidroxi-5-(9h-purin-9-il)tetrahidrofuran-2-il, inhibidor de la replicacion de arn viral dependiente de arn; composicion farmaceutica; uso para el tratamiento de hepatitis c.
|
|
CL2009002208A1
(es)
*
|
2008-12-23 |
2010-10-29 |
Gilead Pharmasset Llc |
Un compuesto (2s)-2-((((2r,3r,4r,5r)-5-(2-amino-6-etoxi-9h-purin-9-il)-4-fluoro-3-hidroxi-4-metiltetrahidrofuran-2-il)metoxi)(hidroxi)fosforilamino)propanoico, inhibidores de la replicacion de arn viral; composicion farmaceutica; y su uso en el tratamiento de infeccion por hepatitis c, virus del nilo occidental, entre otras.
|
|
KR20110104074A
(ko)
|
2008-12-23 |
2011-09-21 |
파마셋 인코포레이티드 |
퓨린 뉴클레오시드의 합성
|
|
US9493774B2
(en)
|
2009-01-05 |
2016-11-15 |
Rxi Pharmaceuticals Corporation |
Inhibition of PCSK9 through RNAi
|
|
CA2751342C
(fr)
|
2009-01-29 |
2019-05-07 |
Alnylam Pharmaceuticals, Inc. |
Formules lipides renfermant un lipide cationique et un lipide cible renfermant de la galactosamine n-acetyle pour la livraison d'acide nucleique
|
|
WO2010086828A2
(fr)
|
2009-02-02 |
2010-08-05 |
Rinat Neuroscience Corporation |
Anticorps monoclonaux agonistes anti-trkb
|
|
WO2010090762A1
(fr)
|
2009-02-04 |
2010-08-12 |
Rxi Pharmaceuticals Corporation |
Duplexes d'arn avec régions de nucléotide phosphorothioate à brin unique pour fonctionnalité supplémentaire
|
|
JP6066035B2
(ja)
|
2009-02-12 |
2017-01-25 |
クルナ・インコーポレーテッド |
グリア細胞由来神経栄養因子(gdnf)関連疾病の、gdnfに対する天然アンチセンス転写物の抑制による治療
|
|
EP3009150B1
(fr)
|
2009-02-12 |
2019-11-13 |
CuRNA, Inc. |
Traitement de maladies liées à un facteur neurotrophique dérivé du cerveau (bdnf) par inhibition du transcrit antisens naturel de bdnf
|
|
US8329882B2
(en)
|
2009-02-18 |
2012-12-11 |
California Institute Of Technology |
Genetic control of mammalian cells with synthetic RNA regulatory systems
|
|
US20120041051A1
(en)
|
2009-02-26 |
2012-02-16 |
Kevin Fitzgerald |
Compositions And Methods For Inhibiting Expression Of MIG-12 Gene
|
|
US8975389B2
(en)
|
2009-03-02 |
2015-03-10 |
Alnylam Pharmaceuticals, Inc. |
Nucleic acid chemical modifications
|
|
ES2845644T3
(es)
|
2009-03-04 |
2021-07-27 |
Curna Inc |
Tratamiento de enfermedades relacionadas con sirtuina1 (SIRT1) mediante inhibición del transcrito del antisentido natural a sirtuina 1
|
|
EP2228059A1
(fr)
|
2009-03-12 |
2010-09-15 |
Universitätsspital Basel |
Composition chimio-thérapeutique pour le traitement du cancer
|
|
CA2754043A1
(fr)
|
2009-03-12 |
2010-09-16 |
Alnylam Pharmaceuticals, Inc. |
Compositions formulees de lipides et procedes d'inhibition de l'expression de genes de eg5 et de vegf
|
|
WO2010107733A2
(fr)
|
2009-03-16 |
2010-09-23 |
Curna, Inc. |
Traitement de maladies associées au facteur nucléaire 2 similaire au dérivé d'érythroïde 2 (nrf2) par inhibition de produit de transcription antisens naturel pour nrf2
|
|
SI3260136T1
(sl)
|
2009-03-17 |
2021-05-31 |
Theraclone Sciences, Inc. |
Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
|
|
WO2010107740A2
(fr)
|
2009-03-17 |
2010-09-23 |
Curna, Inc. |
Traitement des maladies associées à l'homologue du delta-like 1 (dlk1) par inhibition du transcrit antisens naturel de dlk1
|
|
CA2756347A1
(fr)
|
2009-03-24 |
2010-09-30 |
Gilead Calistoga Llc |
Atropisomeres de derives de 2-purinyl-3-tolyl-quinazolinone et procedes d'utilisation
|
|
NZ594343A
(en)
|
2009-03-25 |
2013-10-25 |
Genentech Inc |
Novel anti-alpha5beta1 antibodies and uses thereof
|
|
WO2010114859A1
(fr)
|
2009-04-01 |
2010-10-07 |
Genentech, Inc. |
Traitement de troubles résistant à l'insuline
|
|
WO2010120561A1
(fr)
|
2009-04-01 |
2010-10-21 |
Genentech, Inc. |
Anticorps et immunoconjugués anti-fcrh5 et procédés d'utilisation
|
|
US9145555B2
(en)
|
2009-04-02 |
2015-09-29 |
California Institute Of Technology |
Integrated—ligand-responsive microRNAs
|
|
US8546409B2
(en)
*
|
2009-04-20 |
2013-10-01 |
Gilead Calistoga Llc |
Methods of treatment for solid tumors
|
|
EP3524275A1
(fr)
|
2009-04-22 |
2019-08-14 |
Massachusetts Institute Of Technology |
Suppression immunitaire innée permettant la distribution répétée de longues molécules d'arn
|
|
CA2759506A1
(fr)
|
2009-04-23 |
2010-10-28 |
Theraclone Sciences, Inc. |
Anticorps neutralisant le facteur de croissance des granulocytes et des macrophages (gm-csf)
|
|
WO2010129304A2
(fr)
*
|
2009-04-27 |
2010-11-11 |
Oncomed Pharmaceuticals, Inc. |
Procédé de fabrication de molécules hétéromultimères
|
|
EP2248903A1
(fr)
|
2009-04-29 |
2010-11-10 |
Universitat Autònoma De Barcelona |
Procédés et réactifs pour le transfert génétique efficace et ciblé vers des monocytes et macrophages
|
|
WO2010127271A1
(fr)
|
2009-04-30 |
2010-11-04 |
Intezyne Technologies, Incorporated |
Micelles polymères contenant des anthracyclines utilisables à des fins de traitement du cancer
|
|
US8524784B2
(en)
*
|
2009-04-30 |
2013-09-03 |
Intezyne Technologies, Incorporated |
Polymer micelles containing anthracylines for the treatment of cancer
|
|
CA2760589C
(fr)
|
2009-05-01 |
2019-08-20 |
Joseph Collard |
Oligonucleotides antisens d'hemoglobines
|
|
EP3698631A3
(fr)
|
2009-05-05 |
2020-11-25 |
Arbutus Biopharma Corporation |
Procédés d'administration d'oligonucléotides dans des cellules immunes
|
|
SG175276A1
(en)
|
2009-05-05 |
2011-11-28 |
Novimmune Sa |
Anti-il-17f antibodies and methods of use thereof
|
|
KR102229618B1
(ko)
|
2009-05-05 |
2021-03-18 |
알닐람 파마슈티칼스 인코포레이티드 |
지질 조성물
|
|
CN103223177B
(zh)
|
2009-05-06 |
2016-08-10 |
库尔纳公司 |
通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
|
|
EP2427552B1
(fr)
|
2009-05-06 |
2016-11-16 |
CuRNA, Inc. |
Traitement de maladies liées à la tristétraproline (ttp) par l'inhibition d'un transcrit antisens naturel de ttp
|
|
EP2432881B1
(fr)
|
2009-05-18 |
2017-11-15 |
CuRNA, Inc. |
Traitement des maladies associées aux facteurs de reprogrammation par inhibition du transcrit antisens naturel d'un facteur de reprogrammation
|
|
TWI583692B
(zh)
|
2009-05-20 |
2017-05-21 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
|
WO2011019423A2
(fr)
|
2009-05-20 |
2011-02-17 |
Schering Corporation |
Modulation de récepteurs pilr pour traiter les infections microbiennes
|
|
US8895527B2
(en)
|
2009-05-22 |
2014-11-25 |
Curna, Inc. |
Treatment of transcription factor E3 (TFE3) and insulin receptor substrate 2(IRS2) related diseases by inhibition of natural antisense transcript to TFE3
|
|
JP5960049B2
(ja)
|
2009-05-28 |
2016-08-02 |
クルナ・インコーポレーテッド |
抗ウイルス遺伝子に対する天然アンチセンス転写物の抑制による抗ウイルス遺伝子関連疾患の治療
|
|
SG10201912450XA
(en)
|
2009-06-10 |
2020-03-30 |
Arbutus Biopharma Corp |
Improved lipid formulation
|
|
US20120100206A1
(en)
|
2009-06-11 |
2012-04-26 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. |
Targeted liposomes comprising n-containing bisphosphonates and uses thereof
|
|
CN102695797B
(zh)
|
2009-06-16 |
2018-05-25 |
库尔纳公司 |
通过抑制针对胶原基因的天然反义转录物来治疗胶原基因相关的疾病
|
|
US8951981B2
(en)
|
2009-06-16 |
2015-02-10 |
Curna, Inc. |
Treatment of paraoxonase 1 (PON1) related diseases by inhibition of natural antisense transcript to PON1
|
|
WO2010146511A1
(fr)
|
2009-06-17 |
2010-12-23 |
Pfizer Limited |
Traitement d'une vessie hyperactive
|
|
CA2765889A1
(fr)
|
2009-06-24 |
2010-12-29 |
Opko Curna, Llc |
Traitement de maladies associees au recepteur de facteur necrosant des tumeurs 2 (tnfr2) par inhibition de la transcription antisens naturelle de tnfr2
|
|
CA2765815A1
(fr)
|
2009-06-26 |
2010-12-29 |
Opko Curna, Llc |
Traitement de maladies associees aux genes lies au syndrome de down par inhibition des genes lies au syndrome de down mediee par le produit de transcription antisens naturel
|
|
BRPI1015916A2
(pt)
|
2009-06-26 |
2015-09-01 |
Sea Lane Biotechnologies Llc |
Molécula de ácido nucleico, vetor de expressão, célula hospedeira, bem como método para expressão de um construto de cadeia leve substituta (slc) ou de um polipeptídeo de slc
|
|
US8487083B2
(en)
|
2009-06-30 |
2013-07-16 |
OOO “Oncomax” |
Monoclonal antibodies capable of simultaneously binding domains II and IIIc of type 1 fibroblast growth factor receptor
|
|
US9018187B2
(en)
|
2009-07-01 |
2015-04-28 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods for the delivery of therapeutic agents
|
|
WO2011000106A1
(fr)
|
2009-07-01 |
2011-01-06 |
Protiva Biotherapeutics, Inc. |
Lipides cationiques et procédés améliorés pour l'administration d'agents thérapeutiques
|
|
JP5766188B2
(ja)
|
2009-07-01 |
2015-08-19 |
プロチバ バイオセラピューティクス インコーポレイティッド |
固形腫瘍に治療剤を送達するための脂質製剤
|
|
KR20120051002A
(ko)
|
2009-07-07 |
2012-05-21 |
제넨테크, 인크. |
자가면역 탈수초성 질환의 진단 및 치료
|
|
AU2010272957B2
(en)
*
|
2009-07-17 |
2016-03-03 |
Rigshospitalet |
Loading technique for preparing radionuclide and ionophore containing liposomes in which the ionophore is 2-hydroxyquionoline (carbostyril) or structurally related 2-hydroxyquinolines
|
|
BR112012001325A2
(pt)
|
2009-07-21 |
2017-05-02 |
Gilead Calistoga Llc |
tratamento de distúrbios do fígado com inibidaores de pi3k
|
|
US9937128B2
(en)
*
|
2009-08-03 |
2018-04-10 |
The University Of North Carolina At Chapel Hill |
Liposomes comprising a calcium phosphate-containing precipitate
|
|
JP6128848B2
(ja)
|
2009-08-05 |
2017-05-17 |
クルナ・インコーポレーテッド |
インスリン遺伝子(ins)に対する天然アンチセンス転写物の抑制によるインスリン遺伝子(ins)関連疾患の治療
|
|
EP2464336A4
(fr)
|
2009-08-14 |
2013-11-20 |
Alnylam Pharmaceuticals Inc |
Compositions formulées dans des lipides et procédés pour inhiber l' expression d'un gène du virus ebola
|
|
JP6088246B2
(ja)
|
2009-08-15 |
2017-03-01 |
ジェネンテック, インコーポレイテッド |
以前に治療された乳癌の治療のための抗血管新生療法
|
|
FR2955324A1
(fr)
|
2010-01-15 |
2011-07-22 |
Sanofi Aventis |
[4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones disubstituees
|
|
CN102482671B
(zh)
|
2009-08-25 |
2017-12-01 |
库尔纳公司 |
通过抑制‘含有iq模体的gtp酶激活蛋白’(iqgap)的天然反义转录物而治疗iqgap相关疾病
|
|
CA2772204A1
(fr)
|
2009-08-31 |
2011-03-03 |
Amplimmune, Inc. |
Methodes et compositions permettant d'inhiber les rejets de greffe
|
|
US20110059111A1
(en)
|
2009-09-01 |
2011-03-10 |
Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center |
Mammalian receptors as targets for antibody and active vaccination therapy against mold infections
|
|
US9321823B2
(en)
|
2009-09-02 |
2016-04-26 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
|
ES2497566T3
(es)
|
2009-10-01 |
2014-09-23 |
Cymabay Therapeutics, Inc. |
Sales de tetrazol-1-il-fenoximetil-tiazol-2-il-piperidinil-pirimidina sustituida
|
|
CA2780741C
(fr)
|
2009-10-12 |
2023-04-04 |
Smith Holdings, Llc |
Procedes et compositions de modulation de l'expression genique en utilisant des medicaments a base d'oligonucleotides administres in vivo ou in vitro
|
|
WO2011047267A1
(fr)
*
|
2009-10-15 |
2011-04-21 |
Genentech, Inc. |
Facteurs de croissance chimériques des fibroblastes avec spécificité de récepteur modifiée
|
|
TR201818814T4
(tr)
|
2009-10-16 |
2019-01-21 |
Oncomed Pharm Inc |
Dll4 antagonist antikorlarının ve anti-hipertansif ajanların terapötik kombinasyonu ve kullanımı.
|
|
WO2011049625A1
(fr)
|
2009-10-20 |
2011-04-28 |
Mansour Samadpour |
Procédé de criblage d'aflatoxine dans des produits
|
|
BR112012009409A2
(pt)
|
2009-10-22 |
2017-02-21 |
Genentech Inc |
método de identificação de uma substância inibidora, molécula antagonista, ácido nucleico isolado, vetor, célula hospedeira, método para fabricar a molécula, composição, artigo de fabricação, método de inibição de uma atividade biológica, método de tratamento de uma condição patológica, método para detectar msp em uma amostra e método para detectar hepsina em uma amostra
|
|
EP3444242A3
(fr)
|
2009-11-05 |
2019-03-20 |
Rhizen Pharmaceuticals S.A. |
Nouveaux modulateurs de benzopyran dekinase
|
|
WO2011056234A1
(fr)
|
2009-11-06 |
2011-05-12 |
Fibrogen, Inc. |
Traitement de troubles induits par un rayonnement
|
|
CN102770529B
(zh)
|
2009-11-17 |
2018-06-05 |
Musc研究发展基金会 |
针对人核仁素的人单克隆抗体
|
|
TWI507524B
(zh)
|
2009-11-30 |
2015-11-11 |
Genentech Inc |
診斷及治療腫瘤之組合物及方法
|
|
AU2010328336B2
(en)
|
2009-12-07 |
2017-03-02 |
Arbutus Biopharma Corporation |
Compositions for nucleic acid delivery
|
|
WO2011071957A1
(fr)
|
2009-12-07 |
2011-06-16 |
Sea Lane Biotechnologies, Llc |
Conjugués comprenant un échafaudage de substituts d'anticorps présentant des propriétés pharmacocinétiques améliorées
|
|
BR112012014022A2
(pt)
|
2009-12-11 |
2017-04-04 |
Genecode As |
composto, composição, dispositivo médico e método ex vivo para modulação do crescimento de um neurônico
|
|
WO2011081904A1
(fr)
|
2009-12-14 |
2011-07-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Administration de transthyrétine à travers la barrière hémato-encéphalique en tant que traitement pour la maladie d'alzheimer
|
|
RU2639550C2
(ru)
|
2009-12-16 |
2017-12-21 |
Курна, Инк. |
Лечение заболеваний, связанных с сайт-1 мембраносвязанной пептидазой транскрипционных факторов (mbtps1), путем ингибирования природного антисмыслового транскрипта к mbtps1
|
|
US8691227B2
(en)
|
2009-12-17 |
2014-04-08 |
Merck Sharp & Dohme Corp. |
Methods of treating multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease using agonists antibodies to PILR-α
|
|
CA2784568A1
(fr)
|
2009-12-18 |
2011-06-23 |
Martin A. Maier |
Particules de lipide destinees a la distribution d'acides nucleiques
|
|
CN102770431A
(zh)
|
2009-12-23 |
2012-11-07 |
赛诺菲 |
[4[4-(5-氨基甲基-2-氟-苯基)-哌啶-1-基]-(1h-吡咯并吡啶-基)-甲酮及其合成
|
|
RS53456B
(sr)
|
2009-12-23 |
2014-12-31 |
Sanofi |
Prolekovi [4[4-(5-aminometil-2-fluor-fenil)-piperidin-1-il]-(1h-pirolo-piridin-il)-metanona i njihova sinteza
|
|
CN102781480B
(zh)
|
2009-12-23 |
2018-07-27 |
库尔纳公司 |
通过抑制解偶联蛋白2(ucp2)的天然反义转录物而治疗ucp2相关疾病
|
|
US8940708B2
(en)
|
2009-12-23 |
2015-01-27 |
Curna, Inc. |
Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF
|
|
BR112012015740B1
(pt)
|
2009-12-23 |
2020-09-29 |
Synimmune Gmbh |
Anticorpo anti-flt3, seu uso,bem como composição compreendendo o referido anticorpo e molécula de ácido nucleico
|
|
ES2701626T3
(es)
|
2009-12-28 |
2019-02-25 |
Oncotherapy Science Inc |
Anticuerpos anti-CDH3 y sus usos
|
|
JP5982288B2
(ja)
|
2009-12-29 |
2016-08-31 |
カッパーアールエヌエー,インコーポレイテッド |
腫瘍タンパク質63(p63)に対する天然アンチセンス転写物の阻害による腫瘍タンパク質63関連疾患の治療
|
|
EP2519633B1
(fr)
|
2009-12-29 |
2017-10-25 |
CuRNA, Inc. |
Traitement de maladies liées au facteur respiratoire nucléaire 1 (nrf1) par l'inhibition du produit de transcription antisens naturel de nrf1
|
|
WO2011082187A1
(fr)
|
2009-12-30 |
2011-07-07 |
Genentech, Inc. |
Procédés de modulation d'une réponse biologique à médiation par pdgf-aa
|
|
RU2611187C2
(ru)
|
2010-01-04 |
2017-02-21 |
Курна, Инк. |
Лечение заболеваний, связанных с интерферон-регуляторным фактором 8 (irf8), путем ингибирования природного антисмыслового транскрипта к irf8
|
|
EP2521785B1
(fr)
|
2010-01-06 |
2022-03-09 |
CuRNA, Inc. |
Inhibition de la transcription antisens naturelle du gène de développement du pancrea pour l'utilisation dans le traitement des maladies du développement du pancréa
|
|
JPWO2011083845A1
(ja)
*
|
2010-01-08 |
2013-05-16 |
富士フイルム株式会社 |
腫瘍部位に対する標的化剤
|
|
KR101854926B1
(ko)
|
2010-01-11 |
2018-05-04 |
큐알엔에이, 인크. |
성 호르몬 결합 글로불린 (shbg)에 대한 자연 안티센스 전사체의 저해에 의한 성 호르몬 결합 글로불린 (shbg) 관련된 질환의 치료
|
|
TWI535445B
(zh)
|
2010-01-12 |
2016-06-01 |
安可美德藥物股份有限公司 |
Wnt拮抗劑及治療和篩選方法
|
|
US8883739B2
(en)
|
2010-01-19 |
2014-11-11 |
The Trustees Of Columbia University In The City Of New York |
Osteocalcin as a treatment for male reproductive disorders
|
|
WO2011089211A1
(fr)
|
2010-01-22 |
2011-07-28 |
Synimmune Gmbh |
Anticorps anti-cd133 et leurs procédés d'utilisation
|
|
CA2786568A1
(fr)
|
2010-01-25 |
2011-07-28 |
Curna, Inc. |
Traitement de maladies liees a la rnase h1 par l'inhibition du produit de transcription naturel antisens de la rnase h1
|
|
US8198337B2
(en)
*
|
2010-01-27 |
2012-06-12 |
Momentive Performance Materials Inc. |
Demulsifier compositions and methods for separating emulsions using the same
|
|
US20130052259A1
(en)
|
2010-02-01 |
2013-02-28 |
Yechezkel Barenholz |
Liposomes comprising amphipathic drugs and method for their preparation
|
|
JP5976548B2
(ja)
|
2010-02-22 |
2016-08-23 |
カッパーアールエヌエー,インコーポレイテッド |
Pycr1に対する天然アンチセンス転写物の阻害によるピロリン−5−カルボン酸レダクターゼ1(pycr1)関連疾患の治療
|
|
MA34057B1
(fr)
|
2010-02-23 |
2013-03-05 |
Genentech Inc |
Compositions et methodes pour le diagnostic et le traitement d'une tumeur
|
|
US8975376B2
(en)
|
2010-02-23 |
2015-03-10 |
Sanofi |
Anti-alpha2 integrin antibodies and their uses
|
|
CN103237810A
(zh)
|
2010-02-23 |
2013-08-07 |
霍夫曼-拉罗奇有限公司 |
用于治疗卵巢癌的抗血管发生疗法
|
|
AR080291A1
(es)
|
2010-02-24 |
2012-03-28 |
Rinat Neuroscience Corp |
Anticuerpos antagonistas anti receptor de il-7 y procedimientos
|
|
WO2011106702A2
(fr)
|
2010-02-25 |
2011-09-01 |
The Johns Hopkins University |
Délivrance prolongée d'agents thérapeutiques à un compartiment oculaire
|
|
AU2011225716A1
(en)
|
2010-03-11 |
2012-09-27 |
Pfizer Inc. |
Antibodies with pH dependent antigen binding
|
|
RU2584232C2
(ru)
|
2010-03-22 |
2016-05-20 |
Дженентек, Инк. |
Композиции и способы, используемые для стабилизации белоксодержащих готовых форм
|
|
RU2615143C2
(ru)
|
2010-03-24 |
2017-04-04 |
Адвирна |
Самодоставляющие PHKi соединения уменьшенного размера
|
|
EP2550362B1
(fr)
|
2010-03-25 |
2017-01-04 |
Oregon Health&Science University |
Glycoprotéines du cmv et vecteurs recombinés
|
|
EP3329924B1
(fr)
|
2010-03-29 |
2021-05-05 |
Alnylam Pharmaceuticals, Inc. |
Thérapie d'arndb pour amylose oculaire associée à la transthyrétine (ttr)
|
|
EP2552957A4
(fr)
|
2010-03-29 |
2013-11-20 |
Zymeworks Inc |
Anticorps présentant une fonction effectrice améliorée ou supprimée
|
|
SG183947A1
(en)
|
2010-03-31 |
2012-10-30 |
Boehringer Ingelheim Int |
Anti-cd40 antibodies
|
|
MX2012011171A
(es)
|
2010-03-31 |
2013-02-01 |
Gilead Pharmasset Llc |
Fosforamidatos de nucleosido.
|
|
SI2609923T1
(sl)
|
2010-03-31 |
2017-10-30 |
Gilead Pharmasset Llc |
Postopek za kristalizacijo (s)-izopropil 2-(((s)-(perfluorofenoksi) (fenoksi)fosforil)amino)propanoata
|
|
PL3290428T3
(pl)
|
2010-03-31 |
2022-02-07 |
Gilead Pharmasset Llc |
Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
|
|
US9102938B2
(en)
|
2010-04-01 |
2015-08-11 |
Alnylam Pharmaceuticals, Inc. |
2′ and 5′ modified monomers and oligonucleotides
|
|
EP2556085A2
(fr)
|
2010-04-05 |
2013-02-13 |
Bar-Ilan University |
Polypeptides formant des pores pouvant être activés par une protéase
|
|
EP4385568A3
(fr)
|
2010-04-06 |
2025-02-12 |
Alnylam Pharmaceuticals, Inc. |
Compositions et procédés pour inhiber l'expression du gène cd72/pd-l1
|
|
CN102858979B
(zh)
|
2010-04-09 |
2018-01-26 |
库尔纳公司 |
通过抑制成纤维细胞生长因子21(fgf21)的天然反义转录物而治疗fgf21相关疾病
|
|
WO2011133876A2
(fr)
|
2010-04-22 |
2011-10-27 |
Alnylam Pharmaceuticals, Inc. |
Oligonucléotides comprenant des nucléosides acycliques et abasiques, et analogues
|
|
US20130260460A1
(en)
|
2010-04-22 |
2013-10-03 |
Isis Pharmaceuticals Inc |
Conformationally restricted dinucleotide monomers and oligonucleotides
|
|
US9725479B2
(en)
|
2010-04-22 |
2017-08-08 |
Ionis Pharmaceuticals, Inc. |
5′-end derivatives
|
|
EP2563393B1
(fr)
|
2010-04-26 |
2016-06-08 |
Abraxis BioScience, LLC |
Anticorps se liant aux sparc et leurs utilisations
|
|
JP5787323B2
(ja)
*
|
2010-04-28 |
2015-09-30 |
国立大学法人北海道大学 |
脂質膜構造体
|
|
WO2011139917A1
(fr)
|
2010-04-29 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
Modulation de l'expression de la transthyrétine
|
|
US20130156845A1
(en)
|
2010-04-29 |
2013-06-20 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated single stranded rna
|
|
NZ629829A
(en)
|
2010-04-30 |
2015-11-27 |
Alexion Pharma Inc |
Anti-c5a antibodies and methods for using the antibodies
|
|
JP2013533732A
(ja)
|
2010-05-03 |
2013-08-29 |
ジェネンテック, インコーポレイテッド |
腫瘍の診断と治療のための組成物と方法
|
|
KR20130101442A
(ko)
|
2010-05-03 |
2013-09-13 |
큐알엔에이, 인크. |
시르투인 (sirt)에 대한 자연 안티센스 전사체의 저해에 의한 시르투인 (sirt) 관련된 질환의 치료
|
|
RU2012151500A
(ru)
|
2010-05-03 |
2014-06-10 |
Дженентек, Инк. |
Композиции и способы, пригодные для снижения вязкости белковосодержащих составов
|
|
JP5866106B2
(ja)
|
2010-05-12 |
2016-02-17 |
コロンビア ユニヴァーシティ |
インスリンを産生し分泌する腸内分泌細胞の製造方法
|
|
TWI531370B
(zh)
|
2010-05-14 |
2016-05-01 |
可娜公司 |
藉由抑制par4天然反股轉錄本治療par4相關疾病
|
|
EP2571878B1
(fr)
|
2010-05-17 |
2018-10-17 |
Incozen Therapeutics Pvt. Ltd. |
Nouveau composés de 3,5-disubstitués-3h-imidazo[4,5-b]pyridine et 3,5- disubstitués -3h-[1,2,3]triazolo[4,5-b]pyridine utilisés comme modulateurs des protéines kinases
|
|
DK2571516T3
(en)
|
2010-05-18 |
2018-02-05 |
Neumedicines Inc |
IL-12 FORMULATIONS FOR STIMULATING HEMOPOIES
|
|
WO2011146568A1
(fr)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Prédiction de réponses à un inhibiteur de her
|
|
DK2576783T3
(en)
|
2010-05-26 |
2018-03-12 |
Curna Inc |
TREATMENT OF ATONAL HOMOLOGY 1- (ATOH1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS AT ATOH1
|
|
CA3102008A1
(fr)
|
2010-06-02 |
2011-12-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions et methodes pour traiter une fibrose hepatique
|
|
AU2011261396B2
(en)
|
2010-06-02 |
2015-11-05 |
Dana-Farber Cancer Institute, Inc. |
Humanized monoclonal antibodies and methods of use
|
|
WO2011153243A2
(fr)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Thérapie anti-angiogénique utilisée dans le traitement du cancer de l'estomac
|
|
US9012498B2
(en)
|
2010-06-03 |
2015-04-21 |
Alnylam Pharmaceuticals, Inc. |
Biodegradable lipids for the delivery of active agents
|
|
CA2801182A1
(fr)
|
2010-06-16 |
2011-12-22 |
Metabolex, Inc. |
Agonistes du recepteur gpr120 et leurs utilisations
|
|
US8299117B2
(en)
|
2010-06-16 |
2012-10-30 |
Metabolex Inc. |
GPR120 receptor agonists and uses thereof
|
|
CN107261110A
(zh)
*
|
2010-06-19 |
2017-10-20 |
健康科学西部大学 |
Peg化脂质体包封的糖肽抗生素的新制剂
|
|
ES2676209T3
(es)
|
2010-06-23 |
2018-07-17 |
Metabolex Inc. |
Composiciones de 5-etil-2-{4-[4-(4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina
|
|
PL3586826T3
(pl)
|
2010-06-24 |
2021-10-25 |
F. Hoffmann-La Roche Ag |
Kompozycje i sposoby stabilizowania preparatów zawierających białka
|
|
CN102309448B
(zh)
*
|
2010-06-29 |
2014-07-09 |
中国人民解放军军事医学科学院毒物药物研究所 |
一种肺部给药的环丙沙星药用组合物及其制备方法
|
|
US9006417B2
(en)
|
2010-06-30 |
2015-04-14 |
Protiva Biotherapeutics, Inc. |
Non-liposomal systems for nucleic acid delivery
|
|
PL2591114T3
(pl)
|
2010-07-06 |
2017-08-31 |
Glaxosmithkline Biologicals Sa |
Immunizacja dużych ssaków małymi dawkami rna
|
|
PT3243526T
(pt)
|
2010-07-06 |
2020-03-04 |
Glaxosmithkline Biologicals Sa |
Distribuição de arn para despoletar múltiplas vias imunitárias
|
|
AU2011276234B2
(en)
|
2010-07-06 |
2016-02-25 |
Glaxosmithkline Biologicals S.A. |
Liposomes with lipids having an advantageous pKa- value for RNA delivery
|
|
FI4005592T3
(fi)
|
2010-07-06 |
2023-01-13 |
|
Virionin kaltaisia kuljetuspartikkeleita itsereplikoituville rna-molekyyleille
|
|
PE20130643A1
(es)
|
2010-07-12 |
2013-06-07 |
Covx Technologies Ireland Ltd |
Conjugados de anticuerpos multifuncionales
|
|
US20120208855A1
(en)
|
2010-07-12 |
2012-08-16 |
Sanofi |
Amino-benzoic acid derivatives for use in the treatment of dihydrogenase-related disorders
|
|
EP2593547B1
(fr)
|
2010-07-14 |
2017-11-15 |
CuRNA, Inc. |
Traitement de maladies liées à « discs large homolog » (dlg) par inhibition de transcrit antisens naturel de dlg
|
|
AU2011280969A1
(en)
|
2010-07-23 |
2013-02-07 |
Trustees Of Boston University |
Anti-Despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
|
|
US20130202652A1
(en)
|
2010-07-30 |
2013-08-08 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
|
US20130323269A1
(en)
|
2010-07-30 |
2013-12-05 |
Muthiah Manoharan |
Methods and compositions for delivery of active agents
|
|
US8906943B2
(en)
|
2010-08-05 |
2014-12-09 |
John R. Cashman |
Synthetic compounds and methods to decrease nicotine self-administration
|
|
EP2603237A4
(fr)
|
2010-08-12 |
2014-05-21 |
Theraclone Sciences Inc |
Compositions d'anticorps anti-hemagglutinine et ses méthodes d'utilisation
|
|
EP2420250A1
(fr)
|
2010-08-13 |
2012-02-22 |
Universitätsklinikum Münster |
Anticorps anti-syndecan-4
|
|
EP4549461A3
(fr)
|
2010-08-31 |
2025-08-06 |
Theraclone Sciences, Inc. |
Anticorps neutralisant le virus de l'immunodéficience humaine (vih)
|
|
PT3981427T
(pt)
|
2010-08-31 |
2022-06-27 |
Glaxosmithkline Biologicals Sa |
Lipossomas peguilados para entrega de arn codificador de imunogénio
|
|
PL4008357T3
(pl)
|
2010-08-31 |
2023-03-06 |
Glaxosmithkline Biologicals Sa |
Małe liposomy do dostarczania rna kodującego immunogen
|
|
US8551479B2
(en)
|
2010-09-10 |
2013-10-08 |
Oncomed Pharmaceuticals, Inc. |
Methods for treating melanoma
|
|
US8481680B2
(en)
|
2010-10-05 |
2013-07-09 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
|
KR101886457B1
(ko)
|
2010-10-06 |
2018-08-07 |
큐알엔에이, 인크. |
시알리다아제 4 (neu4)에 대한 자연 안티센스 전사체의 저해에 의한 neu4 관련된 질환의 치료
|
|
TR201903651T4
(tr)
|
2010-10-11 |
2019-04-22 |
Glaxosmithkline Biologicals Sa |
Antijen uygulama platformları.
|
|
CN103180445B
(zh)
|
2010-10-22 |
2018-02-16 |
库尔纳公司 |
通过抑制α‑L‑艾杜糖醛酸酶(IDUA)的天然反义转录物而治疗IDUA相关疾病
|
|
WO2012061129A1
(fr)
|
2010-10-25 |
2012-05-10 |
Genentech, Inc |
Traitement de l'inflammation gastro-intestinale et du parapsoriasis
|
|
DK2633052T3
(en)
|
2010-10-27 |
2018-07-16 |
Curna Inc |
TREATMENT OF INTERFERON-RELATED DEVELOPMENT REGULATOR 1 (IFRD1) -RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPT TO IFRD1
|
|
PE20141162A1
(es)
|
2010-11-04 |
2014-09-18 |
Boehringer Ingelheim Int |
Anticuerpos anti-il-23
|
|
US20140134181A1
(en)
|
2010-11-05 |
2014-05-15 |
Kenneth E. Lipson |
Treatment Method For Lung Remodeling Diseases
|
|
CN110123830A
(zh)
|
2010-11-09 |
2019-08-16 |
阿尔尼拉姆医药品有限公司 |
用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
|
|
US9518114B2
(en)
|
2010-11-12 |
2016-12-13 |
Purdue Research Foundation |
Treating bladder tumor cells using fibronectin attachment protein as a target
|
|
US20140199682A1
(en)
|
2010-11-17 |
2014-07-17 |
Sea Lane Biotechnologies, Llc |
Influenza neutralizing agents
|
|
JP2014505666A
(ja)
|
2010-11-18 |
2014-03-06 |
ザ ジェネラル ホスピタル コーポレイション |
癌治療のための降圧剤の組成物および使用
|
|
CA2818824A1
(fr)
|
2010-11-23 |
2012-05-31 |
Joseph Collard |
Traitement de maladies associees a nanog par l'inhibition d'un transcript antisens naturel de nanog
|
|
AU2011336632B2
(en)
|
2010-11-30 |
2015-09-03 |
Gilead Pharmasset Llc |
Compounds
|
|
EP2648763A4
(fr)
|
2010-12-10 |
2014-05-14 |
Alnylam Pharmaceuticals Inc |
Compositions et procédés d'inhibition de l'expression des gènes klf-1 et bcl11a
|
|
US9193973B2
(en)
|
2010-12-10 |
2015-11-24 |
Alynylam Pharmaceuticals, Inc. |
Compositions and methods for increasing erythropoietin (EPO) production
|
|
CA2821024A1
(fr)
|
2010-12-14 |
2012-06-21 |
Technical University Of Denmark |
Piegeage de radionucleides dans des compositions de nanoparticules
|
|
EP2468259A1
(fr)
*
|
2010-12-23 |
2012-06-27 |
Traslational Cancer Drugs Pharma, S.L. |
Compositions pharmaceutiques de dérivés de pyridinium et de quinolinium
|
|
AU2011353698B2
(en)
|
2011-01-05 |
2017-05-11 |
Livon Laboratories |
Methods of making liposomes, liposome compositions made by the methods, and methods of using the same
|
|
AU2012206945B2
(en)
|
2011-01-11 |
2015-02-19 |
Dimerix Bioscience Pty Ltd |
Combination therapy
|
|
US9999673B2
(en)
|
2011-01-11 |
2018-06-19 |
Alnylam Pharmaceuticals, Inc. |
PEGylated lipids and their use for drug delivery
|
|
US9173894B2
(en)
|
2011-02-02 |
2015-11-03 |
Excaliard Pharamaceuticals, Inc. |
Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (CTGF)
|
|
RU2440142C1
(ru)
|
2011-02-07 |
2012-01-20 |
Общество С Ограниченной Ответственностью "Онкомакс" |
Антитело, останавливающее или замедляющее рост опухоли (варианты), способ подавления роста опухоли, способ диагностики злокачественных образований
|
|
WO2012109495A1
(fr)
|
2011-02-09 |
2012-08-16 |
Metabolic Solutions Development Company, Llc |
Cibles cellulaires de thiazolidinediones
|
|
CA2827301A1
(fr)
|
2011-02-14 |
2012-08-23 |
Theraclone Sciences, Inc. |
Compositions et methodes de therapie et de diagnostic de la grippe
|
|
PL226015B1
(pl)
*
|
2011-03-03 |
2017-06-30 |
Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną |
Liposomowy preparat zawierajacy przeciwnowotworowa substancje aktywna, sposob jego wytwarzania i zawierajaca go kompozycja farmaceutyczna
|
|
WO2012122484A1
(fr)
|
2011-03-09 |
2012-09-13 |
Roberto Polakiewicz |
Procédés et réactifs pour créer des anticorps monoclonaux
|
|
SG193402A1
(en)
|
2011-03-15 |
2013-10-30 |
Theraclone Sciences Inc |
Compositions and methods for the therapy and diagnosis of influenza
|
|
SG10201601789TA
(en)
|
2011-03-16 |
2016-04-28 |
Amgen Inc |
Potent And Selective Inhibitors Of Nav1.3 And Nav1.7
|
|
US10184942B2
(en)
|
2011-03-17 |
2019-01-22 |
University Of South Florida |
Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
|
|
US9181308B2
(en)
|
2011-03-28 |
2015-11-10 |
St. Jude Children's Research Hospital |
Methods and compositions employing immunogenic fusion proteins
|
|
SG10201602369PA
(en)
|
2011-03-29 |
2016-05-30 |
Alnylam Pharmaceuticals Inc |
Double-Stranded RNA (dsRNA) For Inhibiting Expression Of TMPRSS6
|
|
AU2012236304C1
(en)
|
2011-03-31 |
2017-01-05 |
Genentech, Inc. |
Methods of administering beta7 integrin antagonists
|
|
EP2508176A1
(fr)
|
2011-04-08 |
2012-10-10 |
Lipotarg Gmbh |
Nouveau traitement combiné du cancer
|
|
AU2012242642A1
(en)
|
2011-04-13 |
2013-05-02 |
Ionis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
|
ES2669310T3
(es)
|
2011-04-20 |
2018-05-24 |
Medimmune, Llc |
Anticuerpos y otras moléculas que se unen con B7-H1 y PD-1
|
|
KR101589135B1
(ko)
|
2011-04-20 |
2016-01-29 |
주식회사 셀앤바이오 |
인간화 항-emapii 항체 및 이의 용도
|
|
PT2705029T
(pt)
|
2011-05-04 |
2019-02-01 |
Rhizen Pharmaceuticals S A |
Novos compostos como moduladores de proteína quinases
|
|
CN107903325B
(zh)
|
2011-05-16 |
2021-10-29 |
埃泰美德(香港)有限公司 |
多特异性fab融合蛋白及其使用方法
|
|
WO2012166903A1
(fr)
|
2011-06-02 |
2012-12-06 |
President And Fellows Of Harvard College |
Procédés et utilisations associés à des systèmes de culture tissulaire ex vivo
|
|
RU2620980C2
(ru)
|
2011-06-09 |
2017-05-30 |
Курна, Инк. |
Лечение заболеваний, связанных с фратаксином (fxn), путем ингибирования природного антисмыслового транскрипта fxn
|
|
PL2691530T3
(pl)
|
2011-06-10 |
2019-02-28 |
Oregon Health & Science University |
Glikoproteiny i rekombinowane wektory CMV
|
|
CA2839437A1
(fr)
|
2011-06-16 |
2012-12-20 |
Isis Pharmaceuticals, Inc. |
Modulation antisens de l'expression du recepteur 4 du facteur de croissance fibroblastique
|
|
MX344807B
(es)
|
2011-06-21 |
2017-01-09 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para inhibicion de genes para alipoproteina c-iii (apoc3).
|
|
EP3388068A1
(fr)
|
2011-06-21 |
2018-10-17 |
Alnylam Pharmaceuticals, Inc. |
Composition et procédés d'inhibition de l'expression des gènes de la protéine c (proc)
|
|
EP2723865B1
(fr)
|
2011-06-21 |
2019-03-27 |
Alnylam Pharmaceuticals, Inc. |
PROCÉDÉS DE DÉTERMINATION DE L'ACTIVITÉ DU RNAi CHEZ UN SUJET
|
|
EP2537532A1
(fr)
|
2011-06-22 |
2012-12-26 |
J. Stefan Institute |
Composés capables de se lier à une cathepsine, liés à un nanodispositif et leur utilisation thérapeutique et diagnostique
|
|
WO2012178033A2
(fr)
|
2011-06-23 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Arnsi de serpina1 : compositions et méthodes de traitement
|
|
JP2014527036A
(ja)
|
2011-06-27 |
2014-10-09 |
ザ ジャクソン ラボラトリー |
癌および自己免疫疾患の処置のための方法および組成物
|
|
US20150045540A1
(en)
|
2011-06-28 |
2015-02-12 |
Sea Lane Biotechnologies, Llc |
Multispecific stacked variable domain binding proteins
|
|
EP2729165B1
(fr)
|
2011-07-06 |
2017-11-08 |
GlaxoSmithKline Biologicals SA |
Compositions de combinaisons immunogènes et utilisations de celles-ci
|
|
WO2013008240A2
(fr)
|
2011-07-13 |
2013-01-17 |
Yissum Research Development Company Of The Hebrew University Ofjerusalem Ltd. |
Liposomes co-encapsulant un biphosphonate et un agent amphipathique
|
|
MX2014000578A
(es)
|
2011-07-14 |
2014-04-30 |
Pfizer |
Tratamiento con anticuerpos anti-pcsk9.
|
|
US9120858B2
(en)
|
2011-07-22 |
2015-09-01 |
The Research Foundation Of State University Of New York |
Antibodies to the B12-transcobalamin receptor
|
|
WO2013015821A1
(fr)
|
2011-07-22 |
2013-01-31 |
The Research Foundation Of State University Of New York |
Anticorps anti-récepteur de b12-transcobalamine
|
|
US20130022551A1
(en)
|
2011-07-22 |
2013-01-24 |
Trustees Of Boston University |
DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
|
|
US20140328811A1
(en)
|
2011-08-01 |
2014-11-06 |
Alnylam Pharmaceuticals, Inc. |
Method for improving the success rate of hematopoietic stem cell transplants
|
|
CA2845536A1
(fr)
|
2011-08-15 |
2013-02-21 |
Amplimmune, Inc. |
Anticorps anti-b7-h4 et leurs utilisations
|
|
FR2979239A1
(fr)
*
|
2011-08-25 |
2013-03-01 |
Trophos |
Liposome comprenant au moins un derive de cholesterol
|
|
WO2013033069A1
(fr)
|
2011-08-30 |
2013-03-07 |
Theraclone Sciences, Inc. |
Anticorps anti-rhinovirus humain (rvh)
|
|
HUE037829T2
(hu)
|
2011-08-31 |
2018-09-28 |
St Jude Childrens Res Hospital |
Eljárások és készítmények lizoszomális exocitózis aktivitás mértékének detektálására és alkamazási eljárások
|
|
PH12014500544B1
(en)
|
2011-09-09 |
2019-03-13 |
Dept Of Medical Sciences Dmsc |
Dengue-virus serotype neutralizing antibodies
|
|
EP2568289A3
(fr)
|
2011-09-12 |
2013-04-03 |
International AIDS Vaccine Initiative |
Immunosélection du virus de la stomatite vésiculaire recombinant exprimant les protéines du VIH-1 par des anticorps largement neutralisants
|
|
US9434753B2
(en)
|
2011-09-19 |
2016-09-06 |
Gencia Corporation |
Modified creatine compounds
|
|
DK2758533T3
(en)
|
2011-09-20 |
2018-05-28 |
Ionis Pharmaceuticals Inc |
ANTISENCE MODULATION OF GCGR EXPRESSION
|
|
MX2014003313A
(es)
|
2011-09-23 |
2014-07-09 |
Amgen Res Munich Gmbh |
Moleculas de union biespecificas para 5t4 y cd3.
|
|
PT3485903T
(pt)
|
2011-09-23 |
2023-02-17 |
Mereo Biopharma 5 Inc |
Agentes de ligação a vegf/dll4 e utilizações dos mesmos
|
|
CA2849409A1
(fr)
|
2011-09-23 |
2013-03-28 |
Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa |
Agents du facteur de necrose tumorale alpha et utilisations de ceux-ci
|
|
WO2013049328A1
(fr)
|
2011-09-27 |
2013-04-04 |
Alnylam Pharmaceuticals, Inc. |
Lipides di-aliphatiques pegylés substitués
|
|
JP6368645B2
(ja)
|
2011-09-29 |
2018-08-01 |
ピーエルエックス オプコ インコーポレーテッド |
胃腸管に沿った医薬の標的化放出のためのpH依存性担体、それによる組成物、ならびにこれらの製造および使用
|
|
US20130085139A1
(en)
|
2011-10-04 |
2013-04-04 |
Royal Holloway And Bedford New College |
Oligomers
|
|
CN113876945A
(zh)
|
2011-10-06 |
2022-01-04 |
免疫疫苗技术有限公司 |
包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用
|
|
CA2850032C
(fr)
|
2011-10-14 |
2022-06-07 |
Genentech, Inc. |
Anticorps anti-htra1 et leurs procedes d'utilisation
|
|
US8883989B2
(en)
|
2011-10-18 |
2014-11-11 |
Regents Of The University Of Minnesota |
Fractalkine binding polynucleotides and methods of use
|
|
HK1201555A1
(en)
|
2011-10-25 |
2015-09-04 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of gccr expression
|
|
EP2586461A1
(fr)
|
2011-10-27 |
2013-05-01 |
Christopher L. Parks |
Particules virales dérivées d'un virus enveloppé
|
|
JP6251682B2
(ja)
|
2011-10-28 |
2017-12-20 |
ジェネンテック, インコーポレイテッド |
メラノーマ治療の治療の組み合わせ及び方法
|
|
RS63948B1
(sr)
|
2011-10-31 |
2023-02-28 |
Hoffmann La Roche |
Formulacije anti-il13 antitela
|
|
AU2012332176B2
(en)
*
|
2011-11-03 |
2016-03-10 |
Tlc Biopharmaceuticals, Inc. |
Pharmaceutical compositions of hydrophobic camptothecin derivatives
|
|
US10980798B2
(en)
|
2011-11-03 |
2021-04-20 |
Taiwan Liposome Company, Ltd. |
Pharmaceutical compositions of hydrophobic camptothecin derivatives
|
|
CN104053672A
(zh)
|
2011-11-11 |
2014-09-17 |
瑞纳神经科学公司 |
Trop-2特异性抗体及其用途
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對bcma之e3以及cd3的結合分子
|
|
SG11201402283PA
(en)
|
2011-11-16 |
2014-06-27 |
Boehringer Ingelheim Int |
Anti il-36r antibodies
|
|
CA2858876A1
(fr)
|
2011-12-15 |
2013-06-20 |
The University Of Chicago |
Methodes et compositions destines au traitement du cancer utilisant des molecules light mutantes ayant une affinite accrue pour les recepteurs
|
|
WO2013093693A1
(fr)
|
2011-12-22 |
2013-06-27 |
Rinat Neuroscience Corp. |
Anticorps spécifiques de staphylococcus aureus et leurs utilisations
|
|
MX2014007644A
(es)
|
2011-12-22 |
2014-09-26 |
Rinat Neuroscience Corp |
Anticuerpos antagonistas del receptor de hormona de crecimiento humana y metodos para su uso.
|
|
CA3111357A1
(fr)
|
2011-12-23 |
2013-06-27 |
Pfizer Inc. |
Regions constantes d'anticorps modifies pour conjugaison specifique a un site, et leurs procedes et utilisations
|
|
WO2013101771A2
(fr)
|
2011-12-30 |
2013-07-04 |
Genentech, Inc. |
Compositions et méthode pour le traitement de maladies auto-immunes
|
|
EP3447071A1
(fr)
|
2012-01-09 |
2019-02-27 |
Pfizer Healthcare Ireland |
Anticorps mutants et leur conjugaison
|
|
US9636381B2
(en)
|
2012-01-18 |
2017-05-02 |
Neumedicines, Inc. |
Methods for radiation protection by administering IL-12
|
|
CA2862292C
(fr)
|
2012-01-20 |
2019-10-08 |
Sea Lane Biotechnologies, Llc |
Conjugues de molecule de liaison
|
|
US20150004219A1
(en)
|
2012-02-02 |
2015-01-01 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. |
Stable liposomes for drug delivery
|
|
MY169341A
(en)
|
2012-02-06 |
2019-03-21 |
Inhibrx Inc |
Cd47 antibodies and methods of use thereof
|
|
WO2013123407A1
(fr)
*
|
2012-02-17 |
2013-08-22 |
Celsion Corporation |
Formulations de nanoparticules thermosensibles et leur procédé de fabrication
|
|
US9138492B2
(en)
*
|
2012-02-23 |
2015-09-22 |
Canon Kabushiki Kaisha |
Particle containing hydrophobic dye having cyanine structure, and contrast agent containing the particle
|
|
EP2820047B1
(fr)
|
2012-03-01 |
2018-04-25 |
Amgen Research (Munich) GmbH |
Molécules de liaison à un polypeptide à longue durée de vie
|
|
US8865730B2
(en)
|
2012-03-05 |
2014-10-21 |
Gilead Calistoga Llc |
Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
|
|
TR201815503T4
(tr)
|
2012-03-15 |
2018-11-21 |
Curna Inc |
Beyin kaynaklı nörotrofik faktör (bknf) ile ilişkili hastalıkların doğal antisens transkriptinin bknf'ye inhibisyonu ile muamelesi.
|
|
CA2869048C
(fr)
|
2012-03-29 |
2023-10-17 |
Novimmune S.A. |
Anticorps anti-tlr4 et utilisations de ceux-ci
|
|
KR20140144726A
(ko)
|
2012-03-30 |
2014-12-19 |
리젠 파마슈티컬스 소시에떼 아노님 |
C-met 단백질 키나제의 조절제로서의 신규한 3,5-디치환-3h-이미다조[4,5-b]피리딘 및 3,5- 디치환 -3h-[1,2,3]트리아졸로[4,5-b] 피리딘 화합물
|
|
WO2013151649A1
(fr)
|
2012-04-04 |
2013-10-10 |
Sialix Inc |
Composés d'interaction avec des glycanes
|
|
US9133461B2
(en)
|
2012-04-10 |
2015-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the ALAS1 gene
|
|
CA2871462A1
(fr)
|
2012-04-24 |
2013-10-31 |
University Of Miami |
Defense par la perforine-2 contre des pathogenes invasifs et polyresistants
|
|
KR102124758B1
(ko)
|
2012-05-03 |
2020-06-19 |
베링거 인겔하임 인터내셔날 게엠베하 |
항-il-23p19 항체
|
|
JP6392209B2
(ja)
*
|
2012-05-04 |
2018-09-19 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
粘液内層を通過する迅速な透過のための脂質ベース薬物キャリア
|
|
HK1207655A1
(en)
|
2012-05-04 |
2016-02-05 |
Dana-Farber Cancer Institute, Inc. |
Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use
|
|
AU2013202947B2
(en)
|
2012-06-13 |
2016-06-02 |
Ipsen Biopharm Ltd. |
Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
|
|
US9717724B2
(en)
|
2012-06-13 |
2017-08-01 |
Ipsen Biopharm Ltd. |
Methods for treating pancreatic cancer using combination therapies
|
|
AU2013274101B2
(en)
|
2012-06-15 |
2017-09-07 |
The Brigham And Women's Hospital, Inc. |
Compositions for treating cancer and methods for making the same
|
|
WO2013192546A1
(fr)
|
2012-06-22 |
2013-12-27 |
Cytomx Therapeutics, Inc. |
Anticorps activables ayant des fragments stériques ne se liant pas et leurs procédés d'utilisation
|
|
EP2679596B1
(fr)
|
2012-06-27 |
2017-04-12 |
International Aids Vaccine Initiative |
Variante de la protéine env du VIH-1
|
|
US10022326B2
(en)
|
2012-07-18 |
2018-07-17 |
Onyx Therapeutics, Inc. |
Liposomal compositions of epoxyketone-based proteasome inhibitors
|
|
US8603470B1
(en)
|
2012-08-07 |
2013-12-10 |
National Cheng Kung University |
Use of IL-20 antagonists for treating liver diseases
|
|
CN110464709A
(zh)
*
|
2012-08-10 |
2019-11-19 |
德克萨斯州大学系统董事会 |
用于治疗中风的神经保护性脂质体组合物和方法
|
|
WO2014027959A1
(fr)
|
2012-08-14 |
2014-02-20 |
Nanyang Technological University |
Anticorps analogue à l'angiopoïétine 4 et son utilisation dans le traitement d'un cancer
|
|
ES2848025T3
(es)
|
2012-09-04 |
2021-08-05 |
Eleison Pharmaceuticals LLC |
Prevención de la recidiva pulmonar del cáncer con cisplatino complejado con lípidos
|
|
WO2014041179A1
(fr)
|
2012-09-17 |
2014-03-20 |
Chemedest Ltd. |
Traitement d'une neuropathie périphérique à l'aide d'agonistes du récepteur de type 3 de gfr(alpha)3
|
|
CN107892719B
(zh)
|
2012-10-04 |
2022-01-14 |
达纳-法伯癌症研究所公司 |
人单克隆抗-pd-l1抗体和使用方法
|
|
MX372664B
(es)
|
2012-10-05 |
2020-05-06 |
Genentech Inc |
Un antagonista de integrina beta7 para usarse en diagnosticar y tratar la enfermedad inflamatoria intestinal.
|
|
WO2014066328A1
(fr)
|
2012-10-23 |
2014-05-01 |
Oncomed Pharmaceuticals, Inc. |
Méthodes de traitement de tumeurs neuro-endocrines à l'aide d'agents liants de parcours wnt
|
|
CA2889638A1
(fr)
|
2012-10-31 |
2014-05-08 |
Oncomed Pharmaceuticals, Inc. |
Methodes et surveillance d'un traitement par un antagoniste de dll4
|
|
PT2925782T
(pt)
|
2012-12-03 |
2020-04-22 |
Novimmune Sa |
Anticorpos anti-cd47 e métodos de utilização destes
|
|
WO2014092858A1
(fr)
|
2012-12-12 |
2014-06-19 |
Temple University - Of The Commonwealth System Of Higher Education |
Compositions et méthodes de traitement du cancer
|
|
SG11201504764SA
(en)
|
2012-12-19 |
2015-07-30 |
Amplimmune Inc |
Anti-human b7-h4 antibodies and their uses
|
|
ES2764090T3
(es)
|
2012-12-19 |
2020-06-02 |
Univ New York State Res Found |
Composiciones y procedimiento para la liberación activada por la luz de materiales de nanovesículas
|
|
US20160067347A1
(en)
|
2012-12-20 |
2016-03-10 |
Amgen Inc. |
Apj receptor agonists and uses thereof
|
|
GB201223053D0
(en)
|
2012-12-20 |
2013-02-06 |
Medical Res Council |
Receptor
|
|
JP6359031B2
(ja)
|
2012-12-21 |
2018-07-18 |
メディミューン,エルエルシー |
抗h7cr抗体
|
|
US9566325B2
(en)
|
2013-01-07 |
2017-02-14 |
Biomedical Research Models, Inc. |
Therapeutic vaccines for treating herpes simplex virus type-2 infections
|
|
US9920121B2
(en)
|
2013-01-25 |
2018-03-20 |
Amgen Inc. |
Antibodies targeting CDH19 for melanoma
|
|
JO3519B1
(ar)
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
تركيبات أجسام مضادة لأجل cdh19 و cd3
|
|
US10568975B2
(en)
|
2013-02-05 |
2020-02-25 |
The Johns Hopkins University |
Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
|
|
EP2953643B1
(fr)
|
2013-02-06 |
2023-02-22 |
Inhibrx, Inc. |
Anticorps cd47 n'induisant ni l'appauvrissement en globules rouges ni l'appauvrissement en plaquettes et methodes d'utilisation de ceux-ci
|
|
US9534041B2
(en)
|
2013-02-12 |
2017-01-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that neutralize a norovirus
|
|
TW201446792A
(zh)
|
2013-03-12 |
2014-12-16 |
Amgen Inc |
Nav1.7之強效及選擇性抑制劑
|
|
US9302005B2
(en)
|
2013-03-14 |
2016-04-05 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
|
BR112015022936A2
(pt)
|
2013-03-14 |
2017-07-18 |
J Schentag Jerome |
vesículas de colestossoma para a incorporação de moléculas em quilomícrons
|
|
AR095374A1
(es)
|
2013-03-15 |
2015-10-14 |
Amgen Res Munich Gmbh |
Moléculas de unión para bcma y cd3
|
|
EP3594244A1
(fr)
|
2013-03-15 |
2020-01-15 |
Dyax Corp. |
Anticorps de kallicréine anti-plasma
|
|
WO2014152497A2
(fr)
|
2013-03-15 |
2014-09-25 |
The Trustees Of Columbia University In The City Of New York |
Ostéocalcine en tant que traitement de troubles cognitifs
|
|
MX367668B
(es)
|
2013-03-15 |
2019-08-30 |
Dana Farber Cancer Inst Inc |
Anticuerpos neutralizadores de flavivirus y métodos de uso de los mismos.
|
|
US20140283157A1
(en)
|
2013-03-15 |
2014-09-18 |
Diadexus, Inc. |
Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
|
|
UY35484A
(es)
|
2013-03-15 |
2014-10-31 |
Amgen Res Munich Gmbh |
Molécula de unión de cadena simple que comprenden ABP de extremo N
|
|
CA2906697A1
(fr)
|
2013-03-15 |
2014-09-18 |
Gencia Corporation |
Compositions et methodes de traitement d'affections qui touchent l'epiderme
|
|
US9505849B2
(en)
|
2013-03-15 |
2016-11-29 |
Amgen Research (Munich) Gmbh |
Antibody constructs for influenza M2 and CD3
|
|
US11156608B2
(en)
|
2013-03-15 |
2021-10-26 |
The Trustees Of The University Of Pennsylvania |
Method for the site-specific covalent cross-linking of antibodies to surfaces
|
|
EP2968374A4
(fr)
*
|
2013-03-15 |
2016-08-10 |
Alphabet 3 Llc M |
Méthodes et compositions permettant d'améliorer le taux d'oxygène dans des tissus
|
|
WO2014160871A2
(fr)
|
2013-03-27 |
2014-10-02 |
The General Hospital Corporation |
Procédés et agents pour le traitement de la maladie d'alzheimer
|
|
EP3495814A3
(fr)
|
2013-03-27 |
2019-07-17 |
F. Hoffmann-La Roche AG |
Utilisation de biomarqueurs pour évaluer le traitement de troubles inflammatoires gastro-intestinaux avec des antagonistes de l'intégrine beta7
|
|
EP2983787B1
(fr)
|
2013-04-12 |
2019-10-02 |
Icahn School of Medicine at Mount Sinai |
Méthode pour le traitement de l'état de stress post-traumatique
|
|
WO2014179760A1
(fr)
|
2013-05-03 |
2014-11-06 |
The Regents Of The University Of California |
Induction de dinucléotide cyclique de l'interféron de type i
|
|
WO2014182661A2
(fr)
|
2013-05-06 |
2014-11-13 |
Alnylam Pharmaceuticals, Inc |
Dosages et méthodes pour administrer des molécules d'acides nucléiques à formulation lipidique
|
|
PL2981822T3
(pl)
|
2013-05-06 |
2021-07-12 |
Scholar Rock, Inc. |
Kompozycje i sposoby modulacji czynnika wzrostu
|
|
SG11201508264UA
(en)
|
2013-05-07 |
2015-11-27 |
Rinat Neuroscience Corp |
Anti-glucagon receptor antibodies and methods of use thereof
|
|
EP3583950A1
(fr)
|
2013-05-09 |
2019-12-25 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Anticorps vhh à domaine unique dirigé contre les norovirus gi.1 et gii.4 et leur utilisation
|
|
SG11201509618QA
(en)
|
2013-05-24 |
2015-12-30 |
Medimmune Llc |
Anti-b7-h5 antibodies and their uses
|
|
BR112015029838A2
(pt)
|
2013-05-31 |
2017-09-26 |
Genentech Inc |
anticorpos, composições, ácido nucleico isolado, vetor, célula hospedeira isolada, método de produção de anticorpos, composto, conjugado de anticorpo e antibiótico, processo de elaboração do composto, intermediário entre ligante e antibiótico, método de tratamento de infecções bacterianas e método de matar staphylococcus aureus
|
|
BR112015029754A2
(pt)
|
2013-05-31 |
2017-09-26 |
Genentech Inc |
anticorpos anti-teicoico da parede e conjugados
|
|
NZ714765A
(en)
|
2013-06-06 |
2021-12-24 |
Pf Medicament |
Anti-c10orf54 antibodies and uses thereof
|
|
US20160129089A1
(en)
|
2013-06-13 |
2016-05-12 |
Antisense Therapeutics Ltd |
Combination therapy
|
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
|
BR112016001611B1
(pt)
|
2013-07-25 |
2024-01-09 |
Cytomx Therapeutics, Inc |
Anticorpo ativável multiespecífico, uso terapêutico do mesmo, molécula de ácido nucleico isolada, vetor e método para produzir um anticorpo ativável multiespecífico
|
|
WO2015017807A1
(fr)
*
|
2013-08-01 |
2015-02-05 |
University Of Georgia Research Foundation, Inc. |
Formulations liposomales pour le traitement d'infections bactériennes
|
|
SG11201600171SA
(en)
|
2013-08-02 |
2016-02-26 |
Pfizer |
Anti-cxcr4 antibodies and antibody-drug conjugates
|
|
MX2016001854A
(es)
|
2013-08-12 |
2016-09-06 |
Genentech Inc |
Composiciones y metodo para tratar condiciones asociadas con el complemento.
|
|
US10077304B2
(en)
|
2013-08-14 |
2018-09-18 |
The Governing Council Of The University Of Toronto |
Antibodies against frizzled receptor
|
|
WO2015031536A1
(fr)
*
|
2013-08-27 |
2015-03-05 |
Northeastern University |
Système de délivrance de médicament nanoparticulaire et procédé de traitement du cancer et d'un traumatisme neurologique
|
|
PL3041958T3
(pl)
|
2013-09-04 |
2020-11-02 |
Cold Spring Harbor Laboratory |
Redukcja rozpadu mRNA mediowanego sekwencjami nonsensownymi
|
|
IL300444A
(en)
|
2013-09-05 |
2023-04-01 |
Sarepta Therapeutics Inc |
Inclusion of exon 2 is induced by antisense in acid alpha-glucosidase
|
|
EP2848937A1
(fr)
|
2013-09-05 |
2015-03-18 |
International Aids Vaccine Initiative |
Procédés d'identification de nouveaux immunogènes du VIH-1
|
|
TWI688401B
(zh)
|
2013-09-13 |
2020-03-21 |
美商安進公司 |
用於治療骨髓性白血病的表觀遺傳因子與靶向cd33及cd3之雙特異性化合物的組合
|
|
WO2015053910A2
(fr)
*
|
2013-09-16 |
2015-04-16 |
Glycomine Llc |
Préparation pharmaceutique de glucides à usage thérapeutique
|
|
DE102013015334A1
(de)
*
|
2013-09-17 |
2015-03-19 |
Fresenius Medical Care Deutschland Gmbh |
Magnesium-Liposomen-Komplexe
|
|
US10036020B2
(en)
|
2013-09-19 |
2018-07-31 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Compositions and methods for inhibiting JC virus (JCV)
|
|
US20150087810A1
(en)
|
2013-09-25 |
2015-03-26 |
Cytomx Therapeutics, Inc. |
Matrix Metalloproteinase Substrates And Other Cleavable Moieties And Methods Of Use Thereof
|
|
ES2714708T3
(es)
|
2013-10-01 |
2019-05-29 |
Mayo Found Medical Education & Res |
Procedimientos para el tratamiento de cáncer en pacientes con niveles elevados de Bim
|
|
TW202003849A
(zh)
|
2013-10-02 |
2020-01-16 |
美商艾爾妮蘭製藥公司 |
抑制lect2基因表現之組合物及方法
|
|
PE20161130A1
(es)
|
2013-10-04 |
2016-11-25 |
Icahn School Med Mount Sinai |
Composiciones y metodos para inhibir la expresion del gen alas1
|
|
US10058604B2
(en)
|
2013-10-07 |
2018-08-28 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
|
EP3070167A4
(fr)
|
2013-11-06 |
2017-06-07 |
Osaka University |
Anticorps présentant une large activité neutralisante contre le virus de la grippe a de groupe 1
|
|
WO2015087187A1
(fr)
|
2013-12-10 |
2015-06-18 |
Rinat Neuroscience Corp. |
Anticorps anti-sclérostine
|
|
WO2015089375A1
(fr)
|
2013-12-13 |
2015-06-18 |
The General Hospital Corporation |
Espèce tau soluble de poids moléculaire élevé (hmw) et ses applications
|
|
EP3083623A1
(fr)
|
2013-12-20 |
2016-10-26 |
Gilead Calistoga LLC |
Formes polymorphes d'un sel chlorhydrate de la (s)-2-(9h-purine-6-ylamino)propyl)-5-fluoro-3-phénylquinazolin-4(3h)-one
|
|
ES2752552T3
(es)
|
2013-12-20 |
2020-04-06 |
Gilead Calistoga Llc |
Métodos de proceso para inhibidores de fosfatidilinositol 3-quinasa
|
|
JP6552509B2
(ja)
|
2014-01-14 |
2019-07-31 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
選択的atp阻害剤をカプセル化するシクロデキストリン組成物およびその使用
|
|
WO2015116902A1
(fr)
|
2014-01-31 |
2015-08-06 |
Genentech, Inc. |
Récepteurs couplés aux protéines g dans la signalisation hedgehog
|
|
US9840543B2
(en)
|
2014-01-31 |
2017-12-12 |
Boehringer Ingelheim International Gmbh |
Anti-BAFF antibodies
|
|
EP3628328B1
(fr)
|
2014-01-31 |
2022-09-14 |
Cytomx Therapeutics Inc. |
Substrats d'activateur de matriptase et du plasminogène u et d'autres fractions clivables et leurs procédés d'utilisation
|
|
DK3102197T3
(en)
|
2014-02-04 |
2018-11-19 |
Genentech Inc |
Smoothened mutant and methods for its use
|
|
WO2015127351A1
(fr)
|
2014-02-24 |
2015-08-27 |
Celgene Corporation |
Méthodes d'utilisation d'un activateur du céréblon pour l'expansion de cellules neurales et le traitement de troubles du système nerveux central
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
NZ711451A
(en)
|
2014-03-07 |
2016-05-27 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
|
AU2015231164B2
(en)
|
2014-03-19 |
2020-04-09 |
Dana-Farber Cancer Institute, Inc. |
Immunogenetic restriction on elicitation of antibodies
|
|
CN111973740A
(zh)
|
2014-03-21 |
2020-11-24 |
泰华制药国际有限公司 |
针对降钙素基因相关肽的拮抗剂抗体及其使用方法
|
|
KR20230109785A
(ko)
|
2014-03-27 |
2023-07-20 |
다케다 파머수티컬 컴패니 리미티드 |
당뇨병성 황반 부종의 치료를 위한 조성물 및 방법
|
|
SG11201607938UA
(en)
|
2014-03-27 |
2016-10-28 |
Genentech Inc |
Methods for diagnosing and treating inflammatory bowel disease
|
|
JP2017513931A
(ja)
|
2014-04-03 |
2017-06-01 |
インビクタス オンコロジー ピーヴィティー.リミテッド |
超分子コンビナトリアル治療薬
|
|
KR20160145813A
(ko)
|
2014-04-25 |
2016-12-20 |
다나-파버 캔서 인스티튜트 인크. |
중동 호흡기 증후군 코로나바이러스 중화 항체 및 이의 사용 방법
|
|
SI3137114T1
(sl)
|
2014-04-30 |
2021-11-30 |
Pfizer Inc. |
Konjugati protitelo proti PTK7-zdravilo
|
|
WO2015168474A1
(fr)
|
2014-04-30 |
2015-11-05 |
President And Fellows Of Harvard College |
Protéines de fusion pour le traitement du cancer et procédés associés
|
|
WO2015171918A2
(fr)
|
2014-05-07 |
2015-11-12 |
Louisiana State University And Agricultural And Mechanical College |
Compositions et leurs utilisations thérapeutiques
|
|
ES2936810T3
(es)
|
2014-05-16 |
2023-03-22 |
Pfizer |
Anticuerpos biespecíficos con interfaces CH1-CL de ingeniería
|
|
WO2015179654A1
(fr)
|
2014-05-22 |
2015-11-26 |
Mayo Foundation For Medical Education And Research |
Distinction d'anticorps anti-b7-h1 agonistes et antagonistes
|
|
EA028614B1
(ru)
|
2014-05-22 |
2017-12-29 |
Общество С Ограниченной Ответственностью "Русские Фармацевтические Технологии" |
Селективные ингибиторы, нарушающие взаимодействие рецептора фактора роста фибробластов и frs2, для профилактики и лечения рака
|
|
AU2015266664B2
(en)
|
2014-05-30 |
2020-04-30 |
Shanghai Henlius Biotech, Inc. |
Anti-epidermal growth factor receptor (EGFR) antibodies
|
|
JP6803236B2
(ja)
|
2014-06-10 |
2020-12-23 |
アムジェン インコーポレイテッド |
アペリンポリペプチド
|
|
WO2015191362A1
(fr)
|
2014-06-11 |
2015-12-17 |
Gilead Sciences, Inc. |
Méthodes de traitement de maladies cardiovasculaires
|
|
JP6455995B2
(ja)
|
2014-06-13 |
2019-01-23 |
ギリアード サイエンシーズ, インコーポレイテッド |
ホスファチジルイノシトール3−キナーゼ阻害剤
|
|
TWI695011B
(zh)
|
2014-06-18 |
2020-06-01 |
美商梅爾莎納醫療公司 |
抗her2表位之單株抗體及其使用之方法
|
|
JP6655074B2
(ja)
|
2014-06-20 |
2020-02-26 |
ジェネンテック, インコーポレイテッド |
シャガシンに基づく足場組成物、方法及び使用
|
|
EP3160503B1
(fr)
|
2014-06-26 |
2021-02-17 |
The Trustees of Columbia University in the City of New York |
L'inhibition de l'expression de la sérotonine dans des cellules entéroendocrines intestinales provoque leur conversion en cellules positives pour l'insuline
|
|
US10517875B2
(en)
|
2014-07-23 |
2019-12-31 |
Mayo Foundation for Medical Engineering and Research |
Targeting DNA-PKcs and B7-H1 to treat cancer
|
|
CA2955947A1
(fr)
|
2014-07-25 |
2016-01-28 |
Cytomx Therapeutics, Inc. |
Anticorps anti-cd3, anticorps anti-cd3 activables, anticorps anti-cd3 multispecifiques, anticorps anti-cd3 activables multispecifiques et procedes d'utilisation de ces anticorps
|
|
UY36245A
(es)
|
2014-07-31 |
2016-01-29 |
Amgen Res Munich Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
|
MX377344B
(es)
|
2014-07-31 |
2025-03-07 |
Amgen Res Munich Gmbh |
Constructos de anticuerpos de cadena sencilla biespecífica específicos para especies cruzadas optimizadas.
|
|
US20170224816A1
(en)
|
2014-08-06 |
2017-08-10 |
Rinat Neuroscience Corp. |
Methods for reducing ldl-cholesterol
|
|
WO2016020799A1
(fr)
|
2014-08-06 |
2016-02-11 |
Rinat Neuroscience Corp. |
Méthodes pour réduire le cholestérol ldl
|
|
WO2016033424A1
(fr)
|
2014-08-29 |
2016-03-03 |
Genzyme Corporation |
Méthodes de prévention et de traitement d'évènements indésirables cardiovasculaires majeurs à l'aide de composés modulant l'apolipoprotéine b
|
|
WO2016034968A1
(fr)
|
2014-09-02 |
2016-03-10 |
Pfizer Inc. |
Anticorps thérapeutique
|
|
US10472424B2
(en)
|
2014-09-23 |
2019-11-12 |
Pfizer Inc. |
Treatment with anti-PCSK9 antibodies
|
|
EP3201232A1
(fr)
|
2014-10-03 |
2017-08-09 |
Dana-Farber Cancer Institute, Inc. |
Anticorps dirigés contre le récepteur du facteur de nécrose tumorale induit par glucocorticoïdes (gitr) et leurs procédés d'utilisation
|
|
EP3204418B1
(fr)
|
2014-10-06 |
2020-03-25 |
Dana Farber Cancer Institute, Inc. |
Anticorps humanisés dirigés contre récepteur 4 des chimiokines cc (ccr4) et procédés de leur utilisation
|
|
GB201417589D0
(en)
|
2014-10-06 |
2014-11-19 |
Cantab Biopharmaceuticals Patents Ltd |
Pharmaceutical Formulations
|
|
ES2808153T3
(es)
|
2014-10-31 |
2021-02-25 |
Mereo Biopharma 5 Inc |
Terapia de combinación para tratamiento de enfermedad
|
|
US9879087B2
(en)
|
2014-11-12 |
2018-01-30 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
|
WO2016077566A1
(fr)
|
2014-11-12 |
2016-05-19 |
Research Institute At Nationwide Children's Hospital |
Modulation de l'épissage de mdm2 alternatif
|
|
ES2941897T3
(es)
|
2014-11-12 |
2023-05-26 |
Seagen Inc |
Compuestos que interaccionan con glicanos y procedimientos de uso
|
|
US11191811B2
(en)
|
2014-11-19 |
2021-12-07 |
The Trustees Of Columbia University In The City Of New York |
Osteocalcin as a treatment for frailty associated with aging
|
|
CN107206102A
(zh)
|
2014-12-03 |
2017-09-26 |
豪夫迈·罗氏有限公司 |
抗金黄色葡萄球菌抗体利福霉素缀合物及其用途
|
|
EP3226908A1
(fr)
|
2014-12-03 |
2017-10-11 |
F.Hoffmann-La Roche Ag |
Conjugués de rifamycine et d'anticorps anti-staphylococcus aureus et leurs utilisations
|
|
WO2016090170A1
(fr)
|
2014-12-05 |
2016-06-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anticorps puissant anti-neuraminidase d'un sous-type n1 du virus de la grippe a
|
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗pd-1抗體類和使用彼等之方法
|
|
TN2017000246A1
(en)
|
2014-12-11 |
2018-10-19 |
Pf Medicament |
Anti-c10orf54 antibodies and uses thereof
|
|
TW201702218A
(zh)
|
2014-12-12 |
2017-01-16 |
美國杰克森實驗室 |
關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
|
|
EP3233056B1
(fr)
|
2014-12-15 |
2023-11-15 |
The Johns Hopkins University |
Formulations de sunitinib et leurs procédés d'utilisation dans le traitement de troubles oculaires
|
|
CA2970795A1
(fr)
|
2014-12-18 |
2016-06-23 |
Alnylam Pharmaceuticals, Inc. |
Composes reversir
|
|
CA2972800A1
(fr)
|
2015-01-02 |
2016-07-07 |
Dyax Corp. |
Anticorps bispecifiques agissant a l'encontre la kallicreine plasmatique et du facteur xii
|
|
MA41374A
(fr)
|
2015-01-20 |
2017-11-28 |
Cytomx Therapeutics Inc |
Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
|
|
EP3247386A4
(fr)
|
2015-01-20 |
2018-10-03 |
The Children's Medical Center Corporation |
Composés anti-net pour traiter ou prévenir la fibrose et pour faciliter la cicatrisation des plaies
|
|
EP3250184B1
(fr)
|
2015-01-27 |
2024-12-18 |
The Johns Hopkins University |
Formulations d'hydrogel hypotoniques pour le transport amélioré d'agents actifs au niveau de surfaces muqueuses
|
|
JP2018506275A
(ja)
|
2015-01-28 |
2018-03-08 |
ジェネンテック, インコーポレイテッド |
多発性硬化症の遺伝子発現マーカー及び治療
|
|
EP3250588A1
(fr)
|
2015-01-29 |
2017-12-06 |
Board of Trustees of Michigan State University |
Polypeptides cryptiques et leurs utilisations
|
|
SG11201705728RA
(en)
|
2015-02-04 |
2017-08-30 |
Boehringer Ingelheim Int |
Methods of treating inflammatory diseases
|
|
EP3258913A1
(fr)
*
|
2015-02-17 |
2017-12-27 |
Mallinckrodt Nuclear Medicine LLC |
Formulations de liposomes de docétaxel modifié et utilisations associées
|
|
EP3978929A1
(fr)
|
2015-02-19 |
2022-04-06 |
Compugen Ltd. |
Polypeptides pvrig et méthodes de traitement
|
|
US10227408B2
(en)
|
2015-02-19 |
2019-03-12 |
Compugen Ltd. |
Anti-PVRIG antibodies and methods of use
|
|
EP3262072A1
(fr)
|
2015-02-26 |
2018-01-03 |
F. Hoffmann-La Roche AG |
Antagonistes d'intégrine bêta7 et procédés de traitement de la maladie de crohn
|
|
US9895313B2
(en)
|
2015-03-03 |
2018-02-20 |
Cureport, Inc. |
Combination liposomal pharmaceutical formulations
|
|
CN107530291A
(zh)
*
|
2015-03-03 |
2018-01-02 |
奎尔波特股份有限公司 |
双重负载的脂质体药物制剂
|
|
CN114504652A
(zh)
|
2015-03-03 |
2022-05-17 |
科马布有限公司 |
抗体、用途和方法
|
|
JP6826055B2
(ja)
|
2015-03-13 |
2021-02-03 |
サイトメックス セラピューティクス インコーポレイテッド |
抗pdl1抗体、活性化可能抗pdl1抗体、およびその使用方法
|
|
EP3270898B1
(fr)
|
2015-03-17 |
2021-05-05 |
Lipomedix Pharmaceuticals Ltd. |
Procédés de traitement de cancer de la vessie
|
|
MA41795A
(fr)
|
2015-03-18 |
2018-01-23 |
Sarepta Therapeutics Inc |
Exclusion d'un exon induite par des composés antisens dans la myostatine
|
|
EP3069730A3
(fr)
|
2015-03-20 |
2017-03-15 |
International Aids Vaccine Initiative |
Trimères de glycoprotéines de l'enveloppe du vih-1 soluble
|
|
US9931394B2
(en)
|
2015-03-23 |
2018-04-03 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
|
US9758575B2
(en)
|
2015-04-06 |
2017-09-12 |
Yung Shin Pharmaceutical Industrial Co. Ltd. |
Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
|
|
JP6960856B2
(ja)
|
2015-04-08 |
2021-11-05 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
ヒト化インフルエンザモノクローナル抗体およびその使用方法
|
|
AU2016248946C1
(en)
|
2015-04-13 |
2024-10-17 |
Pfizer Inc. |
Therapeutic antibodies and their uses
|
|
EP4276116A3
(fr)
|
2015-04-17 |
2024-01-17 |
Amgen Research (Munich) GmbH |
Constructions d'anticorps bispécifiques pour cdh3 et cd3
|
|
JP6956639B2
(ja)
|
2015-05-01 |
2021-11-02 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
抗ccr4抗体を用いてサイトカイン発現を媒介する方法
|
|
JP7028648B2
(ja)
|
2015-05-04 |
2022-03-02 |
サイトメックス セラピューティクス インコーポレイテッド |
抗cd166抗体、活性化可能抗cd166抗体、およびその使用方法
|
|
HK1250037A1
(zh)
|
2015-05-04 |
2018-11-23 |
Cytomx Therapeutics Inc. |
抗-itga3抗体、可活化的抗-itga3抗体、及其使用方法
|
|
MY194184A
(en)
|
2015-05-04 |
2022-11-17 |
Cytomx Therapeutics Inc |
Anti-cd71 antibodies, activatable anti-cd71 antibodies, and methods of use thereof
|
|
EP3736287A1
(fr)
|
2015-05-11 |
2020-11-11 |
The Johns Hopkins University |
Anticorps auto-immuns destinés à être utilisés pour inhiber la croissance de cellules cancéreuses
|
|
EP3294887A1
(fr)
|
2015-05-14 |
2018-03-21 |
CNIC Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III |
Compositions à base de miarn pour le traitement de tumeurs à cellules b matures
|
|
US11318131B2
(en)
|
2015-05-18 |
2022-05-03 |
Ipsen Biopharm Ltd. |
Nanoliposomal irinotecan for use in treating small cell lung cancer
|
|
AU2016271142A1
(en)
|
2015-05-29 |
2017-11-23 |
Genentech, Inc. |
PD-L1 promoter methylation in cancer
|
|
MA50829A
(fr)
|
2015-06-01 |
2018-04-11 |
Sarepta Therapeutics Inc |
Exclusion d'exon induite pat technologie antisens dans le collagène de type vii
|
|
JP2018517774A
(ja)
|
2015-06-10 |
2018-07-05 |
エリジウム・ヘルス・インコーポレイテッド |
ニコチンアミドリボシドおよびプテロスチルベン組成物ならびに皮膚障害の処置のための方法
|
|
CA2991167A1
(fr)
|
2015-07-02 |
2017-01-05 |
Otsuka Pharmaceutical Co., Ltd. |
Compositions pharmaceutiques lyophilisees
|
|
DK3322733T3
(da)
|
2015-07-13 |
2021-10-18 |
Compugen Ltd |
Hide1-sammensætninger og fremgangsmåder
|
|
US10513558B2
(en)
|
2015-07-13 |
2019-12-24 |
Cytomx Therapeutics, Inc. |
Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof
|
|
CA2989970A1
(fr)
|
2015-07-17 |
2017-01-26 |
Alnylam Pharmaceuticals, Inc. |
Conjugues constitues d'une entite unique a cibles multiples
|
|
US10913802B2
(en)
|
2015-07-21 |
2021-02-09 |
Dyax Corp. |
Monoclonal antibody inhibitor of factor XIIA
|
|
EP3792279A3
(fr)
|
2015-07-29 |
2021-07-07 |
Allergan, Inc. |
Anticorps contenant seulement une chaîne lourde contre ang-2
|
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究(慕尼黑)公司 |
Egfrviii及cd3抗體構築體
|
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Flt3及cd3抗體構築體
|
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究(慕尼黑)公司 |
Cd70及cd3抗體構築體
|
|
EA039859B1
(ru)
|
2015-07-31 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
|
TW202346349A
(zh)
|
2015-07-31 |
2023-12-01 |
德商安美基研究(慕尼黑)公司 |
Dll3及cd3抗體構築體
|
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Msln及cd3抗體構築體
|
|
CA2992788A1
(fr)
|
2015-08-14 |
2017-02-23 |
Allergan, Inc. |
Anticorps a chaine lourde uniquement contre le pgdf
|
|
ES2848118T3
(es)
|
2015-08-20 |
2021-08-05 |
Ipsen Biopharm Ltd |
Terapia de combinación que usa irinotecán liposomal y un inhibidor de PARP para el tratamiento del cáncer
|
|
KR102714060B1
(ko)
|
2015-08-21 |
2024-10-08 |
입센 바이오팜 리미티드 |
리포솜 이리노테칸 및 옥살리플라틴을 포함하는 병용 치료를 이용하여 전이성 췌장암을 치료하는 방법
|
|
EP3344655B1
(fr)
|
2015-09-01 |
2023-07-26 |
Boehringer Ingelheim International GmbH |
Utilisation d'anticorps anti-cd40 pour le traitement de la néphrite lupique
|
|
WO2017048860A1
(fr)
|
2015-09-14 |
2017-03-23 |
Vgsk Technologies, Inc. |
Support stériquement stabilisé pour agents thérapeutiques sous-cutanés, sublinguaux et oraux, compositions et procédés pour le traitement d'un mammifère
|
|
TW201718857A
(zh)
|
2015-09-14 |
2017-06-01 |
艾爾妮蘭製藥公司 |
用於抑制alas1基因表現之組合物及方法
|
|
TWI799366B
(zh)
|
2015-09-15 |
2023-04-21 |
美商建南德克公司 |
胱胺酸結骨架平臺
|
|
PL3350220T3
(pl)
|
2015-09-15 |
2022-01-03 |
Scholar Rock, Inc. |
Przeciwciała przeciwko pro/latentnej miostatynie i ich zastosowania
|
|
AU2016326609B2
(en)
|
2015-09-23 |
2023-03-09 |
Mereo Biopharma 5, Inc. |
Methods and compositions for treatment of cancer
|
|
WO2017058881A1
(fr)
|
2015-09-28 |
2017-04-06 |
The Trustees Of Columbia University In The City Of New York |
Utilisation de la pentoxifylline sous thérapies de blocage des points de contrôle immunitaires pour le traitement du mélanome
|
|
WO2017055966A1
(fr)
|
2015-10-01 |
2017-04-06 |
Pfizer Inc. |
Compositions d'anticorps à faible viscosité
|
|
HUE069935T2
(hu)
|
2015-10-06 |
2025-04-28 |
Hoffmann La Roche |
Módszer szklerózis multiplex kezelésére
|
|
WO2017062835A2
(fr)
|
2015-10-09 |
2017-04-13 |
Sarepta Therapeutics, Inc. |
Compositions et méthodes pour traiter la dystrophie musculaire de duchenne et troubles associés
|
|
WO2023034901A1
(fr)
|
2021-09-01 |
2023-03-09 |
The Broad Institute, Inc. |
Compositions de vaccin à avatar tumoral et leurs utilisations
|
|
GB201518170D0
(en)
|
2015-10-14 |
2015-11-25 |
Cantab Biopharmaceuticals Patents Ltd |
Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
|
|
GB201518171D0
(en)
|
2015-10-14 |
2015-11-25 |
Cantab Biopharmaceuticals Patents Ltd |
Colloidal particles for topical administration with therapeutic agent
|
|
GB201518172D0
(en)
|
2015-10-14 |
2015-11-25 |
Cantab Biopharmaceuticals Patents Ltd |
Colloidal particles for use in medicine
|
|
WO2017066726A1
(fr)
|
2015-10-16 |
2017-04-20 |
Merrimack Pharmaceuticals, Inc. |
Stabilisation de compositions pharmaceutiques de camptothécine
|
|
WO2017066714A1
(fr)
|
2015-10-16 |
2017-04-20 |
Compugen Ltd. |
Conjugués d'anticorps anti-vsig1 et de médicaments
|
|
WO2017075037A1
(fr)
|
2015-10-27 |
2017-05-04 |
Scholar Rock, Inc. |
Facteurs de croissance amorcés et leurs utilisations
|
|
RU2750285C2
(ru)
|
2015-10-30 |
2021-06-25 |
Дженентек, Инк. |
АНТИТЕЛА ПРОТИВ НtrА1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
|
US10875923B2
(en)
|
2015-10-30 |
2020-12-29 |
Mayo Foundation For Medical Education And Research |
Antibodies to B7-H1
|
|
AU2016349954B2
(en)
|
2015-11-05 |
2022-08-25 |
Antisense Therapeutics Ltd |
Mobilizing leukemia cells
|
|
US10751306B2
(en)
|
2015-11-06 |
2020-08-25 |
The Johns Hopkins University |
Methods of treating liver fibrosis by administering 3-bromopyruvate
|
|
WO2017083403A1
(fr)
|
2015-11-10 |
2017-05-18 |
Children's Research Institute, Children's National Medical Center |
Formulation d'échinomycine, procédé de fabrication et méthode d'utilisation de cette dernière
|
|
AU2016353153B2
(en)
|
2015-11-12 |
2023-11-23 |
Seagen Inc. |
Glycan-interacting compounds and methods of use
|
|
BR112018009644A2
(pt)
|
2015-11-12 |
2018-11-06 |
Graybug Vision Inc |
micropartículas agregantes sólidas modificadas na superfície, material injetável, processo para preparação de micropartículas agregantes sólidas modificadas na superfície, método para tratamento de um distúrbio ocular, e, uso de micropartículas agregantes sólidas modificadas na superfície
|
|
CA2949033C
(fr)
|
2015-11-30 |
2025-05-06 |
Pfizer Inc. |
Anticorps et fragments d’anticorps pour conjugaison spécifique à un site
|
|
TWI778491B
(zh)
|
2015-11-30 |
2022-09-21 |
美商輝瑞股份有限公司 |
位點專一性her2抗體藥物共軛體
|
|
JP7090545B2
(ja)
|
2015-12-02 |
2022-06-24 |
ストキューブ アンド シーオー., インコーポレイテッド |
Btn1a1に免疫特異的に結合する抗体及び分子並びにそれらの治療的使用
|
|
US11253590B2
(en)
|
2015-12-02 |
2022-02-22 |
Stsciences, Inc. |
Antibodies specific to glycosylated BTLA (B- and T- lymphocyte attenuator)
|
|
MA43415A
(fr)
|
2015-12-09 |
2018-10-17 |
Modernatx Inc |
Arnm modifié codant pour une uridine diphosphate glucuronosyltransférase et utilisations associées
|
|
WO2017105990A1
(fr)
|
2015-12-14 |
2017-06-22 |
Massachusetts Institute Of Technology |
Microorganismes à encapsulation en polymères mucoadhésifs sensibles au ph
|
|
EP3389720A1
(fr)
|
2015-12-18 |
2018-10-24 |
The General Hospital Corporation |
Polymères polyacétal, conjugués, particules et utilisations associées
|
|
EP3395370B1
(fr)
|
2015-12-21 |
2021-01-20 |
FUJIFILM Corporation |
Liposomes et composition de liposomes
|
|
CN117683769A
(zh)
|
2015-12-23 |
2024-03-12 |
瑞普鲁卡私人有限公司 |
核酸寡聚体及其用途
|
|
US11719704B2
(en)
|
2015-12-30 |
2023-08-08 |
Momenta Pharmaceuticals, Inc. |
Methods related to biologics
|
|
AU2017206069A1
(en)
|
2016-01-08 |
2018-07-19 |
Scholar Rock, Inc. |
Anti-pro/latent myostatin antibodies and methods of use thereof
|
|
US20210206818A1
(en)
|
2016-01-22 |
2021-07-08 |
Modernatx, Inc. |
Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
|
|
JOP20170017B1
(ar)
|
2016-01-25 |
2021-08-17 |
Amgen Res Munich Gmbh |
تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
|
|
SG11201805770UA
(en)
|
2016-02-03 |
2018-08-30 |
Amgen Res Munich Gmbh |
BCMA and CD3 Bispecific T Cell Engaging Antibody Constructs
|
|
LT3411404T
(lt)
|
2016-02-03 |
2022-12-27 |
Amgen Research (Munich) Gmbh |
Psma ir cd3 bispecifiniai, t ląsteles aktyvuojantys antikūno konstruktai
|
|
JP2019509721A
(ja)
|
2016-02-04 |
2019-04-11 |
キュリス,インコーポレイテッド |
突然変異体スムースンド及びその使用方法
|
|
EP3426306A1
(fr)
*
|
2016-03-07 |
2019-01-16 |
Memorial Sloan Kettering Cancer Center |
Liposomes radiomarqués ciblant la moelle osseuse, le système réticulo-endothélial et/ou les noeuds lymphoïdes et méthodes de diagnostic et usage thérapeutique associés
|
|
US11357849B2
(en)
|
2016-03-07 |
2022-06-14 |
Musc Foundation For Research Development |
Anti-nucleolin antibodies
|
|
BR112018068340A2
(pt)
|
2016-03-11 |
2019-01-15 |
Scholar Rock Inc |
imunoglobulinas de ligação ao tgfss1 e usos destas
|
|
CN109476756B
(zh)
|
2016-03-15 |
2022-05-31 |
埃泰美德(香港)有限公司 |
一种多特异性Fab融合蛋白及其用途
|
|
US11060089B2
(en)
|
2016-04-18 |
2021-07-13 |
Sarepta Therapeutics, Inc. |
Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene
|
|
US10973748B2
(en)
|
2016-04-21 |
2021-04-13 |
Versitech Limited |
Compositions and methods for lightening skin and reducing hyperpigmentation
|
|
JP2019517473A
(ja)
|
2016-05-27 |
2019-06-24 |
アレクシオン ファーマシューティカルズ インコーポレイテッドAlexion Pharmaceuticals, Inc. |
難治性全身型重症筋無力症の処置のための方法
|
|
FI3468997T3
(fi)
|
2016-06-08 |
2023-10-31 |
Xencor Inc |
Igg4:ään liittyvien sairauksien hoito anti-cd19-vasta-aineilla, jotka ristisitoutuvat cd32b:een
|
|
ITUA20164630A1
(it)
|
2016-06-23 |
2017-12-23 |
Paolo Blasi |
Adiuvanti farmacologici per la termoablazione tumorale
|
|
WO2018004517A1
(fr)
|
2016-06-27 |
2018-01-04 |
Alexion Pharmaceuticals, Inc. |
Méthodes de traitement de l'hypophosphatasie chez l'enfant et l'adolescent
|
|
US11246832B2
(en)
|
2016-06-28 |
2022-02-15 |
Verily Life Sciences Llc |
Serial filtration to generate small cholesterol-containing liposomes
|
|
WO2018017964A2
(fr)
|
2016-07-21 |
2018-01-25 |
Emory University |
Anticorps contre le virus ebola et agents de liaison dérivés de ceux-ci
|
|
RU2019104896A
(ru)
|
2016-07-22 |
2020-08-24 |
Дана-Фарбер Кэнсер Инститьют, Инк. |
Антитела к глюкокортикоид-индуцированному рецептору фактора некроза опухоли (gitr) и способы их использования
|
|
JP2019528311A
(ja)
|
2016-08-03 |
2019-10-10 |
ネクストキュア インコーポレイテッド |
Lairシグナル伝達を調節するための組成物及び方法
|
|
CN109862896A
(zh)
|
2016-08-03 |
2019-06-07 |
西玛贝医药公司 |
用于治疗炎症性胃肠疾病或胃肠病症的氧亚甲基芳基化合物
|
|
TWI754659B
(zh)
|
2016-08-08 |
2022-02-11 |
台灣微脂體股份有限公司 |
用於製備含有弱酸性劑之微脂體組合物的傳輸載體、方法及套組
|
|
WO2018045379A1
(fr)
|
2016-09-02 |
2018-03-08 |
Dana-Farber Cancer Institute, Inc. |
Composition et méthodes de traitement des déreglements des lymphocytes b
|
|
WO2018048939A1
(fr)
|
2016-09-06 |
2018-03-15 |
Dana-Farber Cancer Institute, Inc. |
Procédés de traitement ou de prévention d'une infection par le virus zika
|
|
WO2018049261A1
(fr)
|
2016-09-09 |
2018-03-15 |
Icellhealth Consulting Llc |
Virus oncolytique exprimant des modulateurs du point de contrôle immunitaire
|
|
WO2018049275A1
(fr)
|
2016-09-09 |
2018-03-15 |
Genentech, Inc. |
Inhibiteurs peptidiques sélectifs de frizzled
|
|
EP4372002A3
(fr)
|
2016-09-14 |
2024-08-14 |
The Trustees Of The University Of Pennsylvania |
Purification et ligature de protéines médiées par la sortase à base de proximité
|
|
BR112019005129A2
(pt)
|
2016-09-16 |
2019-06-04 |
Shanghai Henlius Biotech, Inc. |
anticorpos anti-pd-1
|
|
KR20190067181A
(ko)
|
2016-09-23 |
2019-06-14 |
테바 파마슈티컬스 인터내셔널 게엠베하 |
군발성 두통의 치료
|
|
CA3036632A1
(fr)
|
2016-09-23 |
2018-03-29 |
Teva Pharmaceuticals International Gmbh |
Traitement de la migraine refractaire
|
|
EP3411071A4
(fr)
|
2016-10-20 |
2019-08-28 |
I-Mab |
Nouveaux anticorps monoclonaux anti-cd 47 et leurs utilisations
|
|
SG11201903674YA
(en)
|
2016-10-26 |
2019-05-30 |
Modernatx Inc |
Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
|
|
BR112019007844A2
(pt)
|
2016-11-02 |
2019-07-16 |
Ipsen Biopharm Ltd |
tratamento de câncer gástrico usando terapias de combinação compreendendo irinotecano lipossômico, oxaliplatina, 5-fluoroacila (e leucovorina)
|
|
EP3534947A1
(fr)
|
2016-11-03 |
2019-09-11 |
Kymab Limited |
Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés
|
|
EP3535299A1
(fr)
|
2016-11-04 |
2019-09-11 |
Novimmune S.A. |
Anticorps anti-cd19 et leurs procédés d'utilisation
|
|
CN109996809A
(zh)
|
2016-11-14 |
2019-07-09 |
诺华股份有限公司 |
与促融合蛋白minion相关的组合物、方法和治疗用途
|
|
WO2018094143A1
(fr)
|
2016-11-17 |
2018-05-24 |
Siamab Therapeutics, Inc. |
Composés interagissant avec le glycane et méthodes d'utilisation
|
|
WO2018106738A1
(fr)
|
2016-12-05 |
2018-06-14 |
Massachusetts Institute Of Technology |
Polymères en étoile à bras en brosse, conjugués et particules, et leurs utilisations
|
|
US10772926B2
(en)
|
2016-12-16 |
2020-09-15 |
Nutragen Health Innovations, Inc. |
Natural drugs for the treatment of inflammation and melanoma
|
|
CN110325530B
(zh)
|
2016-12-16 |
2022-01-11 |
辉瑞大药厂 |
Glp-1受体激动剂及其用途
|
|
KR20190098255A
(ko)
|
2017-01-06 |
2019-08-21 |
스칼러 락, 인크. |
이소형-특이적, 콘텍스트-허용성 TGFβ1 억제제 및 그의 용도
|
|
PT3565592T
(pt)
|
2017-01-06 |
2023-05-31 |
Scholar Rock Inc |
Tratamento de doenças metabólicas através da inibição da ativação da miostatina
|
|
SI3565592T1
(sl)
|
2017-01-06 |
2023-05-31 |
Scholar Rock, Inc. |
Zdravljenje presnovnih bolezni z zaviranjem aktivacije miostatina
|
|
EA201991804A1
(ru)
|
2017-02-01 |
2020-02-07 |
МОДЕРНАТиЭкс, ИНК. |
ИММУНОМОДУЛИРУЮЩИЕ ТЕРАПЕВТИЧЕСКИЕ КОМПОЗИЦИИ мРНК, КОДИРУЮЩЕЙ ПЕПТИДЫ С АКТИВИРУЮЩЕЙ ОНКОГЕННОЙ МУТАЦИЕЙ
|
|
JOP20190189A1
(ar)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
|
|
WO2018152496A1
(fr)
|
2017-02-17 |
2018-08-23 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Compositions et méthodes de diagnostic et de traitement de l'infection par le virus zika
|
|
SG11201907889YA
(en)
|
2017-03-03 |
2019-09-27 |
Seattle Genetics Inc |
Glycan-interacting compounds and methods of use
|
|
EP3589657A1
(fr)
|
2017-03-03 |
2020-01-08 |
Rinat Neuroscience Corp. |
Anticorps anti-gitr et leurs méthodes d'utilisation
|
|
JP2020511130A
(ja)
|
2017-03-09 |
2020-04-16 |
サイトメックス セラピューティクス インコーポレイテッド |
Cd147抗体、活性化可能cd147抗体、ならびにその作製および使用の方法
|
|
CA3056797A1
(fr)
|
2017-03-16 |
2018-09-20 |
Children's Medical Center Corporation |
Liposomes ingenierises utilises en tant qu'agents therapeutiques ciblant le cancer
|
|
EP3601350A1
(fr)
|
2017-03-27 |
2020-02-05 |
Boehringer Ingelheim International GmbH |
Polythérapie à base d'anticorps anti il-36r
|
|
US11359200B2
(en)
|
2017-04-09 |
2022-06-14 |
The Cleveland Clinic Foundation |
Cancer treatment by MALAT1 inhibition
|
|
EP3609915A1
(fr)
|
2017-04-12 |
2020-02-19 |
Pfizer Inc |
Anticorps ayant une affinité conditionnelle et leurs procédés d'utilisation
|
|
US11584790B2
(en)
|
2017-04-14 |
2023-02-21 |
Kodiak Sciences Inc. |
Complement factor D antagonist antibodies and conjugates thereof
|
|
TW201902927A
(zh)
|
2017-04-21 |
2019-01-16 |
美商梅利特公司 |
糖尿病相關應用之方法及抗體
|
|
EP3615569A1
(fr)
|
2017-04-25 |
2020-03-04 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Anticorps et procédés de diagnostic et de traitement d'infection par le virus d'epstein barr
|
|
US11918650B2
(en)
|
2017-05-05 |
2024-03-05 |
Amgen Inc. |
Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
|
|
US11318190B2
(en)
|
2017-05-05 |
2022-05-03 |
United States Government As Represented By The Department Of Veterans Affairs |
Methods and compositions for treating liver disease
|
|
CN111201040A
(zh)
|
2017-05-10 |
2020-05-26 |
灰色视觉公司 |
用于医学疗法的缓释微粒及其悬浮液
|
|
US11013905B2
(en)
|
2017-05-11 |
2021-05-25 |
Tci Llc |
Thermal interconnect for implantable blood pump
|
|
US10994025B2
(en)
|
2017-05-12 |
2021-05-04 |
Massachusetts Institute Of Technology |
Argonaute protein-double stranded RNA complexes and uses related thereto
|
|
JP7169298B2
(ja)
|
2017-05-12 |
2022-11-10 |
オーガスタ ユニバーシティ リサーチ インスティテュート,インコーポレーテッド |
ヒトアルファフェトタンパク質特異的t細胞受容体およびその使用
|
|
EP3630167A1
(fr)
|
2017-05-26 |
2020-04-08 |
NovImmune SA |
Anticorps anti-cd47 x anti-mésothéline et procédés d'utilisation correspondants
|
|
US20200148768A1
(en)
|
2017-05-31 |
2020-05-14 |
Stcube & Co., Inc. |
Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
|
|
CN111051346A
(zh)
|
2017-05-31 |
2020-04-21 |
斯特库伯株式会社 |
使用免疫特异性结合btn1a1的抗体和分子治疗癌症的方法
|
|
BR112019025188A2
(pt)
|
2017-06-01 |
2020-06-23 |
Cytomx Therapeutics, Inc. |
Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos
|
|
US11542331B2
(en)
|
2017-06-06 |
2023-01-03 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that bind to BTN1A1 or BTN1A1-ligands
|
|
GB201710838D0
(en)
|
2017-07-05 |
2017-08-16 |
Ucl Business Plc |
Bispecific antibodies
|
|
US10590416B2
(en)
|
2017-07-06 |
2020-03-17 |
Arrowhead Pharmaceuticals, Inc. |
RNAi agents for inhibiting expression of alpha-ENaC and methods of use
|
|
EP3651799A1
(fr)
|
2017-07-13 |
2020-05-20 |
Massachusetts Institute of Technology |
Ciblage du complexe hdac2-sp3 pour améliorer la fonction synaptique
|
|
EP3652210A1
(fr)
|
2017-07-14 |
2020-05-20 |
CytomX Therapeutics, Inc. |
Anticorps anti-cd166 et utilisations associées
|
|
EP3655430A1
(fr)
|
2017-07-19 |
2020-05-27 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Anticorps et procédés de diagnostic et de traitement d'infection par le virus de l'hépatite b
|
|
JP2020530554A
(ja)
|
2017-07-20 |
2020-10-22 |
シートムエックス セラピューティクス,インコーポレイテッド |
活性化抗体の特性を定性的および/または定量的に分析する方法およびその使用
|
|
WO2019016784A1
(fr)
|
2017-07-21 |
2019-01-24 |
Universidade De Coimbra |
Anticorps anti-nucléoline
|
|
MA49634A
(fr)
|
2017-07-21 |
2020-05-27 |
Modernatx Inc |
Arnm modifié codant pour une propionyl-coa-carboxylase et utilisations associées
|
|
US20200179494A1
(en)
|
2017-07-24 |
2020-06-11 |
Modernatx, Inc. |
Modified mRNA Encoding a Glucose 6 Phosphatase and Uses Thereof
|
|
CN116271012A
(zh)
|
2017-07-27 |
2023-06-23 |
瑞颂医药公司 |
高浓度抗c5抗体制剂
|
|
US12358992B2
(en)
|
2017-07-28 |
2025-07-15 |
Scholar Rock, Inc. |
LTBP complex-specific inhibitors of TGF-beta 1 and uses thereof
|
|
RU2020108580A
(ru)
|
2017-08-03 |
2021-09-03 |
Оцука Фармасьютикал Ко., Лтд. |
Лекарственное соединение и способы его очистки
|
|
US11135187B2
(en)
|
2017-08-22 |
2021-10-05 |
National Institutes Of Health (Nih) |
Compositions and methods for treating diabetic retinopathy
|
|
MX2020002198A
(es)
|
2017-08-30 |
2020-07-20 |
Cytomx Therapeutics Inc |
Anticuerpos anti-cd166 activables y métodos de uso de los mismos.
|
|
EP3679070A1
(fr)
|
2017-09-07 |
2020-07-15 |
Augusta University Research Institute, Inc. |
Anticorps dirigés contre la protéine 1 de mort cellulaire programmée
|
|
WO2019055460A1
(fr)
|
2017-09-13 |
2019-03-21 |
The Children's Medical Center Corporation |
Compositions et méthodes pour le traitement de maladies associées aux transposons
|
|
US11364303B2
(en)
|
2017-09-29 |
2022-06-21 |
Pfizer Inc. |
Cysteine engineered antibody drug conjugates
|
|
CN111372950B
(zh)
|
2017-10-12 |
2024-11-05 |
免疫苏醒公司 |
Vegfr-抗体轻链融合蛋白
|
|
CN111247171A
(zh)
|
2017-10-14 |
2020-06-05 |
西托姆克斯治疗公司 |
抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法
|
|
BR112020007586A2
(pt)
|
2017-10-17 |
2020-09-24 |
Rhizen Pharmaceuticals Sa |
moduladores de canal de crac para tratar câncer esofágico
|
|
US11555189B2
(en)
|
2017-10-18 |
2023-01-17 |
Sarepta Therapeutics, Inc. |
Antisense oligomer compounds
|
|
WO2019082124A1
(fr)
|
2017-10-26 |
2019-05-02 |
Rhizen Pharmaceuticals Sa |
Composition et procédé pour le traitement du lymphome diffus à grandes cellules b
|
|
BR112020008182A2
(pt)
|
2017-10-26 |
2020-10-27 |
Alexion Pharmaceuticals, Inc. |
dosagem e administração de anticorpos anti-c5 para tratamento de hemoglobinúria paroxística noturna (hpn) e síndrome hemolítica urêmica atípica (shua)
|
|
IL312910A
(en)
|
2017-10-27 |
2024-07-01 |
Univ New York |
Anti-galectin-9 antibodies and uses thereof
|
|
KR102363746B1
(ko)
|
2017-10-27 |
2022-02-15 |
화이자 인코포레이티드 |
Cd123 특이적 항체 및 항체-약물 접합체 및 그의 용도
|
|
KR20200079256A
(ko)
|
2017-10-30 |
2020-07-02 |
리젠 파마슈티컬스 소시에떼 아노님 |
혈액암 및 고형암을 치료하기 위한 칼슘 방출-활성화된 칼슘 채널 조절제
|
|
WO2019086626A1
(fr)
|
2017-11-03 |
2019-05-09 |
Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (F.S.P.) |
Miarn et combinaisons de ceux-ci pour leur utilisation dans le traitement de néoplasies à lymphocytes b humaines
|
|
JP2021505571A
(ja)
|
2017-12-06 |
2021-02-18 |
ルヒゼン ファーマスティカルズ エスエー |
末梢t細胞リンパ腫および皮膚t細胞リンパ腫を治療するための組成物および方法
|
|
US11946094B2
(en)
|
2017-12-10 |
2024-04-02 |
Augusta University Research Institute, Inc. |
Combination therapies and methods of use thereof
|
|
CN111315780A
(zh)
|
2017-12-11 |
2020-06-19 |
安进公司 |
双特异性抗体产品的连续制造工艺
|
|
TW201940518A
(zh)
|
2017-12-29 |
2019-10-16 |
美商安進公司 |
針對muc17和cd3之雙特異性抗體構建體
|
|
US20190254973A1
(en)
|
2018-02-22 |
2019-08-22 |
Verily Life Sciences Llc |
Combining orthogonal chemistries for preparation of multiplexed nanoparticles
|
|
BR112020016859A2
(pt)
|
2018-02-28 |
2020-12-29 |
Pfizer Inc. |
Variantes de il-15 e usos da mesma
|
|
CN112203679A
(zh)
|
2018-03-02 |
2021-01-08 |
科达制药股份有限公司 |
Il-6抗体及其融合构建体和缀合物
|
|
EP3762420A1
(fr)
|
2018-03-09 |
2021-01-13 |
CytomX Therapeutics, Inc. |
Anticorps activables de cd147 et procédés de fabrication et d'utilisation associés
|
|
CN120399075A
(zh)
|
2018-03-14 |
2025-08-01 |
诺维莫尼公司 |
抗-CD3ε抗体及其应用方法
|
|
TW202003562A
(zh)
|
2018-03-14 |
2020-01-16 |
中國大陸商北京軒義醫藥科技有限公司 |
抗密連蛋白18.2(cldn18.2)抗體
|
|
US12280039B2
(en)
|
2018-03-21 |
2025-04-22 |
Colorado State University Research Foundation |
Cancer vaccine compositions and methods of use thereof
|
|
US10722528B2
(en)
|
2018-03-28 |
2020-07-28 |
Augusta University Research Institute, Inc. |
Compositions and methods for inhibiting metastasis
|
|
EP3774916A2
(fr)
|
2018-04-06 |
2021-02-17 |
Biolegend, Inc. |
Agents anti-tétraspanine 33 et compositions et procédés pour la fabrication et l'utilisation de ces agents
|
|
KR20200141470A
(ko)
|
2018-04-06 |
2020-12-18 |
칠드런'즈 메디컬 센터 코포레이션 |
체세포 재프로그래밍 및 각인의 조정을 위한 조성물 및 방법
|
|
WO2019197607A1
(fr)
|
2018-04-13 |
2019-10-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anticorps anti-ige humains modifiés par fc et procédés d'utilisation
|
|
US12084489B2
(en)
|
2018-05-02 |
2024-09-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies and methods for the diagnosis, prevention, and treatment of Epstein Barr virus infection
|
|
SG11202010580TA
(en)
|
2018-05-23 |
2020-12-30 |
Pfizer |
Antibodies specific for cd3 and uses thereof
|
|
KR102584675B1
(ko)
|
2018-05-23 |
2023-10-05 |
화이자 인코포레이티드 |
GUCY2c에 특이적인 항체 및 이의 용도
|
|
US12404320B2
(en)
|
2018-05-31 |
2025-09-02 |
Alexion Pharmaceuticals, Inc. |
Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) in pediatric patients
|
|
JP7577542B2
(ja)
|
2018-06-04 |
2024-11-05 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
小児患者における非典型溶血性尿毒症症候群(aHUS)の治療のための抗C5抗体の用量および投与
|
|
EP3802594A1
(fr)
|
2018-06-08 |
2021-04-14 |
Pfizer Inc. |
Méthodes de traitement d'une maladie métabolique du fer à l'aide d'un anticorps de neutralisation se liant à l'érhythroferrone
|
|
US10934279B2
(en)
|
2018-06-13 |
2021-03-02 |
Pfizer Inc. |
GLP-1 receptor agonists and uses thereof
|
|
PL3806855T3
(pl)
|
2018-06-15 |
2023-07-24 |
Pfizer Inc. |
Agoniści receptora GLP-1 oraz ich zastosowania
|
|
KR20210022004A
(ko)
|
2018-06-18 |
2021-03-02 |
안위타 바이오사이언시스, 인코포레이티드 |
항-메소텔린 작제물 및 이의 용도
|
|
JP7097465B2
(ja)
|
2018-06-19 |
2022-07-07 |
アルモ・バイオサイエンシーズ・インコーポレイテッド |
キメラ抗原受容体細胞療法と併用するil-10剤の組成およびその使用方法
|
|
JP7550057B2
(ja)
|
2018-06-28 |
2024-09-12 |
クリスパー セラピューティクス アーゲー |
ドナーポリヌクレオチドの挿入によるゲノム編集のための組成物および方法
|
|
JP7538723B2
(ja)
|
2018-06-28 |
2024-08-22 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
抗c5抗体の産生方法
|
|
BR112020024078A2
(pt)
|
2018-06-29 |
2021-02-17 |
Boehringer Ingelheim International Gmbh |
anticorpos anti-cd40 para uso no tratamento de doença autoimune
|
|
MX2020013896A
(es)
|
2018-07-06 |
2021-03-09 |
Pfizer |
Proceso de fabricacion e intermediarios para un compuesto de pirrolo[2,3-d]pirimidina y su uso.
|
|
WO2020014473A1
(fr)
|
2018-07-11 |
2020-01-16 |
Scholar Rock, Inc. |
INHIBITEURS DE TGFβ1 ET LEUR UTILISATION
|
|
LT3677278T
(lt)
|
2018-07-11 |
2022-01-10 |
Scholar Rock, Inc. |
Izoformoms selektyvūs tgfbeta1 inhibitoriai ir jų panaudojimas
|
|
EP3820508A1
(fr)
|
2018-07-11 |
2021-05-19 |
Scholar Rock, Inc. |
Inhibiteurs de tgf?1 sélectifs selon l'isoforme à affinité élevée
|
|
BR112021000934A2
(pt)
|
2018-07-20 |
2021-04-27 |
Pierre Fabre Medicament |
receptor para vista
|
|
EP3837367A1
(fr)
|
2018-08-16 |
2021-06-23 |
Alnylam Pharmaceuticals, Inc. |
Compositions et procédés d'inhibition de l'expression du gène lect2
|
|
US12460000B2
(en)
|
2018-09-07 |
2025-11-04 |
Itabmed (Hk) Limited |
Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof
|
|
US20220023450A1
(en)
*
|
2018-09-11 |
2022-01-27 |
Memorial Sloan Kettering Cancer Center |
Bone marrow-, reticuloendothelial system-, and/or lymph node-targeted radiolabeled liposomes and methods of their diagnostic and therapeutic use
|
|
WO2020061244A2
(fr)
|
2018-09-19 |
2020-03-26 |
Georgia Tech Research Corporation |
Promédicament activé par protéase bactérienne à auto-dosage
|
|
CN113365697B
(zh)
|
2018-09-25 |
2024-07-19 |
百进生物科技公司 |
抗tlr9药剂和组合物及其制备方法和使用方法
|
|
US20210338728A1
(en)
|
2018-09-27 |
2021-11-04 |
Phosphogam, Inc. |
Methods and compositions for the expansion and use of allogeneic gamma/delta-t cells
|
|
AU2019349874A1
(en)
|
2018-09-28 |
2021-04-29 |
Lyvgen Biopharma Holdings Limited |
Anti-CD40 binding molecules having engineered Fc domains and therapeutic uses thereof
|
|
MA53859A
(fr)
|
2018-10-10 |
2022-01-19 |
Boehringer Ingelheim Int |
Procédé de transfert de gaz de membrane dans une culture de bioréacteur à haute densité
|
|
WO2020077212A1
(fr)
|
2018-10-11 |
2020-04-16 |
Amgen Inc. |
Traitement en aval de constructions d'anticorps bispécifiques
|
|
WO2020078270A1
(fr)
|
2018-10-15 |
2020-04-23 |
Elixiron Immunotherapeutics (hong Kong) Limited |
Anticorps dirigés contre le facteur de croissance des granulocytes et des macrophages et leurs utilisations
|
|
US11427591B2
(en)
|
2018-10-17 |
2022-08-30 |
Insilico Medicine Ip Limited |
Kinase inhibitors
|
|
AU2019368287B2
(en)
|
2018-10-23 |
2025-09-18 |
Scholar Rock, Inc. |
RGMc-selective inhibitors and use thereof
|
|
CN112955252B
(zh)
|
2018-10-26 |
2023-11-21 |
康涅狄格大学 |
用于对纳米粒子进行内部和外部修饰的连续处理系统和方法
|
|
WO2020092549A1
(fr)
|
2018-10-30 |
2020-05-07 |
Alexion Pharmaceuticals, Inc. |
Dosage et administration par voie sous-cutanée d'anticorps anti-c5 pour le traitement de l'hémoglobinurie paroxystique nocturne (pnh)
|
|
EP3873540A4
(fr)
|
2018-10-31 |
2022-07-27 |
Mayo Foundation for Medical Education and Research |
Procédés et matériaux pour le traitement du cancer
|
|
EP3873500A4
(fr)
|
2018-10-31 |
2023-01-11 |
Mayo Foundation for Medical Education and Research |
Méthodes et matériaux de traitement du cancer
|
|
CN113260383A
(zh)
|
2018-11-02 |
2021-08-13 |
西托姆克斯治疗公司 |
可活化的抗cd166抗体及其使用方法
|
|
EP3883928A4
(fr)
|
2018-11-22 |
2022-06-29 |
Qilu Regor Therapeutics Inc. |
Agonistes de glp-1r et leurs utilisations
|
|
US20220024999A1
(en)
|
2018-11-29 |
2022-01-27 |
Flagship Pioneering Innovations V, Inc. |
Methods of modulating rna
|
|
US12049505B2
(en)
|
2018-12-06 |
2024-07-30 |
Cytomx Therapeutics, Inc. |
Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
|
|
MX2021006968A
(es)
|
2018-12-12 |
2021-10-13 |
Kite Pharma Inc |
Antígeno quimérico y receptores de las células t, y métodos de uso.
|
|
EP3898698A4
(fr)
|
2018-12-21 |
2023-02-22 |
Multitude Inc. |
Anticorps spécifiques à muc18
|
|
CN113474366B
(zh)
|
2018-12-31 |
2025-01-17 |
动量制药公司 |
产生优特克单抗的方法
|
|
CA3127452A1
(fr)
|
2019-01-22 |
2020-07-30 |
Massachusetts Institute Of Technology |
Barriere hemato-encephalique humaine in vitro
|
|
AU2020212563A1
(en)
|
2019-01-23 |
2021-09-16 |
New York University |
Antibodies specific to delta 1 chain of T cell receptor
|
|
JP2020117502A
(ja)
|
2019-01-28 |
2020-08-06 |
ファイザー・インク |
変形性関節症の徴候および症状を処置する方法
|
|
TW202043267A
(zh)
|
2019-01-30 |
2020-12-01 |
美商供石公司 |
TGFβ之LTBP複合物專一性抑制劑及其用途
|
|
KR102820235B1
(ko)
|
2019-02-15 |
2025-06-16 |
화이자 인코포레이티드 |
결정질 피리미디닐-3,8-다이아자바이사이클로[3.2.1]옥타닐메타논 화합물 및 이의 용도
|
|
WO2020170103A1
(fr)
|
2019-02-18 |
2020-08-27 |
Pfizer Inc. |
Procédé de traitement de la lombalgie chronique
|
|
CN113874394B
(zh)
|
2019-02-20 |
2024-01-19 |
和铂抗体有限公司 |
抗体
|
|
US11739078B2
(en)
|
2019-02-22 |
2023-08-29 |
Insilico Medicine Ip Limited |
Methods of inhibiting kinases
|
|
JP2022523200A
(ja)
|
2019-02-26 |
2022-04-21 |
シートムエックス セラピューティクス,インコーポレイテッド |
活性化可能な免疫チェックポイント阻害剤とコンジュゲートされた活性化可能な抗体の組み合わせ療法
|
|
CA3131900A1
(fr)
|
2019-02-28 |
2020-09-24 |
Georgia Tech Research Corporation |
Compositions et procedes de profilage a porte logique d'activite biologique
|
|
US20200283796A1
(en)
|
2019-03-05 |
2020-09-10 |
Massachusetts Institute Of Technology |
Dna launched rna replicon system (drep) and uses thereof
|
|
JP7561134B2
(ja)
|
2019-03-08 |
2024-10-03 |
マサチューセッツ インスティテュート オブ テクノロジー |
合成腫瘍溶解性lnpレプリコンrnaおよびがん免疫治療のための使用
|
|
KR20220004979A
(ko)
|
2019-03-27 |
2022-01-12 |
유엠씨 우트레크트 홀딩 비.브이. |
조작된 iga 항체 및 사용 방법
|
|
WO2020205716A1
(fr)
|
2019-04-01 |
2020-10-08 |
Genentech, Inc. |
Compositions et procédés de stabilisation de formulations contenant des protéines
|
|
JP7284830B2
(ja)
|
2019-04-02 |
2023-05-31 |
アレイ バイオファーマ インコーポレイテッド |
タンパク質チロシンホスファターゼ阻害剤
|
|
WO2020210805A1
(fr)
|
2019-04-11 |
2020-10-15 |
The Johns Hopkins University |
Nanoparticules pour l'administration de médicaments au cerveau
|
|
PH12021552557A1
(en)
|
2019-04-12 |
2022-07-04 |
Qilu Regor Therapeutics Inc |
Glp-1r agonists and uses thereof
|
|
EP3983447A4
(fr)
|
2019-06-14 |
2023-06-28 |
Dana-Farber Cancer Institute, Inc. |
Anticorps contre muc1 et leurs méthodes d'utilisation
|
|
TW202115086A
(zh)
|
2019-06-28 |
2021-04-16 |
美商輝瑞大藥廠 |
Bckdk抑制劑
|
|
US20220363673A1
(en)
|
2019-06-28 |
2022-11-17 |
Pfizer Inc. |
5-(Thiophen-2-YL)-1 H-Tetrazole Derivative as BCKDK Inhibitors Useful for Treating Various Diseases
|
|
LT6699B
(lt)
|
2019-07-15 |
2020-02-10 |
UAB "Valentis" |
Proliposomų gamybos būdas, naudojant ne daugiau kaip 5 % etanolio, ir jų panaudojimas lipofilinių medžiagų kapsuliavimui
|
|
CN112300279A
(zh)
|
2019-07-26 |
2021-02-02 |
上海复宏汉霖生物技术股份有限公司 |
针对抗cd73抗体和变体的方法和组合物
|
|
US10758329B1
(en)
|
2019-08-20 |
2020-09-01 |
Raymond L. Wright, III |
Hydrating mouth guard
|
|
WO2021046122A1
(fr)
|
2019-09-03 |
2021-03-11 |
Alnylam Pharmaceuticals, Inc. |
Compositions et procédés d'inhibition de l'expression du gène lect2
|
|
EP4034171A1
(fr)
|
2019-09-23 |
2022-08-03 |
Cytomx Therapeutics Inc. |
Anticorps anti-cd47, anticorps anti-cd47 activables, et leurs méthodes d'utilisation
|
|
WO2021062096A1
(fr)
|
2019-09-26 |
2021-04-01 |
Massachusetts Institute Of Technology |
Portes logiques à base de microarn et leurs utilisations
|
|
WO2021062092A1
(fr)
|
2019-09-26 |
2021-04-01 |
Massachusetts Institute Of Technology |
Arn fonctionnel trans-activé par déplacement de brin et ses utilisations
|
|
EP4041767A1
(fr)
|
2019-09-26 |
2022-08-17 |
StCube & Co. |
Anticorps spécifiques dirigés contre ctla-4 glycosylée et leurs procédés d'utilisation
|
|
US20220356234A1
(en)
|
2019-10-02 |
2022-11-10 |
Alexion Pharmaceuticals, Inc. |
Complement inhibitors for treating drug-induced complement-mediated response
|
|
EP4038189A1
(fr)
|
2019-10-04 |
2022-08-10 |
Alnylam Pharmaceuticals, Inc. |
Compositions et méthodes pour le silençage de l'expression génique de l'ugt1a1
|
|
TWI771766B
(zh)
|
2019-10-04 |
2022-07-21 |
美商輝瑞股份有限公司 |
二醯基甘油醯基轉移酶2 抑制劑
|
|
WO2021071830A1
(fr)
|
2019-10-07 |
2021-04-15 |
University Of Virginia Patent Foundation |
Modulation de vaisseaux lymphatiques dans une maladie neurologique
|
|
CN114829404B
(zh)
|
2019-10-09 |
2025-09-09 |
斯特库比公司 |
对糖基化的lag3特异的抗体及其使用方法
|
|
CA3157509A1
(fr)
|
2019-10-10 |
2021-04-15 |
Kodiak Sciences Inc. |
Procedes de traitement d'un trouble oculaire
|
|
US20240092935A1
(en)
|
2019-10-11 |
2024-03-21 |
Beth Israel Deaconess Medical Center, Inc. |
Anti-tn antibodies and uses thereof
|
|
JP2023501912A
(ja)
|
2019-10-21 |
2023-01-20 |
ライゼン ファーマシューティカルズ アーゲー |
急性骨髄性白血病の治療のためのdhodh阻害剤を含む組成物
|
|
US20230040920A1
(en)
|
2019-11-01 |
2023-02-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajb1-prkaca fusion gene expression
|
|
TWI809334B
(zh)
|
2019-12-10 |
2023-07-21 |
美商輝瑞股份有限公司 |
2-((4-((S)-2-(5-氯吡啶-2-基)-2-甲基苯并〔d〕〔1,3〕二氧呃-4-基)哌啶-1-基)甲基)-1-(((S)-氧呾-2-基)甲基)-1H-苯并〔d〕咪唑-6-羧酸1,3-二羥基-2-(羥基甲基)丙烷-2-胺鹽之固體形式
|
|
KR20220123013A
(ko)
|
2019-12-20 |
2022-09-05 |
모멘타 파머슈티컬스 인코포레이티드 |
인테그린 알파 11 베타 1에 대한 항체
|
|
WO2021142427A1
(fr)
|
2020-01-11 |
2021-07-15 |
Scholar Rock, Inc. |
Inhibiteurs de tgfb et leur utilisation
|
|
JP2023511255A
(ja)
|
2020-01-11 |
2023-03-17 |
スカラー ロック インコーポレイテッド |
TGF-β阻害剤及びその使用
|
|
IL294388A
(en)
|
2020-01-14 |
2022-08-01 |
Synthekine Inc |
Il2 orthologs and methods of use
|
|
WO2021146383A1
(fr)
|
2020-01-17 |
2021-07-22 |
BioLegend, Inc. |
Agents anti-tlr7 et compositions et procédés de fabrication et d'utilisation de ceux-ci
|
|
WO2021151079A1
(fr)
|
2020-01-24 |
2021-07-29 |
University Of Virginia Patent Foundation |
Modulation de vaisseaux lymphatiques dans une maladie neurologique
|
|
KR20220140593A
(ko)
|
2020-02-10 |
2022-10-18 |
알닐람 파마슈티칼스 인코포레이티드 |
Vegf-a 발현을 사일런싱하기 위한 조성물 및 방법
|
|
JP2022058085A
(ja)
|
2020-02-24 |
2022-04-11 |
ファイザー・インク |
ジアシルグリセロールアシルトランスフェラーゼ2阻害剤とアセチル-CoAカルボキシラーゼ阻害剤との組合せ
|
|
CA3170563A1
(fr)
|
2020-03-06 |
2021-09-10 |
Raymond P. Goodrich |
Production de vaccins comprenant des particules virales de sras-cov-2 inactivees
|
|
JP2023517044A
(ja)
|
2020-03-09 |
2023-04-21 |
ファイザー・インク |
融合タンパク質およびその使用
|
|
GB202003632D0
(en)
|
2020-03-12 |
2020-04-29 |
Harbour Antibodies Bv |
SARS-Cov-2 (SARS2, COVID-19) antibodies
|
|
WO2021188096A1
(fr)
|
2020-03-17 |
2021-09-23 |
Dst Pharma, Inc. |
Procédés et compositions de traitement d'infections virales
|
|
MX2022011743A
(es)
|
2020-03-26 |
2022-12-08 |
Plx Opco Inc |
Portadores farmaceuticos con capacidad de reconstitucion dependiente del ph y metodos para elaborar y usar los mismos.
|
|
US20230201185A1
(en)
|
2020-03-27 |
2023-06-29 |
Pfizer Inc. |
Treatment of type 2 diabetes or obesity or overweight with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof
|
|
WO2021202443A2
(fr)
|
2020-03-30 |
2021-10-07 |
Alnylam Pharmaceucticals, Inc. |
Compositions et procédés de silençage de l'expression du gène dnajc15
|
|
AR121769A1
(es)
|
2020-04-06 |
2022-07-06 |
Alnylam Pharmaceuticals Inc |
Composiciones y métodos para el silenciamiento de la expresión de myoc
|
|
BR112022020227A2
(pt)
|
2020-04-07 |
2022-11-22 |
Alnylam Pharmaceuticals Inc |
Composições e métodos para silenciamento da expressão de scn9a
|
|
WO2021205322A1
(fr)
|
2020-04-08 |
2021-10-14 |
Pfizer Inc. |
Formes cristallines de 3-cyano-1-[4-[6-(1-méthyl-1h-pyrazo-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-1h-pyrazol-1-yl]cyclobutaneacétonitrile, et utilisation associée
|
|
CA3176425A1
(fr)
|
2020-04-24 |
2021-10-28 |
Millennium Pharmaceuticals, Inc. |
Anticorps anti-cd19 et leurs utilisations
|
|
EP4146688A1
(fr)
|
2020-05-06 |
2023-03-15 |
CRISPR Therapeutics AG |
Peptides masques et anticorps anti-ptk7 masqués les comprenant
|
|
AU2021271317A1
(en)
|
2020-05-15 |
2023-01-19 |
Crispr Therapeutics Ag |
Messenger RNA encoding Cas9 for use in genome-editing systems
|
|
WO2021237097A1
(fr)
|
2020-05-21 |
2021-11-25 |
Alnylam Pharmaceuticals, Inc. |
Compositions et procédés d'inhibition de l'expression du gène marc1
|
|
PT4157832T
(pt)
|
2020-05-27 |
2024-07-30 |
Qilu Regor Therapeutics Inc |
Formas de sal e cristal de agonistas de glp-1r e utilizações dos mesmos
|
|
EP4162033A4
(fr)
|
2020-06-09 |
2024-12-25 |
Alnylam Pharmaceuticals, Inc. |
Compositions de petit arn interférent et procédés de silençage de l'expression de la gpam (glycérol-3-phosphate acyltransférase 1, mitochondriale)
|
|
LT4161927T
(lt)
|
2020-06-09 |
2024-09-25 |
Pfizer Inc. |
Spiro junginiai kaip melanokortino receptoriaus antagonistai ir jų panaudojimas
|
|
EP4165071A4
(fr)
|
2020-06-15 |
2024-07-17 |
Academia Sinica |
Protéine de fusion ac2-fc humanisée pour le traitement et la prévention d'une infection par sars-cov-2
|
|
KR20230025898A
(ko)
|
2020-06-26 |
2023-02-23 |
화이자 인코포레이티드 |
Tl1a 항체를 사용하여 염증성 장 질환을 치료하는 방법
|
|
US20240409617A1
(en)
|
2020-07-03 |
2024-12-12 |
Dana-Farber Cancer Institute, Inc. |
Multispecific coronavirus antibodies
|
|
JP2023533793A
(ja)
|
2020-07-17 |
2023-08-04 |
ファイザー・インク |
治療用抗体およびそれらの使用
|
|
JP2023535225A
(ja)
|
2020-07-24 |
2023-08-16 |
ストランド セラピューティクス インコーポレイテッド |
改変ヌクレオチドを含む脂質ナノ粒子
|
|
IL300110A
(en)
|
2020-07-28 |
2023-03-01 |
Jazz Pharmaceuticals Ireland Ltd |
Chiral synthesis of RAF inhibitors in compressed cyclics
|
|
IL300113A
(en)
|
2020-07-28 |
2023-03-01 |
Jazz Pharmaceuticals Ireland Ltd |
Compressed cyclic RAF inhibitors and methods of using them
|
|
US12234291B2
(en)
|
2020-08-05 |
2025-02-25 |
Synthekine, Inc. |
IL2RB binding molecules and methods of use
|
|
JP7767391B2
(ja)
|
2020-08-05 |
2025-11-11 |
シンセカイン インコーポレイテッド |
IL10Ra結合分子および使用方法
|
|
MX2023001491A
(es)
|
2020-08-05 |
2023-03-08 |
Synthekine Inc |
Moleculas de union a gp130 y metodos de uso.
|
|
WO2022031884A2
(fr)
|
2020-08-05 |
2022-02-10 |
Synthekine, Inc. |
Molécules de liaison à il2rg et procédés d'utilisation
|
|
KR20230061393A
(ko)
|
2020-08-05 |
2023-05-08 |
신테카인, 인크. |
IL10Rb 결합 분자 및 사용 방법
|
|
AR123156A1
(es)
|
2020-08-06 |
2022-11-02 |
Qilu Regor Therapeutics Inc |
Agonistas de glp-1r y sus usos
|
|
EP4196149A1
(fr)
|
2020-08-14 |
2023-06-21 |
Kite Pharma, Inc. |
Amélioration de la fonction de cellules immunitaires
|
|
KR20230069961A
(ko)
|
2020-09-14 |
2023-05-19 |
보르 바이오파마 인크. |
Cd33에 대한 단일 도메인 항체
|
|
EP4213939A1
(fr)
|
2020-09-21 |
2023-07-26 |
Boehringer Ingelheim International GmbH |
Utilisation d'anticorps anti-cd40 pour le traitement d'états inflammatoires
|
|
TW202229349A
(zh)
|
2020-10-06 |
2022-08-01 |
美商山可爾股份有限公司 |
用於治療包括全身性紅斑性狼瘡(sle)的自體免疫疾病之生物標記、方法及組合物
|
|
JP7769695B2
(ja)
|
2020-10-14 |
2025-11-13 |
キル・レガー・セラピューティクス・インコーポレーテッド |
Glp-1rアゴニストの結晶形態およびその使用
|
|
WO2022093640A1
(fr)
|
2020-10-30 |
2022-05-05 |
BioLegend, Inc. |
Agents anti-nkg2c et compositions et méthodes de production et d'utilisation de ceux-ci
|
|
WO2022093641A1
(fr)
|
2020-10-30 |
2022-05-05 |
BioLegend, Inc. |
Agents anti-nkg2a et compositions et méthodes de production et d'utilisation de ceux-ci
|
|
US11058637B1
(en)
*
|
2020-11-25 |
2021-07-13 |
King Abdulaziz University |
Surface-modified emulsomes for intranasal delivery of drugs
|
|
IL303195A
(en)
|
2020-11-25 |
2023-07-01 |
Akagera Medicines Inc |
Lipid nanoparticles for delivery of nucleic acids and related methods of use
|
|
JP2024505790A
(ja)
|
2020-12-18 |
2024-02-08 |
モメンタ ファーマシューティカルズ インコーポレイテッド |
インテグリンアルファ11ベータ1に対する抗体
|
|
MX2023008002A
(es)
|
2021-01-08 |
2023-08-25 |
|
Constructos de expresion y usos de estos.
|
|
US11033495B1
(en)
|
2021-01-22 |
2021-06-15 |
Pacira Pharmaceuticals, Inc. |
Manufacturing of bupivacaine multivesicular liposomes
|
|
US11357727B1
(en)
|
2021-01-22 |
2022-06-14 |
Pacira Pharmaceuticals, Inc. |
Manufacturing of bupivacaine multivesicular liposomes
|
|
US11278494B1
(en)
|
2021-01-22 |
2022-03-22 |
Pacira Pharmaceuticals, Inc. |
Manufacturing of bupivacaine multivesicular liposomes
|
|
US12151024B2
(en)
|
2021-01-22 |
2024-11-26 |
Pacira Pharmaceuticals, Inc. |
Manufacturing of bupivacaine multivesicular liposomes
|
|
US20240317868A1
(en)
|
2021-02-05 |
2024-09-26 |
Boehringer Ingelheim International Gmbh |
Anti-il1rap antibodies
|
|
KR20230153407A
(ko)
|
2021-02-24 |
2023-11-06 |
인실리코 메디신 아이피 리미티드 |
질환의 치료를 위한 유사체
|
|
WO2022192439A1
(fr)
|
2021-03-11 |
2022-09-15 |
Kite Pharma, Inc. |
Amélioration de la fonction de cellules immunitaires
|
|
WO2022195504A1
(fr)
|
2021-03-19 |
2022-09-22 |
Pfizer Inc. |
Méthode de traitement de la douleur due à l'arthrose avec un anticorps anti-ngf
|
|
IL306038A
(en)
|
2021-03-22 |
2023-11-01 |
Massachusetts Inst Technology |
Multicellular microRNA sensing with elemental erns to regulate multipolar gene expression in mammalian cells
|
|
US11952461B2
(en)
|
2021-03-22 |
2024-04-09 |
Sunbio, Inc. |
Siloxy polyethylene glycol and derivatives thereof
|
|
AU2022241935A1
(en)
|
2021-03-22 |
2023-09-28 |
Novimmune S.A. |
Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
|
|
IL305827A
(en)
|
2021-03-22 |
2023-11-01 |
Novimmune Sa |
Bispecific antibodies targeting CD47 and PD-L1 and methods of using them
|
|
WO2022204581A2
(fr)
|
2021-03-26 |
2022-09-29 |
Scholar Rock, Inc. |
Inhibiteurs de tgf-bêta et leur utilisation
|
|
JP2024515066A
(ja)
|
2021-04-09 |
2024-04-04 |
武田薬品工業株式会社 |
補体因子dを標的とする抗体及びその使用
|
|
AU2022261124A1
(en)
|
2021-04-22 |
2023-10-05 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating cancer
|
|
KR20240004286A
(ko)
|
2021-04-26 |
2024-01-11 |
밀레니엄 파머슈티컬스 인코퍼레이티드 |
항 Clec12A 항체 및 이의 용도
|
|
WO2022232035A1
(fr)
|
2021-04-26 |
2022-11-03 |
Millennium Pharmaceuticals, Inc. |
Anticorps anti-adgre2 et leurs utilisations
|
|
CA3217928A1
(fr)
|
2021-05-05 |
2022-11-10 |
Kameswari S. Konduri |
Inhibition de la replication du sars-cov-2 et reduction de l'inflammation pulmonaire par corticosteriods encapsules dans des liposomes
|
|
WO2022235940A1
(fr)
|
2021-05-06 |
2022-11-10 |
Dana-Farber Cancer Institute, Inc. |
Anticorps anti-alk et leurs procédés d'utilisation
|
|
US20240239875A1
(en)
|
2021-05-17 |
2024-07-18 |
Curia Ip Holdings, Llc |
Sars-cov-2 spike protein antibodies
|
|
WO2022245877A1
(fr)
|
2021-05-17 |
2022-11-24 |
Curia Ip Holdings, Llc |
Anticorps dirigés contre la protéine de spicule du sars-cov-2
|
|
WO2022256723A2
(fr)
|
2021-06-03 |
2022-12-08 |
Scholar Rock, Inc. |
Inhibiteurs de tgf-bêta et leur utilisation thérapeutique
|
|
WO2022271867A1
(fr)
|
2021-06-23 |
2022-12-29 |
Scholar Rock, Inc. |
Inhibiteur de la voie de passage de la myostatine en combinaison avec un activateur de la voie de passage glp-1 pour une utilisation dans le traitement de troubles métaboliques
|
|
US20250270562A1
(en)
|
2021-07-09 |
2025-08-28 |
Alnylam Pharmaceuticals, Inc. |
Bis-rnai compounds for cns delivery
|
|
TW202306985A
(zh)
|
2021-07-12 |
2023-02-16 |
美商建南德克公司 |
降低抗體-脂酶結合之結構
|
|
EP4370148A1
(fr)
|
2021-07-14 |
2024-05-22 |
Scholar Rock, Inc. |
Inhibiteurs spécifiques du complexe ltbp de tgf bêta1 et leurs utilisations
|
|
WO2023007374A1
(fr)
|
2021-07-27 |
2023-02-02 |
Pfizer Inc. |
Méthode de traitement de la douleur liée au cancer à l'aide de tanézumab
|
|
GB202111759D0
(en)
|
2021-08-17 |
2021-09-29 |
Cantab Biopharmaceuticals Patents Ltd |
Modified colloidal particles
|
|
GB202111757D0
(en)
|
2021-08-17 |
2021-09-29 |
Cantab Biopharmaceuticals Patents Ltd |
Modified colloidal particles for use in the treatment of haemophilia A
|
|
GB202111758D0
(en)
|
2021-08-17 |
2021-09-29 |
Cantab Biopharmaceuticals Patents Ltd |
Modified colloidal particles for use in the treatment of haemophilia A
|
|
KR20240054335A
(ko)
|
2021-08-31 |
2024-04-25 |
화이자 인코포레이티드 |
2-[(4-{6-[(4-시아노-2-플루오로벤질)옥시]피리딘-2-일}피페리딘-1-일)메틸]-1-[(2s)-옥세탄-2-일메틸]-1h-벤즈이미다졸-6-카르복실산,1,3-디히드록시-2-(히드록시메틸)프로판-2-아민 염의 고체 형태
|
|
MX2024002440A
(es)
|
2021-08-31 |
2024-03-08 |
Alnylam Pharmaceuticals Inc |
Composiciones de acido ribonucleico de interferencia (arni) del efector b similar al factor de fragmentacion de adn subunidad alfa (dffa) que induce la muerte celular (cideb) y metodos de uso de estas.
|
|
WO2023036982A1
(fr)
|
2021-09-10 |
2023-03-16 |
Harbour Antibodies Bv |
Anticorps anti-sars2-s
|
|
GB202112935D0
(en)
|
2021-09-10 |
2021-10-27 |
Harbour Antibodies Bv |
Sars-cov-2 (sars2, covid-19) heavy chain only antibodies
|
|
EP4415713A4
(fr)
|
2021-10-14 |
2025-08-06 |
Pacira Pharmaceuticals Inc |
Formulations de liposomes multivésiculaires de bupivacaïne et leurs utilisations
|
|
WO2023068382A2
(fr)
|
2021-10-20 |
2023-04-27 |
Takeda Pharmaceutical Company Limited |
Compositions ciblant bcma et leurs procédés d'utilisation
|
|
AU2022375820A1
(en)
|
2021-11-01 |
2024-06-13 |
Tome Biosciences, Inc. |
Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
|
|
CA3237090A1
(fr)
|
2021-11-05 |
2023-05-11 |
Dana-Farber Cancer Institute, Inc. |
Anticorps monoclonaux humains contre la grippe largement reactifs et leurs procedes d'utilisation
|
|
AU2022396272A1
(en)
|
2021-11-24 |
2024-06-06 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against ctla-4 and methods of use thereof
|
|
WO2023100061A1
(fr)
|
2021-12-01 |
2023-06-08 |
Pfizer Inc. |
Dérivés d'acide 3-phényl-1-benzothiophène-2-carboxylique utilisés en tant qu'inhibiteurs de kinase alpha-céto-acide à chaîne ramifiée pour le traitement du diabète, de maladies rénales, de la shna et de l'insuffisance cardiaque
|
|
EP4444708B1
(fr)
|
2021-12-06 |
2025-07-30 |
Pfizer Inc. |
Antagonistes du récepteur 4 de la mélanocortine et leurs utilisations
|
|
AU2022403854B2
(en)
|
2021-12-08 |
2025-04-17 |
Array Biopharma Inc. |
Crystalline form of n-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide
|
|
US20250051472A1
(en)
|
2021-12-17 |
2025-02-13 |
Dana-Farber Cancer Institute, Inc. |
Antibodies and uses thereof
|
|
WO2023111817A1
(fr)
|
2021-12-17 |
2023-06-22 |
Pfizer Inc. |
Formes cristallines d'acide [(1r,5s,6r)-3-{2-[(2s)-2-méthylazetidin-1-yl]-6-(trifluorométhyl) pyrimidin-4-yl}-3-azabicyclo[3.1.0]hex-6-yl]acétique
|
|
US20250051755A1
(en)
|
2021-12-17 |
2025-02-13 |
Dana-Farber Cancer Institute, Inc. |
Platform for antibody discovery
|
|
IL313765A
(en)
|
2021-12-22 |
2024-08-01 |
Tome Biosciences Inc |
Joint provision of a gene editor structure and a donor template
|
|
EP4493592A1
(fr)
|
2022-03-14 |
2025-01-22 |
LamKap Bio gamma AG |
Anticorps anti-gpc3xcd28 et anti-gpc3xcd3 bispécifiques et leur combinaison pour la destruction ciblée de cellules malignes positives à gpc3
|
|
CN119562970A
(zh)
|
2022-03-18 |
2025-03-04 |
进化免疫治疗公司 |
双特异性抗体融合分子及其使用方法
|
|
EP4507794A1
(fr)
|
2022-04-11 |
2025-02-19 |
Vor Biopharma Inc. |
Agents de liaison et leurs méthodes d'utilisation
|
|
WO2023205744A1
(fr)
|
2022-04-20 |
2023-10-26 |
Tome Biosciences, Inc. |
Compositions d'insertion de gènes programmable
|
|
IL316186A
(en)
|
2022-04-26 |
2024-12-01 |
Strand Therapeutics Inc |
Lipid nanoparticles containing Venezuelan equine encephalitis (VEE) replicon and uses thereof
|
|
WO2023215831A1
(fr)
|
2022-05-04 |
2023-11-09 |
Tome Biosciences, Inc. |
Compositions d'arn guide pour insertion de gène programmable
|
|
WO2023220641A2
(fr)
|
2022-05-11 |
2023-11-16 |
Juno Therapeutics, Inc. |
Méthodes et utilisations associées à une thérapie par lymphocytes t et leur production
|
|
WO2023225670A2
(fr)
|
2022-05-20 |
2023-11-23 |
Tome Biosciences, Inc. |
Insertion de gène programmable ex vivo
|
|
WO2023228023A1
(fr)
|
2022-05-23 |
2023-11-30 |
Pfizer Inc. |
Traitement du diabète de type 2 ou contrôle de la gestion du poids avec de l'acide 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-méthylbenzo[d][1,3]dioxol-4-yl)pipéridin-1-yl)méthyl)-1-(((s)-oxétan-2-yl)méthyl)-1h-benzo[d]imidazole-6-carboxylique ou un sel pharmaceutique de celui-ci
|
|
JP2025522311A
(ja)
|
2022-05-25 |
2025-07-15 |
アカゲラ・メディスンズ,インコーポレイテッド |
核酸を送達するための脂質ナノ粒子およびその使用方法
|
|
CN120571009A
(zh)
|
2022-06-03 |
2025-09-02 |
泽纳仕生物制药公司 |
用于治疗IgG4相关疾病的方法和组合物
|
|
CN119301155A
(zh)
|
2022-07-19 |
2025-01-10 |
百进生物科技公司 |
抗cd157抗体、其抗原结合片段和组合物及其制备和使用方法
|
|
WO2024030858A1
(fr)
|
2022-08-01 |
2024-02-08 |
Cytomx Therapeutics, Inc. |
Substrats clivables par protéase et procédés d'utilisation associés
|
|
TW202424184A
(zh)
|
2022-08-01 |
2024-06-16 |
美商Cytomx生物製藥公司 |
蛋白酶可切割部分及其使用方法
|
|
AR130077A1
(es)
|
2022-08-01 |
2024-10-30 |
Cytomx Therapeutics Inc |
Substratos escindibles por proteasas, y métodos de uso de los mismos
|
|
EP4565690A1
(fr)
|
2022-08-01 |
2025-06-11 |
CytomX Therapeutics, Inc. |
Fractions clivables par protéase et leurs procédés d'utilisation
|
|
EP4565329A1
(fr)
|
2022-08-01 |
2025-06-11 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Anticorps monoclonaux se liant à la face inférieure de la neuraminidase virale de la grippe
|
|
WO2024030845A1
(fr)
|
2022-08-01 |
2024-02-08 |
Cytomx Therapeutics, Inc. |
Fractions clivables par protéase et procédés d'utilisation associés
|
|
WO2024039670A1
(fr)
|
2022-08-15 |
2024-02-22 |
Dana-Farber Cancer Institute, Inc. |
Anticorps anti-cldn4 et leurs méthodes d'utilisation
|
|
WO2024039672A2
(fr)
|
2022-08-15 |
2024-02-22 |
Dana-Farber Cancer Institute, Inc. |
Anticorps anti-mlsn et leurs méthodes d'utilisation
|
|
WO2024040114A2
(fr)
|
2022-08-18 |
2024-02-22 |
BioLegend, Inc. |
Anticorps anti-axl, leurs fragments de liaison à l'antigène et leurs procédés de fabrication et méthoes d'utilisation
|
|
CA3265385A1
(fr)
|
2022-08-22 |
2024-02-29 |
Abdera Therapeutics Inc. |
Molécules de liaison à dll3 et leurs utilisations
|
|
WO2024059165A1
(fr)
|
2022-09-15 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
Compositions d'arni de 17b-hydroxystéroïde déshydrogénase de type 13 (hsd17b13) et leurs procédés d'utilisation
|
|
IL319486A
(en)
|
2022-10-07 |
2025-05-01 |
Pfizer |
HSD17B13 Inhibitors and/or Retarders
|
|
EP4604955A1
(fr)
|
2022-10-18 |
2025-08-27 |
Pfizer Inc. |
Utilisation de composés de protéine 3 contenant un domaine phospholipase de type patatine
|
|
US20240182468A1
(en)
|
2022-10-18 |
2024-06-06 |
Pfizer Inc. |
Compounds for the activation of ampk
|
|
IL319392A
(en)
|
2022-10-18 |
2025-05-01 |
Pfizer |
Pectin-like phospholipase domain-containing protein 3 (PNPLA3) modification preparations
|
|
IL320152A
(en)
|
2022-10-21 |
2025-06-01 |
Novimmune Sa |
Bispecific antibodies against PD-L1 and CD28 for immune checkpoint-dependent T cell activation
|
|
GB202216284D0
(en)
|
2022-11-02 |
2022-12-14 |
Ucl Business Ltd |
Self-regulation
|
|
CN120731201A
(zh)
|
2022-12-16 |
2025-09-30 |
辉瑞公司 |
含3-氟-4-羟基苯甲酰胺的抑制剂和/或降解剂及其用途
|
|
KR20250122524A
(ko)
|
2022-12-22 |
2025-08-13 |
스칼러 락, 인크. |
미오스타틴 활성화의 선택적이고 강력한 억제 항체
|
|
WO2024138194A1
(fr)
|
2022-12-22 |
2024-06-27 |
Tome Biosciences, Inc. |
Plateformes, compositions et procédés d'insertion de gène programmable in vivo
|
|
WO2024151877A2
(fr)
|
2023-01-11 |
2024-07-18 |
Engage Biologics Inc. |
Systèmes d'expression non virale et leurs procédés d'utilisation
|
|
IL322261A
(en)
|
2023-02-09 |
2025-09-01 |
Alnylam Pharmaceuticals Inc |
Reverser molecules and methods of using them
|
|
WO2024173607A2
(fr)
|
2023-02-14 |
2024-08-22 |
Evolveimmune Therapeutics, Inc. |
Combinaison d'anticorps bispécifiques et de lymphocytes t récepteurs d'antigènes chimériques destinés au traitement
|
|
CN117338722A
(zh)
*
|
2023-02-27 |
2024-01-05 |
北京大学深圳医院(北京大学深圳临床医学院) |
用于治疗肝纤维化的石墨烯量子点脂质体及其制备方法
|
|
WO2024184403A2
(fr)
|
2023-03-06 |
2024-09-12 |
Snipr Biome Aps |
Ciblage de cellules dans des conditions de croissance sous stress
|
|
WO2024187051A1
(fr)
|
2023-03-07 |
2024-09-12 |
Scholar Rock, Inc. |
Inhibiteurs de tgf-bêta destinés à être utilisés pour traiter un cancer résistant ou réfractaire chez des patients
|
|
CN116271240B
(zh)
*
|
2023-03-20 |
2025-04-04 |
中国人民解放军陆军军医大学 |
一种全生物性小口径组织工程血管的构建方法
|
|
WO2024216162A1
(fr)
|
2023-04-12 |
2024-10-17 |
Strand Therapeutics Inc. |
Circuits synthétiques et leurs utilisations
|
|
WO2024226487A1
(fr)
|
2023-04-24 |
2024-10-31 |
Zenas Biopharma, Inc. |
Procédés et compositions pour le traitement de l'anémie hémolytique auto-immune (aiha)
|
|
WO2024234006A1
(fr)
|
2023-05-11 |
2024-11-14 |
Tome Biosciences, Inc. |
Systèmes, compositions et procédés de ciblage de cellules endothéliales sinusoïdales hépatiques (lsecs)
|
|
WO2024238565A1
(fr)
|
2023-05-15 |
2024-11-21 |
Vor Biopharma Inc. |
Module de type egf contenant des agents liants l'hormone type 2 de type mucine (erm2) et procédés d'utilisation associés
|
|
AU2024273758A1
(en)
|
2023-05-17 |
2025-12-04 |
Genentech, Inc. |
Anti-tl1a antibody therapeutic methods
|
|
WO2024243217A1
(fr)
|
2023-05-25 |
2024-11-28 |
BioLegend, Inc. |
Anticorps liant ceacam6 et fragments de liaison à l'antigène de ceux-ci
|
|
WO2024249553A1
(fr)
|
2023-05-31 |
2024-12-05 |
University Of Tartu |
Molécules ciblant des tissus infectés et leurs procédés d'utilisation
|
|
WO2024252327A1
(fr)
|
2023-06-09 |
2024-12-12 |
Pfizer Inc. |
Formes solides de n-(méthoxycarbonyl)-3-méthyl-l-valyl-(4r)-n- {(1s)-1-cyano-2-[(3s)-2-oxopyrrolidin-3-yl]éthyl}-4-(trifluorométhyl)-l-prolinamide et leurs solvates
|
|
GB202310227D0
(en)
|
2023-07-04 |
2023-08-16 |
Snipr Biome Aps |
Production & secretion of auxin-like molecules in bacteria
|
|
WO2025024559A1
(fr)
|
2023-07-24 |
2025-01-30 |
Strand Therapeutics Inc. |
Circuit synthétique à base d'arn pour produire des cellules immunitaires modifiées pour une thérapie cellulaire extracorporelle
|
|
WO2025024704A1
(fr)
|
2023-07-25 |
2025-01-30 |
Strand Therapeutics Inc. |
Polynucléotides comprenant un capteur de reciblage de micro-arn et leurs utilisations
|
|
WO2025038668A1
(fr)
|
2023-08-14 |
2025-02-20 |
Voro Therapeutics, Inc. |
Agents de liaison thérapeutiques favorisant de manière conditionnelle l'activité des cellules myéloïdes contre des cellules cibles et leurs utilisations
|
|
WO2025050069A1
(fr)
|
2023-09-01 |
2025-03-06 |
Tome Biosciences, Inc. |
Insertion de gène programmable à l'aide d'enzymes d'intégration modifiées
|
|
WO2025059037A1
(fr)
|
2023-09-11 |
2025-03-20 |
Evolveimmune Therapeutics, Inc. |
Molécules de fusion d'anticorps bispécifiques ciblant b7-h4 et cd3 et leurs procédés d'utilisation
|
|
WO2025064885A1
(fr)
|
2023-09-20 |
2025-03-27 |
Evolveimmune Therapeutics, Inc. |
Anticorps multispécifiques se liant à cd3 et cd2 et leurs procédés d'utilisation
|
|
WO2025064890A1
(fr)
|
2023-09-20 |
2025-03-27 |
Evolveimmune Therapeutics, Inc. |
Molécules de fusion d'anticorps bispécifiques ciblant cd180 et cd3 et leurs méthodes d'utilisation
|
|
WO2025072313A1
(fr)
|
2023-09-27 |
2025-04-03 |
BioLegend, Inc. |
Anticorps anti-gpc4
|
|
WO2025072888A2
(fr)
|
2023-09-28 |
2025-04-03 |
Novavax, Inc. |
Anticorps de spicule (s) anti-sars-cov-2 et leur utilisation dans le traitement du covid-19
|
|
TW202530264A
(zh)
|
2023-10-02 |
2025-08-01 |
美商澤納仕生物製藥股份有限公司 |
用於治療多發性硬化症之方法及組合物
|
|
US20250171537A1
(en)
|
2023-11-28 |
2025-05-29 |
Novimmune Sa |
Method of treating disease using anti-cd47 x anti-mesothelin antibodies as a sole agent and in combination with anti-pd-1 antibodies
|
|
WO2025117384A1
(fr)
|
2023-12-01 |
2025-06-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anticorps dirigés contre la souche de l'hémagglutinine de la grippe largement neutralisants
|
|
WO2025120500A1
(fr)
|
2023-12-06 |
2025-06-12 |
Pfizer Inc. |
Composés de benzodiazépine utilisés en tant qu'inhibiteurs de protéine n
|
|
US20250223356A1
(en)
|
2024-01-08 |
2025-07-10 |
Zenas Biopharma, Inc. |
Methods and compositions for treating relapsing multiple sclerosis
|
|
WO2025153942A1
(fr)
|
2024-01-16 |
2025-07-24 |
Pfizer Inc. |
Pyrazolo carboxamides de benzodiazépine utilisés en tant qu'inhibiteurs de protéine n
|
|
WO2025155844A1
(fr)
|
2024-01-17 |
2025-07-24 |
Zenas Biopharma, Inc. |
Méthodes et compositions pour le traitement du lupus érythémateux disséminé (sle)
|
|
WO2025224107A1
(fr)
|
2024-04-22 |
2025-10-30 |
Basecamp Research Ltd |
Procédé et compositions pour détecter une édition hors cible
|
|
WO2025224182A2
(fr)
|
2024-04-23 |
2025-10-30 |
Basecamp Research Ltd |
Plate-forme de construction unique pour l'administration simultanée d'une machinerie d'édition de gènes et d'une cargaison d'acide nucléique
|
|
WO2025224648A1
(fr)
|
2024-04-26 |
2025-10-30 |
Pfizer Inc. |
Compositions/formulations orales de l'acide 2-({4-[(2s)-2-(4-chloro-2-fluorophényl)-2-méthyl-1,3-benzodioxol-4-yl]pipéridin-1-yl}méthyl)-1-[(2s)-oxétan-2-ylméthyl]-1h-benzimidazole-6-carboxylique ou d'un sel pharmaceutiquement acceptable de celui-ci
|
|
WO2025240343A1
(fr)
|
2024-05-13 |
2025-11-20 |
Scholar Rock, Inc. |
Inhibiteurs de tgf-bêta pour le traitement du cancer
|
|
WO2025240922A1
(fr)
|
2024-05-17 |
2025-11-20 |
Genentech, Inc. |
Méthodes de traitement d'une maladie intestinale inflammatoire avec un anticorps anti-tl1a
|
|
US12251472B1
(en)
|
2024-05-20 |
2025-03-18 |
Pacira Pharmaceuticals, Inc. |
Manufacturing of bupivacaine multivesicular liposomes
|
|
US12156940B1
(en)
|
2024-05-20 |
2024-12-03 |
Pacira Pharmaceuticals, Inc. |
Manufacturing of bupivacaine multivesicular liposomes
|
|
US12280149B1
(en)
|
2024-05-20 |
2025-04-22 |
Pacira Pharmaceuticals, Inc. |
Manufacturing of bupivacaine multivesicular liposomes
|